document.write('<div class=\"rss_feed\">');
document.write('<div class=\"rss_feed_title\">pubmed: "atrial fibrillation...</div>');
document.write('<ul class=\"rss_item_list\">');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20379640&#x26;dopt=Abstract\">Prevalence of electrocardiographic findings in elderly individuals: the Sao Paulo aging &#x26; health study.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www.scielo.br/scielo.php?script=sci_arttext&#x26;amp;pid=S0066-782X2009001200015&#x26;amp;lng=en&#x26;amp;nrm=iso&#x26;amp;tlng=en"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.scielo.br-img-scielo_en.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20379640">Related Articles</a></td></tr></table>        <p><b>Prevalence of electrocardiographic findings in elderly individuals: the Sao Paulo aging &#x26;amp; health study.</b></p>        <p>Arq Bras Cardiol. 2009 Dec;93(6):602-7, 651-6</p>        <p>Authors:  Kawabata-Yoshihara LA, Bense&#xC3;&#xB1;or IM, Kawabata VS, Menezes PR, Scazufca M, Lotufo PA</p>        <p>BACKGROUND: The determination of the prevalence of electrocardiographic alterations in the older age strata of the Brazilian population represents important information with clinical and epidemiological purpose. OBJECTIVE: To verify the prevalence rates of atrial fibrillation, enlarged Q/QS waves (Minnesota code 1.1-1.2) and left bundle branch block. METHODS: In a population-based study, 1,524 participants (921 women and 603 men) aged &#x26;gt; 65 years and living in Sao Paulo, Brazil, were submitted to electrocardiographic assessment at rest as well as anthropometric and blood pressure measurements, in addition to fasting blood collection for the measurement of glycemia, total cholesterol and fractions. RESULTS: The age-adjusted prevalence for enlarged Q/QS waves was 12.1% (men, 17.2%; women, 9.6%), 2.4% for atrial fibrillation (men 3.9%; women, 2.0%); and 3.1% for left bundle branch block (men, 3.1%; women, 3.8%). For atrial fibrillation (both sexes), enlarged Q/QS waves (men) and left bundle branch block (women) there was an increase in frequency according to the age stratum. After adjusted for age, sex, diabetes mellitus and dyslipidemia, the odds ratio among the frequencies of enlarged Q/QS waves; arterial hypertension was 2.4 (95% CI: 1.4 -3.9) being 5.1 (95%CI: 1.8 -14.4) for women and 1.7 (95%CI: 0.95-3.1] for men. CONCLUSION: The comparison of these data with those from other studies showed a high prevalence of enlarged Q/QS waves in this population, with a direct association with the prevalence of arterial hypertension.</p>        <p>PMID: 20379640 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19538179&#x26;dopt=Abstract\">Postoperative atrial fibrillation - what do we really know?</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19538179">Related Articles</a></td></tr></table>        <p><b>Postoperative atrial fibrillation - what do we really know?</b></p>        <p>Curr Vasc Pharmacol. 2010 Jul;8(4):553-72</p>        <p>Authors:  Banach M, Kourliouros A, Reinhart KM, Benussi S, Mikhailidis DP, Jahangiri M, Baker WL, Galanti A, Rysz J, Camm JA, White CM, Alfieri O</p>        <p>Postoperative atrial fibrillation (POAF) is a common complication following cardiac surgery, occurring in 20% to 60% of patients. Advanced age, history of atrial fibrillation (AF), heart failure, peripheral arterial disease and chronic obstructive pulmonary disease are predictors of POAF. The pathogenesis of AF seems to be multifactorial, and includes electrical and structural remodeling as well as inflammation (a systemic response caused by cardiopulmonary bypass and cardiotomy). Numerous pharmacologic agents can decrease the incidence of POAF. It is also necessary to evaluate an agent&#x27;s ability to decrease stroke, mortality, length of stay and hospital costs. Currently, the use of beta-blockers with adjunctive amiodarone has been shown to reduce POAF and several of its complications. Two therapeutic choices exist in patients with POAF: rate control and rhythm control. The decision which is more important to target should be based on the symptoms of the individual patient. Unlike in patients with chronic AF, POAF is generally transient, and the risks of anticoagulation may outweigh the benefits. Surgical ablation techniques and ablation devices have progressed considerably. This made the procedures quicker and simpler, and therefore feasible in virtually all clinical contexts. In turn, this has raised the issue of post-ablation arrhythmias. Although relapsing AF is generally addressed conservatively, it may require ablation, frequently transseptal. Further research is needed to identify the predictors of POAF and the most effective pharmacological and invasive methods for the prevention and treatment of POAF.</p>        <p>PMID: 19538179 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('</ul>');
document.write('</div>');
document.write('<div class=\"rss_feed\">');
document.write('<div class=\"rss_feed_title\">pubmed: "atrial fibrillation...</div>');
document.write('<ul class=\"rss_item_list\">');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20379640&#x26;dopt=Abstract\">Prevalence of electrocardiographic findings in elderly individuals: the Sao Paulo aging &#x26; health study.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www.scielo.br/scielo.php?script=sci_arttext&#x26;amp;pid=S0066-782X2009001200015&#x26;amp;lng=en&#x26;amp;nrm=iso&#x26;amp;tlng=en"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.scielo.br-img-scielo_en.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20379640">Related Articles</a></td></tr></table>        <p><b>Prevalence of electrocardiographic findings in elderly individuals: the Sao Paulo aging &#x26;amp; health study.</b></p>        <p>Arq Bras Cardiol. 2009 Dec;93(6):602-7, 651-6</p>        <p>Authors:  Kawabata-Yoshihara LA, Bense&#xC3;&#xB1;or IM, Kawabata VS, Menezes PR, Scazufca M, Lotufo PA</p>        <p>BACKGROUND: The determination of the prevalence of electrocardiographic alterations in the older age strata of the Brazilian population represents important information with clinical and epidemiological purpose. OBJECTIVE: To verify the prevalence rates of atrial fibrillation, enlarged Q/QS waves (Minnesota code 1.1-1.2) and left bundle branch block. METHODS: In a population-based study, 1,524 participants (921 women and 603 men) aged &#x26;gt; 65 years and living in Sao Paulo, Brazil, were submitted to electrocardiographic assessment at rest as well as anthropometric and blood pressure measurements, in addition to fasting blood collection for the measurement of glycemia, total cholesterol and fractions. RESULTS: The age-adjusted prevalence for enlarged Q/QS waves was 12.1% (men, 17.2%; women, 9.6%), 2.4% for atrial fibrillation (men 3.9%; women, 2.0%); and 3.1% for left bundle branch block (men, 3.1%; women, 3.8%). For atrial fibrillation (both sexes), enlarged Q/QS waves (men) and left bundle branch block (women) there was an increase in frequency according to the age stratum. After adjusted for age, sex, diabetes mellitus and dyslipidemia, the odds ratio among the frequencies of enlarged Q/QS waves; arterial hypertension was 2.4 (95% CI: 1.4 -3.9) being 5.1 (95%CI: 1.8 -14.4) for women and 1.7 (95%CI: 0.95-3.1] for men. CONCLUSION: The comparison of these data with those from other studies showed a high prevalence of enlarged Q/QS waves in this population, with a direct association with the prevalence of arterial hypertension.</p>        <p>PMID: 20379640 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19538179&#x26;dopt=Abstract\">Postoperative atrial fibrillation - what do we really know?</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19538179">Related Articles</a></td></tr></table>        <p><b>Postoperative atrial fibrillation - what do we really know?</b></p>        <p>Curr Vasc Pharmacol. 2010 Jul;8(4):553-72</p>        <p>Authors:  Banach M, Kourliouros A, Reinhart KM, Benussi S, Mikhailidis DP, Jahangiri M, Baker WL, Galanti A, Rysz J, Camm JA, White CM, Alfieri O</p>        <p>Postoperative atrial fibrillation (POAF) is a common complication following cardiac surgery, occurring in 20% to 60% of patients. Advanced age, history of atrial fibrillation (AF), heart failure, peripheral arterial disease and chronic obstructive pulmonary disease are predictors of POAF. The pathogenesis of AF seems to be multifactorial, and includes electrical and structural remodeling as well as inflammation (a systemic response caused by cardiopulmonary bypass and cardiotomy). Numerous pharmacologic agents can decrease the incidence of POAF. It is also necessary to evaluate an agent&#x27;s ability to decrease stroke, mortality, length of stay and hospital costs. Currently, the use of beta-blockers with adjunctive amiodarone has been shown to reduce POAF and several of its complications. Two therapeutic choices exist in patients with POAF: rate control and rhythm control. The decision which is more important to target should be based on the symptoms of the individual patient. Unlike in patients with chronic AF, POAF is generally transient, and the risks of anticoagulation may outweigh the benefits. Surgical ablation techniques and ablation devices have progressed considerably. This made the procedures quicker and simpler, and therefore feasible in virtually all clinical contexts. In turn, this has raised the issue of post-ablation arrhythmias. Although relapsing AF is generally addressed conservatively, it may require ablation, frequently transseptal. Further research is needed to identify the predictors of POAF and the most effective pharmacological and invasive methods for the prevention and treatment of POAF.</p>        <p>PMID: 19538179 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('</ul>');
document.write('</div>');
document.write('<div class=\"rss_feed\">');
document.write('<div class=\"rss_feed_title\">pubmed: "atrial fibrillation...</div>');
document.write('<ul class=\"rss_item_list\">');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20379640&#x26;dopt=Abstract\">Prevalence of electrocardiographic findings in elderly individuals: the Sao Paulo aging &#x26; health study.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www.scielo.br/scielo.php?script=sci_arttext&#x26;amp;pid=S0066-782X2009001200015&#x26;amp;lng=en&#x26;amp;nrm=iso&#x26;amp;tlng=en"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.scielo.br-img-scielo_en.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20379640">Related Articles</a></td></tr></table>        <p><b>Prevalence of electrocardiographic findings in elderly individuals: the Sao Paulo aging &#x26;amp; health study.</b></p>        <p>Arq Bras Cardiol. 2009 Dec;93(6):602-7, 651-6</p>        <p>Authors:  Kawabata-Yoshihara LA, Bense&#xC3;&#xB1;or IM, Kawabata VS, Menezes PR, Scazufca M, Lotufo PA</p>        <p>BACKGROUND: The determination of the prevalence of electrocardiographic alterations in the older age strata of the Brazilian population represents important information with clinical and epidemiological purpose. OBJECTIVE: To verify the prevalence rates of atrial fibrillation, enlarged Q/QS waves (Minnesota code 1.1-1.2) and left bundle branch block. METHODS: In a population-based study, 1,524 participants (921 women and 603 men) aged &#x26;gt; 65 years and living in Sao Paulo, Brazil, were submitted to electrocardiographic assessment at rest as well as anthropometric and blood pressure measurements, in addition to fasting blood collection for the measurement of glycemia, total cholesterol and fractions. RESULTS: The age-adjusted prevalence for enlarged Q/QS waves was 12.1% (men, 17.2%; women, 9.6%), 2.4% for atrial fibrillation (men 3.9%; women, 2.0%); and 3.1% for left bundle branch block (men, 3.1%; women, 3.8%). For atrial fibrillation (both sexes), enlarged Q/QS waves (men) and left bundle branch block (women) there was an increase in frequency according to the age stratum. After adjusted for age, sex, diabetes mellitus and dyslipidemia, the odds ratio among the frequencies of enlarged Q/QS waves; arterial hypertension was 2.4 (95% CI: 1.4 -3.9) being 5.1 (95%CI: 1.8 -14.4) for women and 1.7 (95%CI: 0.95-3.1] for men. CONCLUSION: The comparison of these data with those from other studies showed a high prevalence of enlarged Q/QS waves in this population, with a direct association with the prevalence of arterial hypertension.</p>        <p>PMID: 20379640 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19538179&#x26;dopt=Abstract\">Postoperative atrial fibrillation - what do we really know?</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19538179">Related Articles</a></td></tr></table>        <p><b>Postoperative atrial fibrillation - what do we really know?</b></p>        <p>Curr Vasc Pharmacol. 2010 Jul;8(4):553-72</p>        <p>Authors:  Banach M, Kourliouros A, Reinhart KM, Benussi S, Mikhailidis DP, Jahangiri M, Baker WL, Galanti A, Rysz J, Camm JA, White CM, Alfieri O</p>        <p>Postoperative atrial fibrillation (POAF) is a common complication following cardiac surgery, occurring in 20% to 60% of patients. Advanced age, history of atrial fibrillation (AF), heart failure, peripheral arterial disease and chronic obstructive pulmonary disease are predictors of POAF. The pathogenesis of AF seems to be multifactorial, and includes electrical and structural remodeling as well as inflammation (a systemic response caused by cardiopulmonary bypass and cardiotomy). Numerous pharmacologic agents can decrease the incidence of POAF. It is also necessary to evaluate an agent&#x27;s ability to decrease stroke, mortality, length of stay and hospital costs. Currently, the use of beta-blockers with adjunctive amiodarone has been shown to reduce POAF and several of its complications. Two therapeutic choices exist in patients with POAF: rate control and rhythm control. The decision which is more important to target should be based on the symptoms of the individual patient. Unlike in patients with chronic AF, POAF is generally transient, and the risks of anticoagulation may outweigh the benefits. Surgical ablation techniques and ablation devices have progressed considerably. This made the procedures quicker and simpler, and therefore feasible in virtually all clinical contexts. In turn, this has raised the issue of post-ablation arrhythmias. Although relapsing AF is generally addressed conservatively, it may require ablation, frequently transseptal. Further research is needed to identify the predictors of POAF and the most effective pharmacological and invasive methods for the prevention and treatment of POAF.</p>        <p>PMID: 19538179 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('</ul>');
document.write('</div>');
document.write('<div class=\"rss_feed\">');
document.write('<div class=\"rss_feed_title\">pubmed: "atrial fibrillation...</div>');
document.write('<ul class=\"rss_item_list\">');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20379640&#x26;dopt=Abstract\">Prevalence of electrocardiographic findings in elderly individuals: the Sao Paulo aging &#x26; health study.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www.scielo.br/scielo.php?script=sci_arttext&#x26;amp;pid=S0066-782X2009001200015&#x26;amp;lng=en&#x26;amp;nrm=iso&#x26;amp;tlng=en"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.scielo.br-img-scielo_en.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20379640">Related Articles</a></td></tr></table>        <p><b>Prevalence of electrocardiographic findings in elderly individuals: the Sao Paulo aging &#x26;amp; health study.</b></p>        <p>Arq Bras Cardiol. 2009 Dec;93(6):602-7, 651-6</p>        <p>Authors:  Kawabata-Yoshihara LA, Bense&#xC3;&#xB1;or IM, Kawabata VS, Menezes PR, Scazufca M, Lotufo PA</p>        <p>BACKGROUND: The determination of the prevalence of electrocardiographic alterations in the older age strata of the Brazilian population represents important information with clinical and epidemiological purpose. OBJECTIVE: To verify the prevalence rates of atrial fibrillation, enlarged Q/QS waves (Minnesota code 1.1-1.2) and left bundle branch block. METHODS: In a population-based study, 1,524 participants (921 women and 603 men) aged &#x26;gt; 65 years and living in Sao Paulo, Brazil, were submitted to electrocardiographic assessment at rest as well as anthropometric and blood pressure measurements, in addition to fasting blood collection for the measurement of glycemia, total cholesterol and fractions. RESULTS: The age-adjusted prevalence for enlarged Q/QS waves was 12.1% (men, 17.2%; women, 9.6%), 2.4% for atrial fibrillation (men 3.9%; women, 2.0%); and 3.1% for left bundle branch block (men, 3.1%; women, 3.8%). For atrial fibrillation (both sexes), enlarged Q/QS waves (men) and left bundle branch block (women) there was an increase in frequency according to the age stratum. After adjusted for age, sex, diabetes mellitus and dyslipidemia, the odds ratio among the frequencies of enlarged Q/QS waves; arterial hypertension was 2.4 (95% CI: 1.4 -3.9) being 5.1 (95%CI: 1.8 -14.4) for women and 1.7 (95%CI: 0.95-3.1] for men. CONCLUSION: The comparison of these data with those from other studies showed a high prevalence of enlarged Q/QS waves in this population, with a direct association with the prevalence of arterial hypertension.</p>        <p>PMID: 20379640 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19538179&#x26;dopt=Abstract\">Postoperative atrial fibrillation - what do we really know?</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19538179">Related Articles</a></td></tr></table>        <p><b>Postoperative atrial fibrillation - what do we really know?</b></p>        <p>Curr Vasc Pharmacol. 2010 Jul;8(4):553-72</p>        <p>Authors:  Banach M, Kourliouros A, Reinhart KM, Benussi S, Mikhailidis DP, Jahangiri M, Baker WL, Galanti A, Rysz J, Camm JA, White CM, Alfieri O</p>        <p>Postoperative atrial fibrillation (POAF) is a common complication following cardiac surgery, occurring in 20% to 60% of patients. Advanced age, history of atrial fibrillation (AF), heart failure, peripheral arterial disease and chronic obstructive pulmonary disease are predictors of POAF. The pathogenesis of AF seems to be multifactorial, and includes electrical and structural remodeling as well as inflammation (a systemic response caused by cardiopulmonary bypass and cardiotomy). Numerous pharmacologic agents can decrease the incidence of POAF. It is also necessary to evaluate an agent&#x27;s ability to decrease stroke, mortality, length of stay and hospital costs. Currently, the use of beta-blockers with adjunctive amiodarone has been shown to reduce POAF and several of its complications. Two therapeutic choices exist in patients with POAF: rate control and rhythm control. The decision which is more important to target should be based on the symptoms of the individual patient. Unlike in patients with chronic AF, POAF is generally transient, and the risks of anticoagulation may outweigh the benefits. Surgical ablation techniques and ablation devices have progressed considerably. This made the procedures quicker and simpler, and therefore feasible in virtually all clinical contexts. In turn, this has raised the issue of post-ablation arrhythmias. Although relapsing AF is generally addressed conservatively, it may require ablation, frequently transseptal. Further research is needed to identify the predictors of POAF and the most effective pharmacological and invasive methods for the prevention and treatment of POAF.</p>        <p>PMID: 19538179 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('</ul>');
document.write('</div>');
document.write('<div class=\"rss_feed\">');
document.write('<div class=\"rss_feed_title\">pubmed: "atrial fibrillation...</div>');
document.write('<ul class=\"rss_item_list\">');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20379640&#x26;dopt=Abstract\">Prevalence of electrocardiographic findings in elderly individuals: the Sao Paulo aging &#x26; health study.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www.scielo.br/scielo.php?script=sci_arttext&#x26;amp;pid=S0066-782X2009001200015&#x26;amp;lng=en&#x26;amp;nrm=iso&#x26;amp;tlng=en"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.scielo.br-img-scielo_en.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20379640">Related Articles</a></td></tr></table>        <p><b>Prevalence of electrocardiographic findings in elderly individuals: the Sao Paulo aging &#x26;amp; health study.</b></p>        <p>Arq Bras Cardiol. 2009 Dec;93(6):602-7, 651-6</p>        <p>Authors:  Kawabata-Yoshihara LA, Bense&#xC3;&#xB1;or IM, Kawabata VS, Menezes PR, Scazufca M, Lotufo PA</p>        <p>BACKGROUND: The determination of the prevalence of electrocardiographic alterations in the older age strata of the Brazilian population represents important information with clinical and epidemiological purpose. OBJECTIVE: To verify the prevalence rates of atrial fibrillation, enlarged Q/QS waves (Minnesota code 1.1-1.2) and left bundle branch block. METHODS: In a population-based study, 1,524 participants (921 women and 603 men) aged &#x26;gt; 65 years and living in Sao Paulo, Brazil, were submitted to electrocardiographic assessment at rest as well as anthropometric and blood pressure measurements, in addition to fasting blood collection for the measurement of glycemia, total cholesterol and fractions. RESULTS: The age-adjusted prevalence for enlarged Q/QS waves was 12.1% (men, 17.2%; women, 9.6%), 2.4% for atrial fibrillation (men 3.9%; women, 2.0%); and 3.1% for left bundle branch block (men, 3.1%; women, 3.8%). For atrial fibrillation (both sexes), enlarged Q/QS waves (men) and left bundle branch block (women) there was an increase in frequency according to the age stratum. After adjusted for age, sex, diabetes mellitus and dyslipidemia, the odds ratio among the frequencies of enlarged Q/QS waves; arterial hypertension was 2.4 (95% CI: 1.4 -3.9) being 5.1 (95%CI: 1.8 -14.4) for women and 1.7 (95%CI: 0.95-3.1] for men. CONCLUSION: The comparison of these data with those from other studies showed a high prevalence of enlarged Q/QS waves in this population, with a direct association with the prevalence of arterial hypertension.</p>        <p>PMID: 20379640 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19538179&#x26;dopt=Abstract\">Postoperative atrial fibrillation - what do we really know?</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19538179">Related Articles</a></td></tr></table>        <p><b>Postoperative atrial fibrillation - what do we really know?</b></p>        <p>Curr Vasc Pharmacol. 2010 Jul;8(4):553-72</p>        <p>Authors:  Banach M, Kourliouros A, Reinhart KM, Benussi S, Mikhailidis DP, Jahangiri M, Baker WL, Galanti A, Rysz J, Camm JA, White CM, Alfieri O</p>        <p>Postoperative atrial fibrillation (POAF) is a common complication following cardiac surgery, occurring in 20% to 60% of patients. Advanced age, history of atrial fibrillation (AF), heart failure, peripheral arterial disease and chronic obstructive pulmonary disease are predictors of POAF. The pathogenesis of AF seems to be multifactorial, and includes electrical and structural remodeling as well as inflammation (a systemic response caused by cardiopulmonary bypass and cardiotomy). Numerous pharmacologic agents can decrease the incidence of POAF. It is also necessary to evaluate an agent&#x27;s ability to decrease stroke, mortality, length of stay and hospital costs. Currently, the use of beta-blockers with adjunctive amiodarone has been shown to reduce POAF and several of its complications. Two therapeutic choices exist in patients with POAF: rate control and rhythm control. The decision which is more important to target should be based on the symptoms of the individual patient. Unlike in patients with chronic AF, POAF is generally transient, and the risks of anticoagulation may outweigh the benefits. Surgical ablation techniques and ablation devices have progressed considerably. This made the procedures quicker and simpler, and therefore feasible in virtually all clinical contexts. In turn, this has raised the issue of post-ablation arrhythmias. Although relapsing AF is generally addressed conservatively, it may require ablation, frequently transseptal. Further research is needed to identify the predictors of POAF and the most effective pharmacological and invasive methods for the prevention and treatment of POAF.</p>        <p>PMID: 19538179 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('</ul>');
document.write('</div>');
document.write('<div class=\"rss_feed\">');
document.write('<div class=\"rss_feed_title\">pubmed: "atrial fibrillation...</div>');
document.write('<ul class=\"rss_item_list\">');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20379640&#x26;dopt=Abstract\">Prevalence of electrocardiographic findings in elderly individuals: the Sao Paulo aging &#x26; health study.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www.scielo.br/scielo.php?script=sci_arttext&#x26;amp;pid=S0066-782X2009001200015&#x26;amp;lng=en&#x26;amp;nrm=iso&#x26;amp;tlng=en"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.scielo.br-img-scielo_en.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20379640">Related Articles</a></td></tr></table>        <p><b>Prevalence of electrocardiographic findings in elderly individuals: the Sao Paulo aging &#x26;amp; health study.</b></p>        <p>Arq Bras Cardiol. 2009 Dec;93(6):602-7, 651-6</p>        <p>Authors:  Kawabata-Yoshihara LA, Bense&#xC3;&#xB1;or IM, Kawabata VS, Menezes PR, Scazufca M, Lotufo PA</p>        <p>BACKGROUND: The determination of the prevalence of electrocardiographic alterations in the older age strata of the Brazilian population represents important information with clinical and epidemiological purpose. OBJECTIVE: To verify the prevalence rates of atrial fibrillation, enlarged Q/QS waves (Minnesota code 1.1-1.2) and left bundle branch block. METHODS: In a population-based study, 1,524 participants (921 women and 603 men) aged &#x26;gt; 65 years and living in Sao Paulo, Brazil, were submitted to electrocardiographic assessment at rest as well as anthropometric and blood pressure measurements, in addition to fasting blood collection for the measurement of glycemia, total cholesterol and fractions. RESULTS: The age-adjusted prevalence for enlarged Q/QS waves was 12.1% (men, 17.2%; women, 9.6%), 2.4% for atrial fibrillation (men 3.9%; women, 2.0%); and 3.1% for left bundle branch block (men, 3.1%; women, 3.8%). For atrial fibrillation (both sexes), enlarged Q/QS waves (men) and left bundle branch block (women) there was an increase in frequency according to the age stratum. After adjusted for age, sex, diabetes mellitus and dyslipidemia, the odds ratio among the frequencies of enlarged Q/QS waves; arterial hypertension was 2.4 (95% CI: 1.4 -3.9) being 5.1 (95%CI: 1.8 -14.4) for women and 1.7 (95%CI: 0.95-3.1] for men. CONCLUSION: The comparison of these data with those from other studies showed a high prevalence of enlarged Q/QS waves in this population, with a direct association with the prevalence of arterial hypertension.</p>        <p>PMID: 20379640 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19538179&#x26;dopt=Abstract\">Postoperative atrial fibrillation - what do we really know?</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19538179">Related Articles</a></td></tr></table>        <p><b>Postoperative atrial fibrillation - what do we really know?</b></p>        <p>Curr Vasc Pharmacol. 2010 Jul;8(4):553-72</p>        <p>Authors:  Banach M, Kourliouros A, Reinhart KM, Benussi S, Mikhailidis DP, Jahangiri M, Baker WL, Galanti A, Rysz J, Camm JA, White CM, Alfieri O</p>        <p>Postoperative atrial fibrillation (POAF) is a common complication following cardiac surgery, occurring in 20% to 60% of patients. Advanced age, history of atrial fibrillation (AF), heart failure, peripheral arterial disease and chronic obstructive pulmonary disease are predictors of POAF. The pathogenesis of AF seems to be multifactorial, and includes electrical and structural remodeling as well as inflammation (a systemic response caused by cardiopulmonary bypass and cardiotomy). Numerous pharmacologic agents can decrease the incidence of POAF. It is also necessary to evaluate an agent&#x27;s ability to decrease stroke, mortality, length of stay and hospital costs. Currently, the use of beta-blockers with adjunctive amiodarone has been shown to reduce POAF and several of its complications. Two therapeutic choices exist in patients with POAF: rate control and rhythm control. The decision which is more important to target should be based on the symptoms of the individual patient. Unlike in patients with chronic AF, POAF is generally transient, and the risks of anticoagulation may outweigh the benefits. Surgical ablation techniques and ablation devices have progressed considerably. This made the procedures quicker and simpler, and therefore feasible in virtually all clinical contexts. In turn, this has raised the issue of post-ablation arrhythmias. Although relapsing AF is generally addressed conservatively, it may require ablation, frequently transseptal. Further research is needed to identify the predictors of POAF and the most effective pharmacological and invasive methods for the prevention and treatment of POAF.</p>        <p>PMID: 19538179 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('</ul>');
document.write('</div>');
document.write('<div class=\"rss_feed\">');
document.write('<div class=\"rss_feed_title\">pubmed: "atrial fibrillation...</div>');
document.write('<ul class=\"rss_item_list\">');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20379640&#x26;dopt=Abstract\">Prevalence of electrocardiographic findings in elderly individuals: the Sao Paulo aging &#x26; health study.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www.scielo.br/scielo.php?script=sci_arttext&#x26;amp;pid=S0066-782X2009001200015&#x26;amp;lng=en&#x26;amp;nrm=iso&#x26;amp;tlng=en"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.scielo.br-img-scielo_en.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20379640">Related Articles</a></td></tr></table>        <p><b>Prevalence of electrocardiographic findings in elderly individuals: the Sao Paulo aging &#x26;amp; health study.</b></p>        <p>Arq Bras Cardiol. 2009 Dec;93(6):602-7, 651-6</p>        <p>Authors:  Kawabata-Yoshihara LA, Bense&#xC3;&#xB1;or IM, Kawabata VS, Menezes PR, Scazufca M, Lotufo PA</p>        <p>BACKGROUND: The determination of the prevalence of electrocardiographic alterations in the older age strata of the Brazilian population represents important information with clinical and epidemiological purpose. OBJECTIVE: To verify the prevalence rates of atrial fibrillation, enlarged Q/QS waves (Minnesota code 1.1-1.2) and left bundle branch block. METHODS: In a population-based study, 1,524 participants (921 women and 603 men) aged &#x26;gt; 65 years and living in Sao Paulo, Brazil, were submitted to electrocardiographic assessment at rest as well as anthropometric and blood pressure measurements, in addition to fasting blood collection for the measurement of glycemia, total cholesterol and fractions. RESULTS: The age-adjusted prevalence for enlarged Q/QS waves was 12.1% (men, 17.2%; women, 9.6%), 2.4% for atrial fibrillation (men 3.9%; women, 2.0%); and 3.1% for left bundle branch block (men, 3.1%; women, 3.8%). For atrial fibrillation (both sexes), enlarged Q/QS waves (men) and left bundle branch block (women) there was an increase in frequency according to the age stratum. After adjusted for age, sex, diabetes mellitus and dyslipidemia, the odds ratio among the frequencies of enlarged Q/QS waves; arterial hypertension was 2.4 (95% CI: 1.4 -3.9) being 5.1 (95%CI: 1.8 -14.4) for women and 1.7 (95%CI: 0.95-3.1] for men. CONCLUSION: The comparison of these data with those from other studies showed a high prevalence of enlarged Q/QS waves in this population, with a direct association with the prevalence of arterial hypertension.</p>        <p>PMID: 20379640 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19538179&#x26;dopt=Abstract\">Postoperative atrial fibrillation - what do we really know?</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19538179">Related Articles</a></td></tr></table>        <p><b>Postoperative atrial fibrillation - what do we really know?</b></p>        <p>Curr Vasc Pharmacol. 2010 Jul;8(4):553-72</p>        <p>Authors:  Banach M, Kourliouros A, Reinhart KM, Benussi S, Mikhailidis DP, Jahangiri M, Baker WL, Galanti A, Rysz J, Camm JA, White CM, Alfieri O</p>        <p>Postoperative atrial fibrillation (POAF) is a common complication following cardiac surgery, occurring in 20% to 60% of patients. Advanced age, history of atrial fibrillation (AF), heart failure, peripheral arterial disease and chronic obstructive pulmonary disease are predictors of POAF. The pathogenesis of AF seems to be multifactorial, and includes electrical and structural remodeling as well as inflammation (a systemic response caused by cardiopulmonary bypass and cardiotomy). Numerous pharmacologic agents can decrease the incidence of POAF. It is also necessary to evaluate an agent&#x27;s ability to decrease stroke, mortality, length of stay and hospital costs. Currently, the use of beta-blockers with adjunctive amiodarone has been shown to reduce POAF and several of its complications. Two therapeutic choices exist in patients with POAF: rate control and rhythm control. The decision which is more important to target should be based on the symptoms of the individual patient. Unlike in patients with chronic AF, POAF is generally transient, and the risks of anticoagulation may outweigh the benefits. Surgical ablation techniques and ablation devices have progressed considerably. This made the procedures quicker and simpler, and therefore feasible in virtually all clinical contexts. In turn, this has raised the issue of post-ablation arrhythmias. Although relapsing AF is generally addressed conservatively, it may require ablation, frequently transseptal. Further research is needed to identify the predictors of POAF and the most effective pharmacological and invasive methods for the prevention and treatment of POAF.</p>        <p>PMID: 19538179 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('</ul>');
document.write('</div>');
document.write('<div class=\"rss_feed\">');
document.write('<div class=\"rss_feed_title\">pubmed: "atrial fibrillation...</div>');
document.write('<ul class=\"rss_item_list\">');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20379640&#x26;dopt=Abstract\">Prevalence of electrocardiographic findings in elderly individuals: the Sao Paulo aging &#x26; health study.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www.scielo.br/scielo.php?script=sci_arttext&#x26;amp;pid=S0066-782X2009001200015&#x26;amp;lng=en&#x26;amp;nrm=iso&#x26;amp;tlng=en"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.scielo.br-img-scielo_en.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20379640">Related Articles</a></td></tr></table>        <p><b>Prevalence of electrocardiographic findings in elderly individuals: the Sao Paulo aging &#x26;amp; health study.</b></p>        <p>Arq Bras Cardiol. 2009 Dec;93(6):602-7, 651-6</p>        <p>Authors:  Kawabata-Yoshihara LA, Bense&#xC3;&#xB1;or IM, Kawabata VS, Menezes PR, Scazufca M, Lotufo PA</p>        <p>BACKGROUND: The determination of the prevalence of electrocardiographic alterations in the older age strata of the Brazilian population represents important information with clinical and epidemiological purpose. OBJECTIVE: To verify the prevalence rates of atrial fibrillation, enlarged Q/QS waves (Minnesota code 1.1-1.2) and left bundle branch block. METHODS: In a population-based study, 1,524 participants (921 women and 603 men) aged &#x26;gt; 65 years and living in Sao Paulo, Brazil, were submitted to electrocardiographic assessment at rest as well as anthropometric and blood pressure measurements, in addition to fasting blood collection for the measurement of glycemia, total cholesterol and fractions. RESULTS: The age-adjusted prevalence for enlarged Q/QS waves was 12.1% (men, 17.2%; women, 9.6%), 2.4% for atrial fibrillation (men 3.9%; women, 2.0%); and 3.1% for left bundle branch block (men, 3.1%; women, 3.8%). For atrial fibrillation (both sexes), enlarged Q/QS waves (men) and left bundle branch block (women) there was an increase in frequency according to the age stratum. After adjusted for age, sex, diabetes mellitus and dyslipidemia, the odds ratio among the frequencies of enlarged Q/QS waves; arterial hypertension was 2.4 (95% CI: 1.4 -3.9) being 5.1 (95%CI: 1.8 -14.4) for women and 1.7 (95%CI: 0.95-3.1] for men. CONCLUSION: The comparison of these data with those from other studies showed a high prevalence of enlarged Q/QS waves in this population, with a direct association with the prevalence of arterial hypertension.</p>        <p>PMID: 20379640 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19538179&#x26;dopt=Abstract\">Postoperative atrial fibrillation - what do we really know?</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19538179">Related Articles</a></td></tr></table>        <p><b>Postoperative atrial fibrillation - what do we really know?</b></p>        <p>Curr Vasc Pharmacol. 2010 Jul;8(4):553-72</p>        <p>Authors:  Banach M, Kourliouros A, Reinhart KM, Benussi S, Mikhailidis DP, Jahangiri M, Baker WL, Galanti A, Rysz J, Camm JA, White CM, Alfieri O</p>        <p>Postoperative atrial fibrillation (POAF) is a common complication following cardiac surgery, occurring in 20% to 60% of patients. Advanced age, history of atrial fibrillation (AF), heart failure, peripheral arterial disease and chronic obstructive pulmonary disease are predictors of POAF. The pathogenesis of AF seems to be multifactorial, and includes electrical and structural remodeling as well as inflammation (a systemic response caused by cardiopulmonary bypass and cardiotomy). Numerous pharmacologic agents can decrease the incidence of POAF. It is also necessary to evaluate an agent&#x27;s ability to decrease stroke, mortality, length of stay and hospital costs. Currently, the use of beta-blockers with adjunctive amiodarone has been shown to reduce POAF and several of its complications. Two therapeutic choices exist in patients with POAF: rate control and rhythm control. The decision which is more important to target should be based on the symptoms of the individual patient. Unlike in patients with chronic AF, POAF is generally transient, and the risks of anticoagulation may outweigh the benefits. Surgical ablation techniques and ablation devices have progressed considerably. This made the procedures quicker and simpler, and therefore feasible in virtually all clinical contexts. In turn, this has raised the issue of post-ablation arrhythmias. Although relapsing AF is generally addressed conservatively, it may require ablation, frequently transseptal. Further research is needed to identify the predictors of POAF and the most effective pharmacological and invasive methods for the prevention and treatment of POAF.</p>        <p>PMID: 19538179 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('</ul>');
document.write('</div>');
document.write('<div class=\"rss_feed\">');
document.write('<div class=\"rss_feed_title\">pubmed: "atrial fibrillation...</div>');
document.write('<ul class=\"rss_item_list\">');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20379640&#x26;dopt=Abstract\">Prevalence of electrocardiographic findings in elderly individuals: the Sao Paulo aging &#x26; health study.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www.scielo.br/scielo.php?script=sci_arttext&#x26;amp;pid=S0066-782X2009001200015&#x26;amp;lng=en&#x26;amp;nrm=iso&#x26;amp;tlng=en"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.scielo.br-img-scielo_en.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20379640">Related Articles</a></td></tr></table>        <p><b>Prevalence of electrocardiographic findings in elderly individuals: the Sao Paulo aging &#x26;amp; health study.</b></p>        <p>Arq Bras Cardiol. 2009 Dec;93(6):602-7, 651-6</p>        <p>Authors:  Kawabata-Yoshihara LA, Bense&#xC3;&#xB1;or IM, Kawabata VS, Menezes PR, Scazufca M, Lotufo PA</p>        <p>BACKGROUND: The determination of the prevalence of electrocardiographic alterations in the older age strata of the Brazilian population represents important information with clinical and epidemiological purpose. OBJECTIVE: To verify the prevalence rates of atrial fibrillation, enlarged Q/QS waves (Minnesota code 1.1-1.2) and left bundle branch block. METHODS: In a population-based study, 1,524 participants (921 women and 603 men) aged &#x26;gt; 65 years and living in Sao Paulo, Brazil, were submitted to electrocardiographic assessment at rest as well as anthropometric and blood pressure measurements, in addition to fasting blood collection for the measurement of glycemia, total cholesterol and fractions. RESULTS: The age-adjusted prevalence for enlarged Q/QS waves was 12.1% (men, 17.2%; women, 9.6%), 2.4% for atrial fibrillation (men 3.9%; women, 2.0%); and 3.1% for left bundle branch block (men, 3.1%; women, 3.8%). For atrial fibrillation (both sexes), enlarged Q/QS waves (men) and left bundle branch block (women) there was an increase in frequency according to the age stratum. After adjusted for age, sex, diabetes mellitus and dyslipidemia, the odds ratio among the frequencies of enlarged Q/QS waves; arterial hypertension was 2.4 (95% CI: 1.4 -3.9) being 5.1 (95%CI: 1.8 -14.4) for women and 1.7 (95%CI: 0.95-3.1] for men. CONCLUSION: The comparison of these data with those from other studies showed a high prevalence of enlarged Q/QS waves in this population, with a direct association with the prevalence of arterial hypertension.</p>        <p>PMID: 20379640 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19538179&#x26;dopt=Abstract\">Postoperative atrial fibrillation - what do we really know?</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19538179">Related Articles</a></td></tr></table>        <p><b>Postoperative atrial fibrillation - what do we really know?</b></p>        <p>Curr Vasc Pharmacol. 2010 Jul;8(4):553-72</p>        <p>Authors:  Banach M, Kourliouros A, Reinhart KM, Benussi S, Mikhailidis DP, Jahangiri M, Baker WL, Galanti A, Rysz J, Camm JA, White CM, Alfieri O</p>        <p>Postoperative atrial fibrillation (POAF) is a common complication following cardiac surgery, occurring in 20% to 60% of patients. Advanced age, history of atrial fibrillation (AF), heart failure, peripheral arterial disease and chronic obstructive pulmonary disease are predictors of POAF. The pathogenesis of AF seems to be multifactorial, and includes electrical and structural remodeling as well as inflammation (a systemic response caused by cardiopulmonary bypass and cardiotomy). Numerous pharmacologic agents can decrease the incidence of POAF. It is also necessary to evaluate an agent&#x27;s ability to decrease stroke, mortality, length of stay and hospital costs. Currently, the use of beta-blockers with adjunctive amiodarone has been shown to reduce POAF and several of its complications. Two therapeutic choices exist in patients with POAF: rate control and rhythm control. The decision which is more important to target should be based on the symptoms of the individual patient. Unlike in patients with chronic AF, POAF is generally transient, and the risks of anticoagulation may outweigh the benefits. Surgical ablation techniques and ablation devices have progressed considerably. This made the procedures quicker and simpler, and therefore feasible in virtually all clinical contexts. In turn, this has raised the issue of post-ablation arrhythmias. Although relapsing AF is generally addressed conservatively, it may require ablation, frequently transseptal. Further research is needed to identify the predictors of POAF and the most effective pharmacological and invasive methods for the prevention and treatment of POAF.</p>        <p>PMID: 19538179 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('</ul>');
document.write('</div>');
document.write('<div class=\"rss_feed\">');
document.write('<div class=\"rss_feed_title\">pubmed: "atrial fibrillation...</div>');
document.write('<ul class=\"rss_item_list\">');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20379640&#x26;dopt=Abstract\">Prevalence of electrocardiographic findings in elderly individuals: the Sao Paulo aging &#x26; health study.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www.scielo.br/scielo.php?script=sci_arttext&#x26;amp;pid=S0066-782X2009001200015&#x26;amp;lng=en&#x26;amp;nrm=iso&#x26;amp;tlng=en"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.scielo.br-img-scielo_en.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20379640">Related Articles</a></td></tr></table>        <p><b>Prevalence of electrocardiographic findings in elderly individuals: the Sao Paulo aging &#x26;amp; health study.</b></p>        <p>Arq Bras Cardiol. 2009 Dec;93(6):602-7, 651-6</p>        <p>Authors:  Kawabata-Yoshihara LA, Bense&#xC3;&#xB1;or IM, Kawabata VS, Menezes PR, Scazufca M, Lotufo PA</p>        <p>BACKGROUND: The determination of the prevalence of electrocardiographic alterations in the older age strata of the Brazilian population represents important information with clinical and epidemiological purpose. OBJECTIVE: To verify the prevalence rates of atrial fibrillation, enlarged Q/QS waves (Minnesota code 1.1-1.2) and left bundle branch block. METHODS: In a population-based study, 1,524 participants (921 women and 603 men) aged &#x26;gt; 65 years and living in Sao Paulo, Brazil, were submitted to electrocardiographic assessment at rest as well as anthropometric and blood pressure measurements, in addition to fasting blood collection for the measurement of glycemia, total cholesterol and fractions. RESULTS: The age-adjusted prevalence for enlarged Q/QS waves was 12.1% (men, 17.2%; women, 9.6%), 2.4% for atrial fibrillation (men 3.9%; women, 2.0%); and 3.1% for left bundle branch block (men, 3.1%; women, 3.8%). For atrial fibrillation (both sexes), enlarged Q/QS waves (men) and left bundle branch block (women) there was an increase in frequency according to the age stratum. After adjusted for age, sex, diabetes mellitus and dyslipidemia, the odds ratio among the frequencies of enlarged Q/QS waves; arterial hypertension was 2.4 (95% CI: 1.4 -3.9) being 5.1 (95%CI: 1.8 -14.4) for women and 1.7 (95%CI: 0.95-3.1] for men. CONCLUSION: The comparison of these data with those from other studies showed a high prevalence of enlarged Q/QS waves in this population, with a direct association with the prevalence of arterial hypertension.</p>        <p>PMID: 20379640 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19538179&#x26;dopt=Abstract\">Postoperative atrial fibrillation - what do we really know?</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19538179">Related Articles</a></td></tr></table>        <p><b>Postoperative atrial fibrillation - what do we really know?</b></p>        <p>Curr Vasc Pharmacol. 2010 Jul;8(4):553-72</p>        <p>Authors:  Banach M, Kourliouros A, Reinhart KM, Benussi S, Mikhailidis DP, Jahangiri M, Baker WL, Galanti A, Rysz J, Camm JA, White CM, Alfieri O</p>        <p>Postoperative atrial fibrillation (POAF) is a common complication following cardiac surgery, occurring in 20% to 60% of patients. Advanced age, history of atrial fibrillation (AF), heart failure, peripheral arterial disease and chronic obstructive pulmonary disease are predictors of POAF. The pathogenesis of AF seems to be multifactorial, and includes electrical and structural remodeling as well as inflammation (a systemic response caused by cardiopulmonary bypass and cardiotomy). Numerous pharmacologic agents can decrease the incidence of POAF. It is also necessary to evaluate an agent&#x27;s ability to decrease stroke, mortality, length of stay and hospital costs. Currently, the use of beta-blockers with adjunctive amiodarone has been shown to reduce POAF and several of its complications. Two therapeutic choices exist in patients with POAF: rate control and rhythm control. The decision which is more important to target should be based on the symptoms of the individual patient. Unlike in patients with chronic AF, POAF is generally transient, and the risks of anticoagulation may outweigh the benefits. Surgical ablation techniques and ablation devices have progressed considerably. This made the procedures quicker and simpler, and therefore feasible in virtually all clinical contexts. In turn, this has raised the issue of post-ablation arrhythmias. Although relapsing AF is generally addressed conservatively, it may require ablation, frequently transseptal. Further research is needed to identify the predictors of POAF and the most effective pharmacological and invasive methods for the prevention and treatment of POAF.</p>        <p>PMID: 19538179 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('</ul>');
document.write('</div>');
document.write('<div class=\"rss_feed\">');
document.write('<div class=\"rss_feed_title\">pubmed: "atrial fibrillation...</div>');
document.write('<ul class=\"rss_item_list\">');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20379640&#x26;dopt=Abstract\">Prevalence of electrocardiographic findings in elderly individuals: the Sao Paulo aging &#x26; health study.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www.scielo.br/scielo.php?script=sci_arttext&#x26;amp;pid=S0066-782X2009001200015&#x26;amp;lng=en&#x26;amp;nrm=iso&#x26;amp;tlng=en"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.scielo.br-img-scielo_en.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20379640">Related Articles</a></td></tr></table>        <p><b>Prevalence of electrocardiographic findings in elderly individuals: the Sao Paulo aging &#x26;amp; health study.</b></p>        <p>Arq Bras Cardiol. 2009 Dec;93(6):602-7, 651-6</p>        <p>Authors:  Kawabata-Yoshihara LA, Bense&#xC3;&#xB1;or IM, Kawabata VS, Menezes PR, Scazufca M, Lotufo PA</p>        <p>BACKGROUND: The determination of the prevalence of electrocardiographic alterations in the older age strata of the Brazilian population represents important information with clinical and epidemiological purpose. OBJECTIVE: To verify the prevalence rates of atrial fibrillation, enlarged Q/QS waves (Minnesota code 1.1-1.2) and left bundle branch block. METHODS: In a population-based study, 1,524 participants (921 women and 603 men) aged &#x26;gt; 65 years and living in Sao Paulo, Brazil, were submitted to electrocardiographic assessment at rest as well as anthropometric and blood pressure measurements, in addition to fasting blood collection for the measurement of glycemia, total cholesterol and fractions. RESULTS: The age-adjusted prevalence for enlarged Q/QS waves was 12.1% (men, 17.2%; women, 9.6%), 2.4% for atrial fibrillation (men 3.9%; women, 2.0%); and 3.1% for left bundle branch block (men, 3.1%; women, 3.8%). For atrial fibrillation (both sexes), enlarged Q/QS waves (men) and left bundle branch block (women) there was an increase in frequency according to the age stratum. After adjusted for age, sex, diabetes mellitus and dyslipidemia, the odds ratio among the frequencies of enlarged Q/QS waves; arterial hypertension was 2.4 (95% CI: 1.4 -3.9) being 5.1 (95%CI: 1.8 -14.4) for women and 1.7 (95%CI: 0.95-3.1] for men. CONCLUSION: The comparison of these data with those from other studies showed a high prevalence of enlarged Q/QS waves in this population, with a direct association with the prevalence of arterial hypertension.</p>        <p>PMID: 20379640 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19538179&#x26;dopt=Abstract\">Postoperative atrial fibrillation - what do we really know?</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19538179">Related Articles</a></td></tr></table>        <p><b>Postoperative atrial fibrillation - what do we really know?</b></p>        <p>Curr Vasc Pharmacol. 2010 Jul;8(4):553-72</p>        <p>Authors:  Banach M, Kourliouros A, Reinhart KM, Benussi S, Mikhailidis DP, Jahangiri M, Baker WL, Galanti A, Rysz J, Camm JA, White CM, Alfieri O</p>        <p>Postoperative atrial fibrillation (POAF) is a common complication following cardiac surgery, occurring in 20% to 60% of patients. Advanced age, history of atrial fibrillation (AF), heart failure, peripheral arterial disease and chronic obstructive pulmonary disease are predictors of POAF. The pathogenesis of AF seems to be multifactorial, and includes electrical and structural remodeling as well as inflammation (a systemic response caused by cardiopulmonary bypass and cardiotomy). Numerous pharmacologic agents can decrease the incidence of POAF. It is also necessary to evaluate an agent&#x27;s ability to decrease stroke, mortality, length of stay and hospital costs. Currently, the use of beta-blockers with adjunctive amiodarone has been shown to reduce POAF and several of its complications. Two therapeutic choices exist in patients with POAF: rate control and rhythm control. The decision which is more important to target should be based on the symptoms of the individual patient. Unlike in patients with chronic AF, POAF is generally transient, and the risks of anticoagulation may outweigh the benefits. Surgical ablation techniques and ablation devices have progressed considerably. This made the procedures quicker and simpler, and therefore feasible in virtually all clinical contexts. In turn, this has raised the issue of post-ablation arrhythmias. Although relapsing AF is generally addressed conservatively, it may require ablation, frequently transseptal. Further research is needed to identify the predictors of POAF and the most effective pharmacological and invasive methods for the prevention and treatment of POAF.</p>        <p>PMID: 19538179 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('</ul>');
document.write('</div>');
document.write('<div class=\"rss_feed\">');
document.write('<div class=\"rss_feed_title\">pubmed: "atrial fibrillation...</div>');
document.write('<ul class=\"rss_item_list\">');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20706307&#x26;dopt=Abstract\">[Magnetic navigation for ablation of cardiac arrhythmias]</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www.tidsskriftet.no/index.php?seks_id=1998565"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.tidsskriftet.no-filer-tidsskriftet_logo.jpg" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20706307">Related Articles</a></td></tr></table>        <p><b>[Magnetic navigation for ablation of cardiac arrhythmias]</b></p>        <p>Tidsskr Nor Laegeforen. 2010 Aug 12;130(15):1467-70</p>        <p>Authors:  Chen J, Hoff PI, Solheim E, Schuster P, Off MK, Ohm OJ</p>        <p>BACKGROUND: The first use of magnetic navigation for radiofrequency ablation of supraventricular tachycardias, was published in 2004. Subsequently, the method has been used for treatment of most types of tachyarrhythmias. This paper provides an overview of the method, with special emphasis on usefulness of a new remote-controlled magnetic navigation system. MATERIAL AND METHODS: The paper is based on our own scientific experience and literature identified through a non-systematic search in PubMed. RESULTS: The magnetic navigation system consists of two external electromagnets (to be placed on opposite sides of the patient), which guide an ablation catheter (with a small magnet at the tip of the catheter) to the target area in the heart. The accuracy of this procedure is higher than that with manual navigation. Personnel can be quickly trained to use remote magnetic navigation, but the procedure itself is time-consuming, particularly for patients with atrial fibrillation. The major advantage is a considerably lower radiation burden to both patient and operator, in some studies more than 50 %, and a corresponding reduction in physical strain on the operator. The incidence of procedure-related complications seems to be lower than that observed with use of manually operated ablation catheters. Work is ongoing to improve magnetic ablation catheters and methods that can simplify mapping procedures and improve efficacy of arrhythmia ablation. The basic cost for installing a complete magnetic navigation laboratory may be three times that of a conventional electrophysiological laboratory. INTERPRETATION: The new magnetic navigation system has proved to be applicable during ablation for a variety of tachyarrhythmias, but is still under development.</p>        <p>PMID: 20706307 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20682531&#x26;dopt=Abstract\">Catheter entrapment in a pulmonary vein: a unique complication of pulmonary vein isolation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www.chestjournal.org/cgi/pmidlookup?view=long&#x26;amp;pmid=20682531"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--highwire.stanford.edu-icons-externalservices-pubmed-standard-chest_final.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20682531">Related Articles</a></td></tr></table>        <p><b>Catheter entrapment in a pulmonary vein: a unique complication of pulmonary vein isolation.</b></p>        <p>Chest. 2010 Aug;138(2):422-5</p>        <p>Authors:  Monney P, Pascale P, Fromer M, Pruvot E</p>        <p>Ablation strategies for the treatment of atrial fibrillation (AF) are associated with several potential complications. During electro-anatomic mapping of the left atrium (LA) before ablation, the ablation catheter was entrapped in the right inferior pulmonary vein (RIPV). After multiple unsuccessful gentle tractions, stronger maneuvers with rotation of the catheter slowly allowed its retrieval. Examination of the catheter showed a thin, translucent membrane covering its tip, suggesting complete stripping of a vein branch. Occlusion of the superior branch of the RIPV was confirmed by LA angiogram. During the following days, no pericardial effusion was noted, but the patient complained of light chest pain and mild hemoptysis, spontaneously resolving within 48 h. This case shows that catheter entrapment and mechanical disruption of a PV branch can be a rare potential complication of AF ablation. In this case, the outcome was spontaneously favorable and symptoms only included transient mild hemoptysis.</p>        <p>PMID: 20682531 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20667341&#x26;dopt=Abstract\">Recurrent atrial arrhythmia after minimally invasive pulmonary vein isolation for atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0003-4975(10)00929-X"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20667341">Related Articles</a></td></tr></table>        <p><b>Recurrent atrial arrhythmia after minimally invasive pulmonary vein isolation for atrial fibrillation.</b></p>        <p>Ann Thorac Surg. 2010 Aug;90(2):510-5</p>        <p>Authors:  Zeng Y, Cui Y, Li Y, Liu X, Xu C, Han J, Meng X</p>        <p>BACKGROUND: Minimally invasive pulmonary vein isolation was developed as a treatment of lone atrial fibrillation. Until recently, electrophysiological studies in patients with recurrent arrhythmias had not been described. METHODS: One hundred thirty patients underwent mini-maze pulmonary vein isolation. We performed catheter ablation guided by CARTO mapping in 8 recurrent patients (mean 61.8 + or - 12.7 years old; male:female ratio, 5:3) 5.0 + or - 14 months after the original surgical procedure. RESULTS: Recurrent atrial fibrillation occurred in 4 patients, atrial tachycardia occurred in 1 patient, and atrial flutter was present in 3 patients. CARTO mapping revealed that in 3 atrial fibrillation patients, gaps in the lesion were present at the roof and the bottom of the pulmonary vein. One of these patients was also found to have microreentry around the base of the left atrial appendage. The fourth recurrent atrial fibrillation patient was found to have a gap in the pulmonary vein isolation ring. One patient with atrial tachycardia was documented to have ectopic focus between the left atrial appendage and left superior pulmonary vein. In the 3 patients with atrial flutter, it was found to be localized to the mitral valve annulus in 2 patients, and to the left atrial roof of the remaining patient. All 8 patients underwent ablation successfully. At the latest follow-up, all patients were free of arrhythmias and independent of antiarrhythmic drugs. CONCLUSIONS: Pulmonary vein conduction at the roof and the bottom of the pulmonary vein after pulmonary vein isolation is the dominant factor responsible for recurrent atrial tachyarrhythmia. Left atrial-related flutter is a common form of arrhythmia.</p>        <p>PMID: 20667341 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20667333&#x26;dopt=Abstract\">Invited commentary.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0003-4975(10)00642-9"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20667333">Related Articles</a></td></tr></table>        <p><b>Invited commentary.</b></p>        <p>Ann Thorac Surg. 2010 Aug;90(2):479-80</p>        <p>Authors:  Creswell LL</p>        <p></p>        <p>PMID: 20667333 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20667332&#x26;dopt=Abstract\">New-onset postoperative atrial fibrillation and long-term survival after aortic valve replacement surgery.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0003-4975(10)00494-7"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td></tr></table>        <p><b>New-onset postoperative atrial fibrillation and long-term survival after aortic valve replacement surgery.</b></p>        <p>Ann Thorac Surg. 2010 Aug;90(2):474-9</p>        <p>Authors:  Filardo G, Hamilton C, Hamman B, Hebeler RF, Adams J, Grayburn P</p>        <p>BACKGROUND: Atrial fibrillation (AF) is recognized as a common complication of open cardiac surgery, occurring in up to 65% of patients. The advancing age and increasing risk profile of patients receiving aortic valve replacement (AVR) surgery is expected to raise incidence of new-onset postoperative AF resulting in potentially higher risk of adverse outcomes. In the early postoperative course, new-onset post-AVR AF is considered relatively easy to treat and is believed to have little impact on patients&#x27; long-term outcome. However, the effect of new-onset post-AVR AF on long-term survival is unclear. METHODS: Survival was assessed in 1,039 consecutive patients without preoperative AF who underwent AVR with or without simultaneous coronary artery bypass graft at Baylor University Medical Center, Dallas, Texas between January 1, 1997 and December 31, 2006. RESULTS: Ten-year unadjusted survival was 50.8% for patients with new-onset postoperative AF and 59.4% for patients without. A propensity-adjusted model controlling for risk factors identified by the Society of Thoracic Surgeons and other clinical-nonclinical details was used to investigate the association between new-onset AF post-AVR and survival. After adjustment, new-onset AF post-AVR was significantly associated with increased risk of death (hazard ratio: 1.48; 95% confidence interval 1.12 to 1.96). CONCLUSIONS: This study provides evidence that new-onset post-AVR AF is significantly associated with increased long-term risk of mortality independent of the preoperative severity of disease. After controlling for a comprehensive array of risk factors associated with post-AVR adverse outcomes, risk of long-term mortality in patients who developed new-onset post-AVR AF was 48% higher than in patients without it.</p>        <p>PMID: 20667332 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20667327&#x26;dopt=Abstract\">Invited commentary.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0003-4975(10)00872-6"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20667327">Related Articles</a></td></tr></table>        <p><b>Invited commentary.</b></p>        <p>Ann Thorac Surg. 2010 Aug;90(2):449-50</p>        <p>Authors:  Albacker TB</p>        <p></p>        <p>PMID: 20667327 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20667326&#x26;dopt=Abstract\">The impact of new-onset postoperative atrial fibrillation on mortality after coronary artery bypass grafting.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0003-4975(10)00698-3"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td></tr></table>        <p><b>The impact of new-onset postoperative atrial fibrillation on mortality after coronary artery bypass grafting.</b></p>        <p>Ann Thorac Surg. 2010 Aug;90(2):443-9</p>        <p>Authors:  Bramer S, van Straten AH, Soliman Hamad MA, Berreklouw E, Martens EJ, Maessen JG</p>        <p>BACKGROUND: New-onset postoperative atrial fibrillation (POAF) is a frequent rhythm disturbance after coronary artery bypass grafting (CABG). This study investigated the independent effect of POAF on early and late mortality after isolated CABG. METHODS: Data of patients who consecutively underwent isolated CABG between January 2003 and December 2007 were prospectively collected. The analysis included 5098 patients with preoperative sinus rhythm and no history of atrial fibrillation. Logistic regression analysis for early mortality and Cox regression analysis for late mortality were performed. Propensity score matching was performed to eliminate the effect of confounders. RESULTS: Median follow-up was 2.5 years. POAF was documented in 1122 patients (22.0%). Early mortality was more frequent in POAF patients (3.1%) vs non-POAF patients (1.6%, p = 0.002), but multivariate logistic regression analysis could not identify POAF as an independent predictor of early mortality (p = 0.169). This outcome did not change after adjusting for quintiles of the propensity score of POAF (p = 0.100). Multivariate Cox proportional hazard analyses demonstrated POAF was an independent predictor of overall and late mortality with hazard ratios of 1.35 (p = 0.012 and p = 0.039, respectively). Analyses after propensity score matching showed that patients with POAF had similar hazard ratios of 1.36 for overall mortality and 1.34 for late mortality (p = 0.009 and p = 0.042, respectively). CONCLUSIONS: POAF is an independent predictor of overall and late mortality after isolated CABG but not of early mortality.</p>        <p>PMID: 20667326 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20667313&#x26;dopt=Abstract\">Risk factors for atrial fibrillation after lung cancer surgery: analysis of the Society of Thoracic Surgeons general thoracic surgery database.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0003-4975(10)00745-9"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20667313">Related Articles</a></td></tr></table>        <p><b>Risk factors for atrial fibrillation after lung cancer surgery: analysis of the Society of Thoracic Surgeons general thoracic surgery database.</b></p>        <p>Ann Thorac Surg. 2010 Aug;90(2):368-74</p>        <p>Authors:  Onaitis M, D&#x27;Amico T, Zhao Y, O&#x27;Brien S, Harpole D</p>        <p>BACKGROUND: Atrial fibrillation is responsible for significant morbidity after lung cancer surgery, and preoperative and perioperative risk factors are not well described. METHODS: The Society of Thoracic Surgeons (STS) database was queried for all lobectomy and pneumonectomy patients with a diagnosis of lung cancer. A multivariable logistic regression model was developed to predict the risk of atrial arrhythmia as a function of preoperative and perioperative factors. Generalized estimating equations methodology was used to account for correlation among observations from the same institution. Missing data were handled using the method of chained equations with 10 randomly imputed data sets. RESULTS: A total of 13,906 patients who underwent resection for lung cancer at participating institutions had complete information for postoperative atrial arrhythmia, of whom 1,755 (12.6%) experienced the outcome. Multivariable logistic analysis indentified increasing age, increasing extent of operation, male sex, nonblack race, and stage II or greater tumors as predictors of postoperative atrial fibrillation. CONCLUSIONS: Analysis of the STS database has identified five variables that predict postoperative atrial fibrillation. This predictive model may be useful to develop strategies for risk stratification, prophylaxis, and treatment.</p>        <p>PMID: 20667313 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20659953&#x26;dopt=Abstract\">Atrial fibrillation: Ablation of atrial fibrillation: for whom and how?</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://heart.bmj.com/cgi/pmidlookup?view=long&#x26;amp;pmid=20659953"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--highwire.stanford.edu-icons-externalservices-pubmed-custom-bmjjournals_final.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20659953">Related Articles</a></td></tr></table>        <p><b>Atrial fibrillation: Ablation of atrial fibrillation: for whom and how?</b></p>        <p>Heart. 2010 Aug;96(16):1325-30</p>        <p>Authors:  Kirchhof P, Eckardt L</p>        <p></p>        <p>PMID: 20659953 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20659943&#x26;dopt=Abstract\">Long-term outcome after catheter ablation for atrial fibrillation: safety, efficacy and impact on prognosis.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://heart.bmj.com/cgi/pmidlookup?view=long&#x26;amp;pmid=20659943"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--highwire.stanford.edu-icons-externalservices-pubmed-custom-bmjjournals_final.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20659943">Related Articles</a></td></tr></table>        <p><b>Long-term outcome after catheter ablation for atrial fibrillation: safety, efficacy and impact on prognosis.</b></p>        <p>Heart. 2010 Aug;96(16):1259-63</p>        <p>Authors:  Hunter RJ, Schilling RJ</p>        <p>Catheter ablation of atrial fibrillation (AF) continues to expand and evolve. Large registries like the worldwide survey have provided insight into methods, safety and efficacy of catheter ablation for AF in the short term, and how these are changing. Long-term follow-up data are also emerging answering important questions about safety and efficacy over subsequent years. A small number of studies have attempted to examine whether catheter ablation of AF impacts on hard end points such as stroke and death and hence improve prognosis. This article reviews the current literature providing insight into these rapidly changing areas.</p>        <p>PMID: 20659943 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20635592&#x26;dopt=Abstract\">Ashman phenomenon: an often unrecognized entity in daily clinical practice.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20635592">Related Articles</a></td></tr></table>        <p><b>Ashman phenomenon: an often unrecognized entity in daily clinical practice.</b></p>        <p>Acta Clin Croat. 2010 Mar;49(1):99-100</p>        <p>Authors:  Lakusi&#xC4;&#x87; N, Mahovi&#xC4;&#x87; D, Slivnjak V</p>        <p></p>        <p>PMID: 20635592 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20599309&#x26;dopt=Abstract\">Cardiovascular disease and CKD: core curriculum 2010.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0272-6386(10)00717-1"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20599309">Related Articles</a></td></tr></table>        <p><b>Cardiovascular disease and CKD: core curriculum 2010.</b></p>        <p>Am J Kidney Dis. 2010 Aug;56(2):399-417</p>        <p>Authors:  Shastri S, Sarnak MJ</p>        <p></p>        <p>PMID: 20599309 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20593568&#x26;dopt=Abstract\">A no-surgery fix for atrial fibrillation.  Catheter ablation can halt atrial fibrillation, but side effects and durability pose problems.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20593568">Related Articles</a></td></tr></table>        <p><b>A no-surgery fix for atrial fibrillation.  Catheter ablation can halt atrial fibrillation, but side effects and durability pose problems.</b></p>        <p>Harv Heart Lett. 2010 May;20(9):4-5</p>        <p>Authors: </p>        <p></p>        <p>PMID: 20593568 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20524718&#x26;dopt=Abstract\">Non-antiarrhythmic drugs to prevent atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://content.wkhealth.com/linkback/openurl?issn=1175-3277&#x26;amp;volume=10&#x26;amp;issue=3&#x26;amp;spage=165"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--adisonline.com-PublishingImages-wk-adis1.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20524718">Related Articles</a></td></tr></table>        <p><b>Non-antiarrhythmic drugs to prevent atrial fibrillation.</b></p>        <p>Am J Cardiovasc Drugs. 2010;10(3):165-73</p>        <p>Authors:  Moro C, Hern&#xC3;&#xA1;ndez-Madrid A, Mat&#xC3;&#xAD;a R</p>        <p>Atrial fibrillation (AF) is the most frequent arrhythmia found in clinical practice. The majority of patients with AF are still candidates for antiarrhythmic drug treatment, not only for acute reversion to sinus rhythm but also for long-term treatment to prevent recurrences of AF. Currently available antiarrhythmic drugs, however, are unable to provide complete efficacy in all patients, and present problematic risks of proarrhythmia. The progressively increasing prevalence of AF supports the need to develop improved therapeutic approaches for the clinical management of arrhythmia. Accordingly, new treatment techniques aimed at suppressing the origin of the arrhythmogenic foci have been developed in the last decade. However, ablative treatments are only available for selected patients. Because of these factors, and also because primary prevention of AF should be our goal, the introduction of non-antiarrhythmic agents that could prevent both new-onset AF and recurrences of AF may eventually improve patient outcomes and reduce the incidence of this epidemic disease. The potential clinical value of these non-antiarrhythmic options is currently under active investigation. There is now clinical and experimental evidence that many drugs may have beneficial effects in preventing AF through several possible mechanisms. Non-antiarrhythmic drugs, such as ACE inhibitors and angiotensin receptor blockers, HMG-CoA reductase inhibitors (statins), corticosteroids, and N-3 polyunsaturated fatty acids may have a positive effect in patients with AF or in preventing AF in patients at risk.</p>        <p>PMID: 20524718 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20498284&#x26;dopt=Abstract\">Imaging modalities for measurements of left atrial volume in patients with atrial fibrillation: what do we choose?</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://europace.oxfordjournals.org/cgi/pmidlookup?view=long&#x26;amp;pmid=20498284"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--highwire.stanford.edu-icons-externalservices-pubmed-custom-oxfordjournals_final.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20498284">Related Articles</a></td></tr></table>        <p><b>Imaging modalities for measurements of left atrial volume in patients with atrial fibrillation: what do we choose?</b></p>        <p>Europace. 2010 Jun;12(6):766-7</p>        <p>Authors:  de Groot NM, Schalij MJ</p>        <p></p>        <p>PMID: 20498284 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20491019&#x26;dopt=Abstract\">[Medical practice and patients with atrial fibrillation - results from Polish global registry AF]</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20491019">Related Articles</a></td></tr></table>        <p><b>[Medical practice and patients with atrial fibrillation - results from Polish global registry AF]</b></p>        <p>Kardiol Pol. 2010 May;68(5):555-6</p>        <p>Authors:  Raczak G</p>        <p></p>        <p>PMID: 20491019 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20491018&#x26;dopt=Abstract\">Baseline characteristics of patients from Poland enrolled in the global registry of patients with recently diagnosed atrial fibrillation (RecordAF).</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/></tr></table>        <p><b>Baseline characteristics of patients from Poland enrolled in the global registry of patients with recently diagnosed atrial fibrillation (RecordAF).</b></p>        <p>Kardiol Pol. 2010 May;68(5):546-54</p>        <p>Authors:  Opolski G, Kosior DA, Kurzelewski M, Skrzy&#xC5;&#x84;ska M, Zag&#xC3;&#xB3;rski A, Janion M, Muzolf M, Wlaz&#xC5;&#x82;owski R, Pankiewicz B, &#xC5;&#x81;oboz-Grudzie&#xC5;&#x84; K, Breithardt G,  </p>        <p>BACKGROUND: The RecordAF study is the first worldwide, prospective, observational survey on the management of patients with recently diagnosed atrial fibrillation (AF). AIM: This paper presents the baseline characteristics of the Polish patients enrolled in this registry. METHODS: The registry enrolled patients &#x26;gt; or = 18 years old with recently diagnosed AF (&#x26;lt; or = 12 months from diagnosis), eligible for rhythm or rate control strategy. The planned follow-up is 12 months. The aim of the registry is to prospectively assess the efficacy of treatment defined as (a) maintenance of sinus rhythm or (b) optimal rate control, as well as (c) the incidence of cardiovascular events. RESULTS: A total of 303 Polish patients were enrolled in 21 centres across Poland (mean age 63 +/- 12 years, M/F ratio 174/129). Hypertension was present in 71.5% of the study subjects, ischaemic heart disease in 18.9%, and diabetes in 12.3%. In 47 (15.6%) patients, no potential cause of AF could be established. Symptoms related to AF were reported by 89.1% of patients. Mean duration of AF history was 2.9 +/- 3.5 months. At the time of inclusion, 191 (63.0%) patients were in sinus rhythm, and 211 (69.6%) patients were assigned to rhythm control strategy. Rhythm control strategy was chosen more frequently in patients with a history of paroxysmal AF and those in sinus rhythm at inclusion. Rate control strategy was chosen more frequently in those with a history of persistent AF in the previous year or presenting with AF at inclusion. CONCLUSIONS: Analysis of the baseline characteristics of the Polish population of the RecordAF study indicates a high prevalence of co-morbidities among patients with AF. The choice of treatment strategy was associated with rhythm status at inclusion and AF pattern within the previous 12 months. The RecordAF study will provide prospective data on treatment decisions and treatment success of rhythm- or rate-control strategies in patients with AF treated by office- or hospital-based cardiologists.</p>        <p>PMID: 20491018 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20438307&#x26;dopt=Abstract\">In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://informahealthcare.com/doi/abs/10.3109/08037051.2010.481811"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--informahealthcare.com-userimages-ContentEditor-1258375244362-ihc-linkout.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20438307">Related Articles</a></td></tr></table>        <p><b>In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.</b></p>        <p>Blood Press. 2010 Jun;19(3):169-75</p>        <p>Authors:  Wachtell K, Gerdts E, Aurigemma GP, Boman K, Dahl&#xC3;&#xB6;f B, Nieminen MS, Olsen MH, Okin PM, Palmieri V, Rokkedal JE, Devereux RB</p>        <p>OBJECTIVE: It is unclear whether improvement of left atrial (LA) and ventricular (LV) structure results in reduction in new-onset atrial fibrillation (AF). The aim of the present study was to examine whether changes in-treatment LA diameter were related to changes in risk of new-onset AF. METHODS: We followed 939 hypertensive patients with electrocardiographic LV hypertrophy randomized to atenolol or losartan-based regimens in the LIFE Study for a mean of 4.8 years with echocardiograms at enrolment and annually during treatment. RESULTS: New-onset AF occurred in 46 patients (10.2/1000 patient-years of follow-up). At baseline, patients with new-onset AF were older, had higher systolic blood pressure and heart rate as well as higher prevalence of LA dilatation, but had similar prevalences of LV hypertrophy and mitral or aortic valve disease. In univariate Cox analysis baseline LA diameter (HR=4.67 per cm increase [95% CI 2.86-7.65], p&#x26;lt;0.001) and LV mass index (HR=1.11 per 10 g/m(2) increase [95% CI 1.02-1.22], p&#x26;lt;0.05) both predicted new-onset AF. In multivariate analysis, increased baseline LA diameter increased the risk of new-onset AF (HR=5.16 per cm [95% CI 2.85-9.35], p&#x26;lt;0.001) whereas reduction of in-treatment LA diameter reduced the risk (HR=0.21 per cm lower LA diameter during treatment [95% CI 0.14-0.32], p&#x26;lt;0.001) with adjustment for in-treatment LV mass in-treatment systolic blood pressure, age and Framingham risk score. CONCLUSION: LA diameter at baseline and during antihypertensive treatment were equally strong predictors of new-onset AF independent of the level of arterial pressure, LV mass and other covariates. Prevention of AF during antihypertensive treatment may be improved by antihypertensive therapy that reduces LA size in addition to controlling blood pressure.</p>        <p>PMID: 20438307 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20388635&#x26;dopt=Abstract\">Guidelines for antithrombotic therapy in atrial fibrillation: understanding the reasons for non-adherence and moving forwards with simplifying risk stratification for stroke and bleeding.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://europace.oxfordjournals.org/cgi/pmidlookup?view=long&#x26;amp;pmid=20388635"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--highwire.stanford.edu-icons-externalservices-pubmed-custom-oxfordjournals_final.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20388635">Related Articles</a></td></tr></table>        <p><b>Guidelines for antithrombotic therapy in atrial fibrillation: understanding the reasons for non-adherence and moving forwards with simplifying risk stratification for stroke and bleeding.</b></p>        <p>Europace. 2010 Jun;12(6):761-3</p>        <p>Authors:  Fauchier L, Lip GY</p>        <p></p>        <p>PMID: 20388635 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20359865&#x26;dopt=Abstract\">Low wall velocity of left atrial appendage measured by trans-thoracic echocardiography predicts thrombus formation caused by atrial appendage dysfunction.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0894-7317(10)00139-2"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20359865">Related Articles</a></td></tr></table>        <p><b>Low wall velocity of left atrial appendage measured by trans-thoracic echocardiography predicts thrombus formation caused by atrial appendage dysfunction.</b></p>        <p>J Am Soc Echocardiogr. 2010 May;23(5):545-552.e1</p>        <p>Authors:  Tamura H, Watanabe T, Hirono O, Nishiyama S, Sasaki S, Shishido T, Miyashita T, Miyamoto T, Nitobe J, Kayama T, Kubota I</p>        <p>BACKGROUND: Atrial fibrillation is associated with ischemic stroke because of thrombi that form within the left atrial appendage (LAA). The aim of this study was to develop a new parameter for LAA function that is easily performed using transthoracic echocardiography (TTE). METHODS: TTE and transesophageal echocardiography were performed in 106 patients with stroke. LAA wall motion velocity (TTE-LAWV) was measured using Doppler tissue imaging at the LAA tip. RESULTS: TTE-LAWV was significantly lower in patients with atrial fibrillation and LAA thrombus than in those with atrial fibrillation and no LAA thrombus and in sinus rhythm (7.5 +/- 1.9 vs 10.0 +/- 3.4 and 13.8 +/- 5.7 cm/s, respectively, P &#x26;lt; .05). TTE-LAWV was significantly correlated with LAA emptying flow velocity (R = 0.462, P &#x26;lt; .05). The multivariate logistic regression analysis showed that TTE-LAWV &#x26;lt; 8.7 cm/s was an independent predictor of LAA thrombus formation (odds ratio, 9.473; 95% confidence interval, 1.172-76.55; P &#x26;lt; .05). CONCLUSION: TTE-LAWV can noninvasively evaluate LAA dysfunction and assist in the detection of LAA thrombus.</p>        <p>PMID: 20359865 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20357014&#x26;dopt=Abstract\">Right mini-thoracotomy for left maze with transesophageal echo guidance.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://icvts.ctsnetjournals.org/cgi/pmidlookup?view=long&#x26;amp;pmid=20357014"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--highwire.stanford.edu-icons-externalservices-pubmed-standard-icvts_final_free.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20357014">Related Articles</a></td></tr></table>        <p><b>Right mini-thoracotomy for left maze with transesophageal echo guidance.</b></p>        <p>Interact Cardiovasc Thorac Surg. 2010 Jun;10(6):843-6</p>        <p>Authors:  Vanelli P, Lemma M, Antona C</p>        <p>Minimally invasive surgery (MIS) is widening with the development of new specialized instrumentation, allied with improved surgical experience and techniques, some of which have shown to be effective for the ablation of atrial fibrillation (AF). These developments enable us to achieve a so-called &#x27;ideal procedure&#x27;, epicardially on beating hearts, with less operative risk, high cure rates and rapid patient recovery. Epicor (St Jude Medical, Sunnyvale, CA, USA) low profile (LP) system is a device using high intensity focused ultrasound (HIFU). We describe the use of this technology for ablation of AF through MIS approach using transesophageal echocardiography (TEE) to pilot the ablation on mitral isthmus. Ten patients underwent monolateral small thoracotomy, through the 4th intercostal space. HIFU was carried out in all cases to create an epicardial box lesion of the pulmonary veins (PVs) and mitral isthmus. TEE was employed to guide the positioning of the ablation device on mitral isthmus, in all patients. There were no mortalities or major complications, including pacemaker implantation. One patient had postoperative atrial tachycardia and was cardioverted before hospital discharge. Three patients had a postoperative AF and were scheduled for cardioversion after three months, and one patient spontaneously revealed a normal sinus rhythm (SR). During the follow-up period, all patients recorded a normal SR. We consider Epicor LP system safe and effective for AF ablation through a single right minimal invasive approach.</p>        <p>PMID: 20357014 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20353962&#x26;dopt=Abstract\">Atrial autonomic innervation remodelling and atrial fibrillation inducibility after epicardial ganglionic plexi ablation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://europace.oxfordjournals.org/cgi/pmidlookup?view=long&#x26;amp;pmid=20353962"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--highwire.stanford.edu-icons-externalservices-pubmed-custom-oxfordjournals_final.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20353962">Related Articles</a></td></tr></table>        <p><b>Atrial autonomic innervation remodelling and atrial fibrillation inducibility after epicardial ganglionic plexi ablation.</b></p>        <p>Europace. 2010 Jun;12(6):805-10</p>        <p>Authors:  Zhao QY, Huang H, Zhang SD, Tang YH, Wang X, Zhang YG, Salim M, Okello E, Deng HP, Yu SB, Huang CX</p>        <p>AIMS: The effects of ganglionated plexi (GP) ablation on atrial fibrillation (AF) inducibility and atrial autonomic innervation remodelling have not been elucidated. METHODS AND RESULTS: Thirteen dogs were randomly divided into sham-operated group and GP ablation group. All animals underwent a right thoracotomy at the fourth intercostal space. Atrial fibrillation inducibility was assessed by burst rapid pacing at right atrium (RA). After anterior right GP and inferior right GP ablation, AF inducibility was assessed in the GP ablation group. The animals were allowed to recover for 8 weeks, after which, AF was measured again. The levels of atrial natriuretic peptide (ANP) in blood and atrial tissues were examined by radioimmunoassay. Immunocytochemical staining of cardiac nerves was performed in tissues from the dogs. Atrial fibrillation was induced easily in the GP ablation group after 8 weeks although AF was not observed in the sham-operated group, and after instant GP ablation. Compared with that in the sham-operated group, the levels of ANP in the blood and RA increased significantly 8 weeks after GP ablation (111.4 +/- 18.2 vs. 175.1 +/- 25.9; 184.9 +/- 36.3 vs. 299.1 +/- 32.5; P &#x26;lt; 0.05). In the GP ablation group, the density of growth-associated protein 43-positive, tyrosine hydroxylase-positive, and choline acetyltransferase-positive nerves in the RA was 821 +/- 752, 481 +/- 627, and 629 +/- 644 per mm(2), respectively, which was significantly (P &#x26;lt; 0.01) lower than the nerve density in sham-operated tissues (2590 +/- 841, 1752 +/- 605, and 3147 +/- 886 per mm(2), respectively). CONCLUSION: Atrial autonomic innervations remodelling may be the mechanism of induced AF after GP ablation.</p>        <p>PMID: 20353962 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20348143&#x26;dopt=Abstract\">The likelihood of decreasing strokes in atrial fibrillation patients by strict application of guidelines.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://europace.oxfordjournals.org/cgi/pmidlookup?view=long&#x26;amp;pmid=20348143"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--highwire.stanford.edu-icons-externalservices-pubmed-custom-oxfordjournals_final.gif" border="0"/></a> </td></tr></table>        <p><b>The likelihood of decreasing strokes in atrial fibrillation patients by strict application of guidelines.</b></p>        <p>Europace. 2010 Jun;12(6):779-84</p>        <p>Authors:  Pisters R, van Oostenbrugge RJ, Knottnerus IL, de Vos CB, Boreas A, Lodder J, Prins MH, Crijns HJ, Tieleman RG</p>        <p>AIMS: Despite the known increased stroke risk associated with AF and the benefit of oral anticoagulation (OAC) in high-risk patients, still approximately 20% of all ischaemic strokes are atrial fibrillation (AF) related. We aimed to evaluate the frequency of inappropriate anticoagulation in all patients admitted with AF associated ischaemic stroke and calculate the theoretical number of preventable strokes in case of proper guideline adherence and assess secondary stroke prevention at discharge. METHODS AND RESULTS: In this cross-sectional study, all patients with ischaemic strokes admitted to our hospital during May 2003-August 2006 in whom the diagnosis AF was either known or established during hospital stay were identified. We studied if their admission and discharge antithrombotic therapy was in accordance with the published guidelines. Subsequently, we calculated the number of preventable strokes in case AF patients would have received adequate antithrombotic treatment on admission. On admission, in 51% of the OAC eligible known AF patients the drug was withheld. Improved antithrombotic guideline adherence potentially would have prevented 20 out of the 89 (22%) ischaemic strokes. At discharge at least 10% of the patients were still insufficiently protected against recurrent stroke. CONCLUSION: Many known AF patients admitted with ischaemic stroke lack adequate antithrombotic treatment on admission. Antithrombotic guideline adherence in these patients has the potential to prevent a substantial number strokes. Secondary stroke prevention at discharge is also suboptimal.</p>        <p>PMID: 20348143 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20233760&#x26;dopt=Abstract\">A new use for an old technique?</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://europace.oxfordjournals.org/cgi/pmidlookup?view=long&#x26;amp;pmid=20233760"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--highwire.stanford.edu-icons-externalservices-pubmed-custom-oxfordjournals_final.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20233760">Related Articles</a></td></tr></table>        <p><b>A new use for an old technique?</b></p>        <p>Europace. 2010 Jun;12(6):768-9</p>        <p>Authors:  Stafford PJ</p>        <p></p>        <p>PMID: 20233760 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20200016&#x26;dopt=Abstract\">Effect of continuous versus episodic amiodarone treatment on quality of life in persistent atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://europace.oxfordjournals.org/cgi/pmidlookup?view=long&#x26;amp;pmid=20200016"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--highwire.stanford.edu-icons-externalservices-pubmed-custom-oxfordjournals_final.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20200016">Related Articles</a></td></tr></table>        <p><b>Effect of continuous versus episodic amiodarone treatment on quality of life in persistent atrial fibrillation.</b></p>        <p>Europace. 2010 Jun;12(6):785-91</p>        <p>Authors:  Ahmed S, Ranchor AV, Crijns HJ, Van Veldhuisen DJ, Van Gelder IC,  </p>        <p>AIMS: Amiodarone is associated with significant adverse effects. We hypothesized that episodic amiodarone treatment would be associated with better quality of life (QoL) compared with continuous treatment in the prevention of recurrent atrial fibrillation (AF). METHODS AND RESULTS: Quality of life was assessed in 158 patients from the Continuous vs. Episodic Prophylactic Treatment with Amiodarone for the Prevention of AF (CONVERT) study, using the Short Form (SF)-36 health survey and University of Toronto AF Severity Scale (AF severity scale) questionnaires at baseline and 1 year. The episodic group received amiodarone 1 month peri-cardioversion, the continuous group continued amiodarone. Patients were assessed for major adverse events and maintenance of sinus rhythm during follow-up (i.e. no AF recurrences at every follow-up visit). Quality of life (assessed by SF-36 and AF severity scale) was comparable between both treatment groups at baseline and 12 months, with similar incidence rates of major adverse events. Fewer patients in the episodic group had maintenance of sinus rhythm during follow-up [27 (36%) vs. 49 (59%), P = 0.004]. In the episodic group, maintenance of sinus rhythm was associated with a significant improvement on four SF-36 subscales and AF severity scale at 12 months. In contrast, in the continuous group no significant differences in QoL were seen between patients with continued maintenance of sinus rhythm compared with those with AF recurrence at the end of follow-up. CONCLUSION: Quality of life was comparable in the episodic and continuous treated group after 12 months of follow-up. Continued maintenance of sinus rhythm was associated with an improvement in QoL in the episodic but not the continuous treated group.</p>        <p>PMID: 20200016 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20185485&#x26;dopt=Abstract\">Measurement of left atrial volume in patients undergoing ablation for atrial fibrillation: comparison of angiography and electro-anatomic (CARTO) mapping with real-time three-dimensional echocardiography.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://europace.oxfordjournals.org/cgi/pmidlookup?view=long&#x26;amp;pmid=20185485"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--highwire.stanford.edu-icons-externalservices-pubmed-custom-oxfordjournals_final.gif" border="0"/></a> </td></tr></table>        <p><b>Measurement of left atrial volume in patients undergoing ablation for atrial fibrillation: comparison of angiography and electro-anatomic (CARTO) mapping with real-time three-dimensional echocardiography.</b></p>        <p>Europace. 2010 Jun;12(6):792-7</p>        <p>Authors:  M&#xC3;&#xBC;ller H, Burri H, Gentil P, Lerch R, Shah D</p>        <p>AIMS: Left atrial (LA) volume can be determined during radiofrequency catheter ablation (RFCA) of atrial fibrillation (AF) with angiography or electro-anatomic (CARTO) mapping. We compared these volumes with LA volume measured using transthoracic real-time three-dimensional echocardiography (3DE). METHODS AND RESULTS: One hundred and twenty-seven consecutive patients undergoing RFCA for AF were studied using biplane pulmonary vein angiography with opacification of the LA. LA volume was calculated from the diameter measurements with a formula using an ellipsoid model. A subset of 22 patients also underwent LA volume determination by CARTO mapping. These volumes were then correlated with LA volume determined non-invasively by real-time 3DE. Linear regression showed a significant correlation between LA volume determined by angiography and 3DE volume (r = 0.56, P &#x26;lt; 0.0001). Bland-Altman analysis showed a bias of 38 +/- 22 ml by the angiographic method. LA volume measured using CARTO correlated better (r = 0.67, P &#x26;lt; 0.001), but 3DE yielded smaller values (mean difference of -30 +/- 19 ml). CONCLUSION: LA volume determination by angiography and CARTO mapping correlate significantly with 3DE volume. However, both invasive techniques yield larger values for LA volume. The results indicate that LA volume obtained by angiography or CARTO should not be used as baseline value for non-invasive follow-up of LA remodelling by 3DE.</p>        <p>PMID: 20185485 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20185484&#x26;dopt=Abstract\">Alterations of atrial electrophysiology induced by electrolyte variations: combined computational and P-wave analysis.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://europace.oxfordjournals.org/cgi/pmidlookup?view=long&#x26;amp;pmid=20185484"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--highwire.stanford.edu-icons-externalservices-pubmed-custom-oxfordjournals_final.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20185484">Related Articles</a></td></tr></table>        <p><b>Alterations of atrial electrophysiology induced by electrolyte variations: combined computational and P-wave analysis.</b></p>        <p>Europace. 2010 Jun;12(6):842-9</p>        <p>Authors:  Severi S, Pogliani D, Fantini G, Fabbrini P, Vigan&#xC3;&#xB2; MR, Galbiati E, Bonforte G, Vincenti A, Stella A, Genovesi S</p>        <p>AIMS: Haemodialysis (HD) therapy represents a unique model to test in vivo, in humans, the effects of changes in plasma ionic concentrations. Episodes of paroxysmal atrial fibrillation (AF) often occur during the treatment. We investigated the effects of HD-induced electrolyte variations on atrial electrophysiology by analysing ECG P-wave duration (PWd), which reflects atrial conduction velocity (CV), and simulated atrial action potential (AP). METHODS AND RESULTS: In 20 end-stage renal disease patients PWd (signal-averaged ECG), heart rate (HR), blood pressure, Na(+), K(+), Ca(2+), and Mg(2+) plasma concentrations were measured before and after HD session. The Courtemanche computational model of human atrial myocyte was used to simulate the atrial AP. AP upstroke duration (AP(ud)), AP duration and atrial cell effective refractory period (ERP) were computed. Extracellular electrolyte concentrations and HR were imposed to the average values measured in vivo. HD decreased K(+) (from 4.9 +/- 0.5 to 3.9 +/- 0.4 mmol/L, P &#x26;lt; 0.001) and Mg(2+) (0.92 +/- 0.08 to 0.86 +/- 0.05 mmol/L, P &#x26;lt; 0.05), and increased Na(+) (139.8 +/- 3.4 to 141.6 +/- 3.1 mmol/L, P &#x26;lt; 0.05) and Ca(2+) (1.18 +/- 0.09 to 1.30 +/- 0.07 mmol/L, P &#x26;lt; 0.001) plasma concentrations. PWd systematically increased in all the patients after HD (131 +/- 11 to 140 +/- 12 ms, P &#x26;lt; 0.001), indicating an intra-atrial conduction slowing. PWd increments were inversely correlated with K(+) variations (R = 0.73, P &#x26;lt; 0.01). Model-based analysis indicated an AP(ud) increase (from 2.58 to 2.94 ms) after HD, coherent with experimental observations on PWd, and a reduction of ERP by 12 ms. CONCLUSION: Changes of plasma ionic concentrations may lead to modifications of atrial electrophysiology that can favour AF onset, namely a decrease of atrial CV and a decrease of atrial ERP.</p>        <p>PMID: 20185484 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20106795&#x26;dopt=Abstract\">Predicting recurrence of atrial fibrillation after electrical cardioversion: gauging atrial damage.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://europace.oxfordjournals.org/cgi/pmidlookup?view=long&#x26;amp;pmid=20106795"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--highwire.stanford.edu-icons-externalservices-pubmed-custom-oxfordjournals_final.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20106795">Related Articles</a></td></tr></table>        <p><b>Predicting recurrence of atrial fibrillation after electrical cardioversion: gauging atrial damage.</b></p>        <p>Europace. 2010 Jun;12(6):764-5</p>        <p>Authors:  Siu CW, Tse HF</p>        <p></p>        <p>PMID: 20106795 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20084318&#x26;dopt=Abstract\">Constant use of oral anticoagulants: implications in the control of their adequate levels.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www.scielo.br/scielo.php?script=sci_arttext&#x26;amp;pid=S0066-782X2009001100017&#x26;amp;lng=en&#x26;amp;nrm=iso&#x26;amp;tlng=en"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.scielo.br-img-scielo_en.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20084318">Related Articles</a></td></tr></table>        <p><b>Constant use of oral anticoagulants: implications in the control of their adequate levels.</b></p>        <p>Arq Bras Cardiol. 2009 Nov;93(5):549-54</p>        <p>Authors:  Esmerio FG, Souza EN, Leiria TL, Lunelli R, Moraes MA</p>        <p>BACKGROUND: Inappropriate and subtherapeutic anticoagulants dosages may result in severe thromboembolic and bleeding complications. The use of this treatment requires special attention and strict clinical and laboratory follow-up. OBJECTIVE: To identify factors associated with appropriate control of the oral anticoagulant use, assessing the patients&#x27; knowledge and perception of the treatment. METHODS: A cross-sectional study which included 140 patients followed in the oral anticoagulation outpatient clinic from November 2005 to June 2006. A structured questionnaire was drafted and applied to obtain the clinical characteristics of the patients and their knowledge about the treatment, their compliance with the treatment (Morisky s test) and their perception of the treatment. RESULTS: The main indications for the use of oral anticoagulation therapy were atrial fibrillation (61.4%) and a prosthetic heart valve (55%). The duration of anticoagulation ranged from 24 to 72 months, and phenprocoumon (58%) was the most commonly used anticoagulant. As to the perception of the treatment, 95% of the patients mentioned concern about daily use of this medication. Periodic blood tests (21.4%) and the strict intake of oral anticoagulant (12.8%) were considered limiting factors. Adequate knowledge was outstanding in patients with an international normalized ratio (INR) outside the therapeutic range (64%), compared to patients with an INR within the therapeutic range (62%), as well as compliance with treatment in patients with an INR within the therapeutic range (54%), but with no statistical significance. CONCLUSION: The results of this study show a prevalence of patients using oral anticoagulant with an INR within optimal values, although a high percentage of patients do not comply with the treatment. In this population it is clearly seen that they do not fully understand the treatment.</p>        <p>PMID: 20084318 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20084310&#x26;dopt=Abstract\">Predictors of atrial fibrillation after ablation of typical atrial flutter.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www.scielo.br/scielo.php?script=sci_arttext&#x26;amp;pid=S0066-782X2009001100008&#x26;amp;lng=en&#x26;amp;nrm=iso&#x26;amp;tlng=en"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.scielo.br-img-scielo_en.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20084310">Related Articles</a></td></tr></table>        <p><b>Predictors of atrial fibrillation after ablation of typical atrial flutter.</b></p>        <p>Arq Bras Cardiol. 2009 Nov;93(5):484-9</p>        <p>Authors:  Melo SL, Scanavacca M, Pisani C, Nascimento R, Darrieux F, Hachul D, Hardy C, Sosa E</p>        <p>BACKGROUND: The occurrence of atrial fibrillation (AF) after successful ablation of cavotricuspid isthmus-dependent atrial flutter (CTI-AFL) is an important medical event, but predictors of this event are still controversial. OBJECTIVE: To determine the incidence of AF and its predictors in patients undergoing ablation of cavotricuspid isthmus-dependent atrial flutter (CTI-AFL). METHODS: Fifty two patients with CTI-AFL underwent ablation from January 2003 to March 2004, in Instituto do Cora&#xC3;&#xA7;&#xC3;&#xA3;o (InCor), Hospital das Cl&#xC3;&#xAD;nicas da Faculdade de Medicina da Universidade de S&#xC3;&#xA3;o Paulo. RESULTS: During the mean follow-up period of 26.2 +/- 9.2 months, 16 (30.8%) patients presented AF. The univariate analysis revealed two clinical variables as predictive of the occurrence of AF after ablation of CTI-AFL for three years or longer (RR: 3.00; p = 0.020). In the multivariate analysis, these factors were independent variables associated with the occurrence of AF after ablation of CTI-AFL. CONCLUSION: AF is frequently observed during the follow-up of patients undergoing ablation of CTI-AFL. Persistent CTI-AFL and history of arrhythmia for more than three years are predictors of the occurrence of AF during the clinical follow-up.</p>        <p>PMID: 20084310 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20076857&#x26;dopt=Abstract\">Another oral thrombin inhibitor for stroke prevention in atrial fibrillation?</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20076857">Related Articles</a></td></tr></table>        <p><b>Another oral thrombin inhibitor for stroke prevention in atrial fibrillation?</b></p>        <p>Thromb Haemost. 2010 Mar 1;103(3):481-3</p>        <p>Authors:  Eikelboom JW, Weitz JI</p>        <p></p>        <p>PMID: 20076857 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20076850&#x26;dopt=Abstract\">Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/></tr></table>        <p><b>Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation.</b></p>        <p>Thromb Haemost. 2010 Mar 1;103(3):604-12</p>        <p>Authors:  Olsson SB, Rasmussen LH, Tveit A, Jensen E, Wessman P, Panfilov S, W&#xC3;&#xA5;hlander K</p>        <p>AZD0837 is an investigational oral anticoagulant which is converted to the active form, AR-H067637, a selective direct thrombin inhibitor. The present study, a multicentre, randomised, parallel-group, dose-guiding study, assessed the safety and tolerability of an immediate-release formulation of AZD0837 compared with dose-adjusted warfarin in the prevention of stroke and systemic embolic events in atrial fibrillation (AF) patients. Two hundred fifty AF patients with at least one additional risk factor for stroke were randomised to receive either immediate-release AZD0837 (150mg twice daily [bid] or 350mg bid, blinded treatment) or dose-adjusted warfarin (international normalised ratio 2.0-3.0, open treatment) for three months. The safety and tolerability of 150mg bid AZD0837 appeared to be as good as that of warfarin. Total bleeding events were six with 150mg bid AZD0837, 15 with 350mg bid AZD0837 and eight with warfarin. Alanine aminotransferase elevations (&#x26;gt;3xupper limit of normal) were infrequent, without apparent differences between treatment groups. A numerically higher incidence of serious adverse events was observed with 350mg bid AZD0837 compared with 150mg bid, with six of 13 being cardiac related, all with different diagnoses. An increase in mean serum creatinine of approximately 10% was observed in both AZD0837 groups, which returned to baseline after completion of therapy. There were no strokes, transient ischaemic attacks or cerebral haemorrhages with any of the treatments. In conclusion, the safety and tolerability of 150mg bid immediate-release AZD0837 appeared to be as good as that of dose-adjusted warfarin. However, larger studies will be needed to define the safety profile of AZD0837.</p>        <p>PMID: 20076850 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20074590&#x26;dopt=Abstract\">Angiotensin-(1-7) prevents atrial fibrosis and atrial fibrillation in long-term atrial tachycardia dogs.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0167-0115(10)00008-X"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20074590">Related Articles</a></td></tr></table>        <p><b>Angiotensin-(1-7) prevents atrial fibrosis and atrial fibrillation in long-term atrial tachycardia dogs.</b></p>        <p>Regul Pept. 2010 Jun 8;162(1-3):73-8</p>        <p>Authors:  Liu E, Yang S, Xu Z, Li J, Yang W, Li G</p>        <p>Renin-angiotensin system (RAS) is activated in the fibrillating atria. Angiotensin-(1-7) [Ang-(1-7)] counterbalances the actions of angiotensin II (Ang II). To investigate the effects of Ang-(1-7) on the long-term atrial tachycardia-induced atrial fibrosis and atrial fibrillation (AF) vulnerability, eighteen dogs were assigned to sham group, paced group, or paced+Ang-(1-7) group, 6 dogs in each group. Rapid atrial pacing at 500 bpm was maintained for 14 days, but dogs in the sham group were instrumented without pacing. During the pacing, Ang-(1-7) (6 microg x kg(-1) x h(-1)) was given intravenously. After pacing, atrial mRNA expression of ERK1/ERK2 and atrial fibrosis were assessed, the inducibility and duration of AF were measured. Compared with sham, ERK1/ERK2 mRNA expression was increased in the paced group (P&#x26;lt;0.05). Atrial tissue from the paced dogs showed a large amount of interstitial fibrosis, and the inducible rate of AF was increased at various BCLs in paced dogs (P&#x26;lt;0.01). Compared with the paced group, Ang-(1-7) prevented the increase of ERK1/ERK2 mRNA expression (P&#x26;lt;0.01 and P&#x26;lt;0.05, respectively), and attenuated the interstitial fibrosis (P&#x26;lt;0.01). Inducibility and duration of AF were reduced by Ang-(1-7) at various BCLs. In conclusion, Ang-(1-7) reduced AF vulnerability in chronic paced atria, and antifibrotic actions contributed to its preventive effects on AF.</p>        <p>PMID: 20074590 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20047928&#x26;dopt=Abstract\">Changes in P-wave area and P-wave duration after circumferential pulmonary vein isolation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://europace.oxfordjournals.org/cgi/pmidlookup?view=long&#x26;amp;pmid=20047928"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--highwire.stanford.edu-icons-externalservices-pubmed-custom-oxfordjournals_final.gif" border="0"/></a> </td></tr></table>        <p><b>Changes in P-wave area and P-wave duration after circumferential pulmonary vein isolation.</b></p>        <p>Europace. 2010 Jun;12(6):798-804</p>        <p>Authors:  Van Beeumen K, Houben R, Tavernier R, Ketels S, Duytschaever M</p>        <p>AIMS: The effect of circumferential pulmonary vein isolation (CPVI) on P-wave characteristics is not clear. We used the signal-averaged (SA) electrocardiogram (ECG) and the ECG derived vector cardiogram (dVCG) to study the influence of CPVI on P-wave duration (PWD) and P-wave area (PWA) and studied whether changes were associated with successful outcome after initial CPVI. METHODS AND RESULTS: Thirty-nine patients (56 +/- 10 years, 72% males) underwent CPVI for paroxysmal or persistent atrial fibrillation (AF). For each patient, an ECG recording was taken at the start and end of the ablation procedure. dVCG was derived using the inverse Dower transform. PWD was defined by manual annotation of earliest onset and latest offset of the SA-P-wave. PWA was calculated as the area under the SA-ECG curve averaged for the 12 ECG leads (PWA-ECG) and SA-dVCG curve (PWA-dVCG). Successful outcome after CPVI was defined as freedom from symptomatic and asymptomatic AF at the end of follow-up (11 +/- 5 months). Average PWD decreased from 132 +/- 14 to 126 +/- 16 ms (P &#x26;lt; 0.01). PWA-ECG and PWA-dVCG decreased markedly from 4.64 +/- 1.40 to 3.65 +/- 1.61 mVms (P &#x26;lt; 0.001) and from 4.27 +/- 1.66 to 2.48 +/- 1.59 mVms (P &#x26;lt; 0.001). Parameters of PWA were not different between successes (n = 31) and failures (n = 8). In contrast, PWD after ablation was significantly shorter in patients with successful outcome (123 +/- 16 vs. 135 +/- 11 ms, P &#x26;lt; 0.05). CONCLUSION: (i) CPVI results in a modest but significant shortening in PWD and a marked decrease in PWA. (ii) PWD was significantly shorter in cases of successful outcome after CPVI.</p>        <p>PMID: 20047928 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20035390&#x26;dopt=Abstract\">Interassay reproducibility of myocardial perfusion gated SPECT in patients with atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://dx.doi.org/10.1007/s12350-009-9186-6"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--production.springer.de-OnlineResources-Logos-springerlink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20035390">Related Articles</a></td></tr></table>        <p><b>Interassay reproducibility of myocardial perfusion gated SPECT in patients with atrial fibrillation.</b></p>        <p>J Nucl Cardiol. 2010 Jun;17(3):450-8</p>        <p>Authors:  Aguad&#xC3;&#xA9;-Bruix S, Romero-Farina G, Cuberas-Borros G, Mil&#xC3;&#xA0;-Lopez M, Pubul-N&#xC3;&#xBA;&#xC3;&#xB1;ez V, Siurana-Escuer R, Garc&#xC3;&#xAD;a-Dorado D, Candell-Riera J</p>        <p>AIM: The aim of this study was to assess interassay reproducibility of myocardial perfusion gated-SPECT for calculation of end-diastolic volume (EDV), end-systolic volume (ESV), and left ventricular ejection fraction (LVEF) in patients with atrial fibrillation (AF). METHODS: One hundred and fifteen consecutive patients with AF from three participating hospitals (mean age 68.9 years, 39 women) were included in the study. All patients underwent two image gated acquisitions at rest with a 30 minute interval between them. Quantitative data were obtained using the QGS and ECT software algorithms. RESULTS: Heart rate was similar in both studies: 74.94 +/- 15.2 vs 73.03 +/- 15.57. QGS yielded an LVEF of 54.4%/53.8%, an EDV of 100 mL/101.5 mL, and an ESV of 51 mL/52.3 mL; and ECT showed an LVEF of 63.6%/62.9%, an EDV of 125.8 mL/127.4 mL and ESV of 54.1 mL/56.3 mL. Correlation between the two acquisitions was high (&#x26;gt;0.948) for both methods for LVEF, EDV and ESV. Regression and Bland-Altman graphics showed a good agreement between all parameters. Interassay variation coefficients for each method (QGS/ECT) were 5.29% vs 4.83% for LVEF, 4.94% vs 5.17% for EDV, and 9.94% vs 12.78% for ESV. CONCLUSIONS: Interassay reproducibility of LVEF and EDV with gated-SPECT in patients with AF is good, whereas for ESV it is suboptimal, particularly when ESV is small.</p>        <p>PMID: 20035390 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19593943&#x26;dopt=Abstract\">Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers have no beneficial effect on ablation outcome in chronic persistent atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19593943">Related Articles</a></td></tr></table>        <p><b>Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers have no beneficial effect on ablation outcome in chronic persistent atrial fibrillation.</b></p>        <p>Acta Cardiol. 2009 Jun;64(3):335-40</p>        <p>Authors:  Zheng B, Kang J, Tian Y, Tang R, Long D, Yu R, He H, Zhang M, Shi L, Tao H, Liu X, Dong J, Ma C</p>        <p>OBJECTIVE: Previous studies have shown that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) could reverse structural and electrical atria remodelling and decrease atrial fibrillation (AF) onset or recurrence. The aim of this retrospective study was to investigate whether ACEIs/ARBs had beneficial effects on ablation outcome of chronic persistent AF. METHODS AND RESULTS: This study included 139 patients with chronic persistent AF who underwent radiofrequency ablation in our centre. Patients were divided into an ACEIs/ARBs group or a non-ACEIs/ARBs group. During follow-up (14.6 +/- 8.9 months) after AF ablation, AF-free survival in the ACEIs/ARBs group was not significantly different from the non-ACEIs/ARBs group (P = 0.339). Univariate analysis showed that predictors for AF-free survival were AF history (HR, 1.064; 95% CI, 1.021-1.108; P = 0.003) and duration of chronic persistent AF (HR, 1.012; 95% CI, 1.005-1.019; P = 0.001). Multivariate analysis showed that predictors for AF-free survival were AF history (HR, 1.051; 95% CI, 1.004-1.101; P = 0.035) and duration of chronic persistent AF (HR, 1.012; 95% CI, 1.004-1.020; P = 0.004). ACEIs/ARBs therapy was not a predictor for AF-free survival neither in univariate nor multivariate analysis. CONCLUSION: In this observational study, no effect of ACEIs or ARBs was seen on the AF recurrence after ablation of chronic persistent AF.ACEIs/ARBs did not help to predict a better ablation outcome. Predictors for ablation outcome are AF history and duration of chronic persistent AF.</p>        <p>PMID: 19593943 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19484619&#x26;dopt=Abstract\">Does GISSI-AF change the concept of using RAS inhibitors in the primary prevention of atrial fibrillation in hypertensive patients?</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://informahealthcare.com/doi/abs/10.1080/08037050903040777"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--informahealthcare.com-userimages-ContentEditor-1258375244362-ihc-linkout.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19484619">Related Articles</a></td></tr></table>        <p><b>Does GISSI-AF change the concept of using RAS inhibitors in the primary prevention of atrial fibrillation in hypertensive patients?</b></p>        <p>Blood Press. 2009;18(3):92-3</p>        <p>Authors:  Kjeldsen SE, Oparil S, Hedner T, Narkiewicz K</p>        <p></p>        <p>PMID: 19484619 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19249911&#x26;dopt=Abstract\">New insights into mechanisms of atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19249911">Related Articles</a></td></tr></table>        <p><b>New insights into mechanisms of atrial fibrillation.</b></p>        <p>Physiol Res. 2010;59(1):1-12</p>        <p>Authors:  Aldhoon B, Melenovsk&#xC3;&#xBD; V, Peichl P, Kautzner J</p>        <p>Although atrial fibrillation (AF) is the most common cardiac arrhythmia in clinical practice, precise mechanisms that lead to the onset and persistence of AF have not completely been elucidated. Over the last decade, outstanding progress has been made in understanding the complex pathophysiology of AF. The key role of ectopic foci in pulmonary veins as a trigger of AF has been recognized. Furthermore, structural remodeling was identified as the main mechanism for AF persistence, confirming predominant role of atrial fibrosis. Systemic inflammatory state, oxidative stress injury, autonomic balance and neurohormonal activation were discerned as important modifiers that affect AF susceptibility. This new understanding of AF pathophysiology has led to the emergence of novel therapies. Ablative interventions, renin-angiotensin system blockade, modulation of oxidative stress and targeting tissue fibrosis represent new approaches in tackling AF. This review aims to provide a brief summary of novel insights into AF mechanisms and consequent therapeutic strategies.</p>        <p>PMID: 19249911 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=18180057&#x26;dopt=Abstract\">The quality of anticoagulation on functional outcome and mortality for TIA/stroke in atrial fibrillation patients.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0167-5273(07)01984-5"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=18180057">Related Articles</a></td></tr></table>        <p><b>The quality of anticoagulation on functional outcome and mortality for TIA/stroke in atrial fibrillation patients.</b></p>        <p>Int J Cardiol. 2009 Feb 6;132(1):109-13</p>        <p>Authors:  Poli D, Antonucci E, Marcucci R, Mannini L, Falciani M, Abbate R, Gensini GF, Prisco D</p>        <p>BACKGROUND: In atrial fibrillation (AF) patients stroke is nearly twice as likely to be fatal as non-AF patients and functional deficits are more likely to be severe among survivors. The incidence of stroke among AF patients is greatly reduced by oral anticoagulant treatment (OAT). However, fluctuation of anticoagulation levels is intrinsically related to OAT and often international normalized ratio (INR) is out of the therapeutic range. METHODS: Since the "anticoagulation history" is an ongoing process, we performed this prospective study in 578 AF patients to investigate the role of the whole quality of OAT and of INR levels at the occurrence of transient ischemic attack (TIA) or stroke on the severity of cerebral ischemia. RESULTS: During follow-up 13 patients had TIA and 18 had stroke (rate 1.67 x 100 pt/years). In relation to the quality of anticoagulant treatment, no significant differences were found in the time spent below and within the intended therapeutic range, between patients with and without TIA/stroke. Patients with TIA/stroke spent a longer time above the intended therapeutic range with respect to other patients, even if this difference was not confirmed at multivariate analysis. Forty-six percent of patients with TIA and 66% of patients with stroke had INR&#x26;gt;or=2 at the occurrence of ischemic event. CONCLUSION: The severity of stroke was not related to the whole quality of anticoagulation or to INR at the event.</p>        <p>PMID: 18180057 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('</ul>');
document.write('</div>');
document.write('<div class=\"rss_feed\">');
document.write('<div class=\"rss_feed_title\">pubmed: "atrial fibrillation...</div>');
document.write('<ul class=\"rss_item_list\">');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20605835&#x26;dopt=Abstract\">Obstructive sleep apnea is a risk factor for stroke and atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www.chestjournal.org/cgi/pmidlookup?view=long&#x26;amp;pmid=20605835"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--highwire.stanford.edu-icons-externalservices-pubmed-standard-chest_final.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20605835">Related Articles</a></td></tr></table>        <p><b>Obstructive sleep apnea is a risk factor for stroke and atrial fibrillation.</b></p>        <p>Chest. 2010 Jul;138(1):239; author reply 239-40</p>        <p>Authors:  Johnson KG, Johnson DC</p>        <p></p>        <p>PMID: 20605835 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20598971&#x26;dopt=Abstract\">The MOnitoring Resynchronization dEvices and CARdiac patiEnts (MORE-CARE) study: rationale and design.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0002-8703(10)00330-3"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20598971">Related Articles</a></td></tr></table>        <p><b>The MOnitoring Resynchronization dEvices and CARdiac patiEnts (MORE-CARE) study: rationale and design.</b></p>        <p>Am Heart J. 2010 Jul;160(1):42-8</p>        <p>Authors:  Burri H, Quesada A, Ricci RP, Boriani G, Davinelli M, Favale S, Da Costa A, Kautzner J, Moser R, Navarro X, Santini M</p>        <p>BACKGROUND: With the advent of remote monitoring, current models of implantable cardioverter defibrillators (ICDs) have the possibility of sending automatic alert messages that allow early diagnosis of events such as lung fluid overload, atrial fibrillation and device integrity issues. Timely treatment of these events has the potential to improve patient outcome, but this has not as yet been proven. METHODS: The MORE-CARE study is a multicenter randomized controlled trial evaluating the efficacy of advanced device diagnostics and remote monitoring in improving the outcome of patients with biventricular ICDs. Up to 1720 patients with a standard indication for a biventricular ICD will be randomized to standard in-office follow-up, or to a remote monitoring strategy using the CareLink network and involving automatic alerts for lung fluid overload, atrial fibrillation, and device integrity issues. The first phase aims at evaluating the delay between an alert event, and clinical action to the event. The second phase of the study will evaluate whether the remote monitoring strategy results in a significant reduction of a combined end point of total mortality or cardiovascular and device-related hospitalization. The duration of the study will be event-driven due to its sequential design. CONCLUSION: MORE-CARE will evaluate the efficacy of remote monitoring for improving patient outcome in patients implanted with a biventricular ICD.</p>        <p>PMID: 20598971 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20598970&#x26;dopt=Abstract\">Cryptogenic Stroke and underlying Atrial Fibrillation (CRYSTAL AF): design and rationale.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0002-8703(10)00268-1"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20598970">Related Articles</a></td></tr></table>        <p><b>Cryptogenic Stroke and underlying Atrial Fibrillation (CRYSTAL AF): design and rationale.</b></p>        <p>Am Heart J. 2010 Jul;160(1):36-41.e1</p>        <p>Authors:  Sinha AM, Diener HC, Morillo CA, Sanna T, Bernstein RA, Di Lazzaro V, Passman R, Beckers F, Brachmann J</p>        <p>BACKGROUND: Patients with atrial fibrillation (AF) are at increased risk for ischemic stroke. In patients who have suffered a stroke, screening for AF is routinely performed only for a short period after the stroke as part of the evaluation for possible causes. If AF is detected after an ischemic stroke, oral anticoagulation therapy is recommended for secondary stroke prevention. In 25% to 30% of stroke patients, the stroke mechanism cannot be determined (cryptogenic stroke). The incidence of paroxysmal AF undetected by short-term monitoring in patients with cryptogenic stroke is unknown, but has important therapeutic implications on patient care. The optimum monitoring duration and method of AF detection after stroke are unknown. The purpose of this study is to evaluate the incidence of AF and time to AF detection in patients with cryptogenic stroke using an insertable cardiac monitor. STUDY DESIGN: The CRYSTAL AF trial is a randomized prospective study to evaluate a novel approach to long-term monitoring for AF detection in patients with cryptogenic stroke. Four hundred fifty cryptogenic stroke patients (by definition, without a history of AF) will be enrolled at approximately 50 sites in Europe, Canada, and the United States. Patients will be randomized in a 1:1 fashion to standard arrhythmia monitoring (control arm) or implantation of the subcutaneous cardiac monitor (Reveal XT; Medtronic, Inc, Minneapolis, MN) (continuous monitoring arm). OUTCOMES: The primary end point is time to detection of AF within 6 months after stroke. The clinical follow-up period will be at least 12 months. Study completion is expected at the end of 2012.</p>        <p>PMID: 20598970 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20558140&#x26;dopt=Abstract\">Functional dominant-negative mutation of sodium channel subunit gene SCN3B associated with atrial fibrillation in a Chinese GeneID population.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0006-291X(10)01152-6"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20558140">Related Articles</a></td></tr></table>        <p><b>Functional dominant-negative mutation of sodium channel subunit gene SCN3B associated with atrial fibrillation in a Chinese GeneID population.</b></p>        <p>Biochem Biophys Res Commun. 2010 Jul 16;398(1):98-104</p>        <p>Authors:  Wang P, Yang Q, Wu X, Yang Y, Shi L, Wang C, Wu G, Xia Y, Yang B, Zhang R, Xu C, Cheng X, Li S, Zhao Y, Fu F, Liao Y, Fang F, Chen Q, Tu X, Wang QK</p>        <p>Atrial fibrillation (AF) is the most common cardiac arrhythmia in the clinic, and accounts for more than 15% of strokes. Mutations in cardiac sodium channel alpha, beta1 and beta2 subunit genes (SCN5A, SCN1B, and SCN2B) have been identified in AF patients. We hypothesize that mutations in the sodium channel beta3 subunit gene SCN3B are also associated with AF. To test this hypothesis, we carried out a large scale sequencing analysis of all coding exons and exon-intron boundaries of SCN3B in 477 AF patients (28.5% lone AF) from the GeneID Chinese Han population. A novel A130V mutation was identified in a 46-year-old patient with lone AF, and the mutation was absent in 500 controls. Mutation A130V dramatically decreased the cardiac sodium current density when expressed in HEK293/Na(v)1.5 stable cell line, but did not have significant effect on kinetics of activation, inactivation, and channel recovery from inactivation. When co-expressed with wild type SCN3B, the A130V mutant SCN3B negated the function of wild type SCN3B, suggesting that A130V acts by a dominant negative mechanism. Western blot analysis with biotinylated plasma membrane protein extracts revealed that A130V did not affect cell surface expression of Na(v)1.5 or SCN3B, suggesting that mutant A130V SCN3B may not inhibit sodium channel trafficking, instead may affect conduction of sodium ions due to its malfunction as an integral component of the channel complex. This study identifies the first AF-associated mutation in SCN3B, and suggests that mutations in SCN3B may be a new pathogenic cause of AF.</p>        <p>PMID: 20558140 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20193182&#x26;dopt=Abstract\">[Chronic outcome of patients with paroxysmal atrial fibrillation post catheter ablation]</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20193182">Related Articles</a></td></tr></table>        <p><b>[Chronic outcome of patients with paroxysmal atrial fibrillation post catheter ablation]</b></p>        <p>Zhonghua Xin Xue Guan Bing Za Zhi. 2009 Dec;37(12):1101-4</p>        <p>Authors:  Lin YB, Xia YL, Gao LJ, Chu ZL, Cong PX, Chang D, Yin XM, Zhang SL, Yang DH, Yang YZ</p>        <p>OBJECTIVE: High short-term successful rate was reported for catheter ablation in patients with paroxysmal atrial fibrillation (AF), we analyzed the long-term outcome (success rate, anticoagulation therapy and embolism event, anti-arrhythmic therapy and death post procedure) of catheter ablation for paroxysmal AF in this study. METHODS: From January 2000 to December 2004, 106 consecutive patients with drug-refractory paroxysmal AF underwent catheter ablation and were followed-up for (60.7 + or - 11.8) months. Segmental pulmonary vein isolation (SPVI) was routinely performed by radiofrequency energy under the guidance of circular mapping catheter. The patients were followed up with 24 h-holter, ECG, telephone or letter. Data on recurrence of AF, the anticoagulation medication and the incidence of embolism, anti-arrhythmic therapy were obtained. RESULTS: There were 9 patients lost to follow up. In the remaining 97 patients [65 males, (54.8 + or - 11.2) years old], 3 cases died from cancer, sinus rhythm was maintained in 68 patients (Group S, 72.3%) and AF recurrence evidenced in 26 patients (Group R, 27.7%). In Group S, 56 patients (82.4%) discontinued anticoagulation medication, and 12 patients continued to take aspirin. There was no embolism event in Group S during follow-up. In Group R, 1 patient continued to take warfarin; 11 patients continued to take aspirin and 2 patients suffered from cerebral embolism. Anticoagulation medication was discontinued in 14 patients (53.8%) and 1 patient suffered form cerebral embolism. The incidence of embolism event in Group R is significantly higher than in Group S (P &#x26;lt; 0.01). More patients discontinued anti-arrhythmic medication in Group S than in Group R (80.9% vs. 56.0%, P &#x26;lt; 0.05). CONCLUSION: Catheter ablation is associated with satisfactory long-term success rate, reduced anti-arrhythmia medication, improved quality of life in patients with paroxysmal AF.</p>        <p>PMID: 20193182 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19923144&#x26;dopt=Abstract\">Outcome of atrial fibrillation among patients with end-stage renal disease.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://ndt.oxfordjournals.org/cgi/pmidlookup?view=long&#x26;amp;pmid=19923144"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--highwire.stanford.edu-icons-externalservices-pubmed-custom-oxfordjournals_final.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19923144">Related Articles</a></td></tr></table>        <p><b>Outcome of atrial fibrillation among patients with end-stage renal disease.</b></p>        <p>Nephrol Dial Transplant. 2010 Apr;25(4):1225-30</p>        <p>Authors:  Chou CY, Kuo HL, Wang SM, Liu JH, Lin HH, Liu YL, Huang CC</p>        <p>BACKGROUND: End-stage renal disease (ESRD) patients are more at risk for atrial fibrillation (AF) than the general population. However, the prognosis in ESRD patients with paroxysmal AF (PaAF), permanent AF (PAF) and paroxysmal AF transformed to permanent AF (TAF) is unknown. METHODS: In this retrospective longitudinal study, all ESRD patients with PaAF, PAF and TAF between January 2001 and December 2007 were reviewed. The development of thromboembolic events (TEE) was analyzed using Kaplan-Meier analysis and Cox regression. RESULTS: A total of 81 patients with PaAF, 49 patients with PAF and 89 patients with TAF were reviewed. Seventy-two (32.9%) patients developed TEE, and 63 (28.8%) patients died in 36.9 +/- 21.9 months. Patient survival was not significantly different between patients with different types of AF (P = 0.728). Patients with PaAF had a significantly lower TEE-free survival compared to patients with PAF (P = 0.036). In multivariate Cox regression, patients with paroxysmal AF were more at risk for TEE (P = 0.045) with a hazard ratio of 1.61 (95% confidence interval: 1.01-2.58). PaAF and congestive heart failure, hypertension, age older than 75 years, diabetes, and previous stroke or transient ischemic stroke (CHADS(2)) score were independently associated with an increase in TEE risk (P = 0.028 and P = 0.03). CONCLUSION: Patient survival is not different in patients with paroxysmal and permanent atrial fibrillation. However, patients with paroxysmal AF are more at risk for the development of TEE than those with permanent AF.</p>        <p>PMID: 19923144 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19845751&#x26;dopt=Abstract\">Brain natriuretic peptide as a predictor of delayed atrial fibrillation after ischaemic stroke and transient ischaemic attack.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www3.interscience.wiley.com/resolve/openurl?genre=article&#x26;amp;sid=nlm:pubmed&#x26;amp;issn=1351-5101&#x26;amp;date=2010&#x26;amp;volume=17&#x26;amp;issue=2&#x26;amp;spage=326"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www3.interscience.wiley.com-aboutus-images-wiley_interscience_pubmed_logo_120x27.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19845751">Related Articles</a></td></tr></table>        <p><b>Brain natriuretic peptide as a predictor of delayed atrial fibrillation after ischaemic stroke and transient ischaemic attack.</b></p>        <p>Eur J Neurol. 2010 Feb;17(2):326-31</p>        <p>Authors:  Okada Y, Shibazaki K, Kimura K, Iguchi Y, Miki T</p>        <p>BACKGROUND AND PURPOSE: We investigated whether the brain natriuretic peptide (BNP) level can serve as a predictive biological marker of delayed atrial fibrillation (AF). METHODS: Two hundred and thirty seven consecutive patients admitted to our institution with acute ischaemic stroke or transient ischaemic attack (TIA) within 24 h of onset were enrolled. The patients were classified according to the presence or absence of AF upon admission [AF and sinus rhythm (SR) groups]. The SR group was subdivided based on the development of AF after admission (new- and non-AF groups). We compared the characteristics between the AF and SR groups, and between the new- and non-AF groups. The factors associated with new-AF were investigated by multivariate logistic regression analysis. RESULTS: Amongst the enrolled patients, 72 (30.4%) had AF upon admission (AF group), and 13 (5.5%) developed AF thereafter (new-AF group). The plasma BNP level was significantly higher in the AF, than in the SR group (401.7 vs. 92.1 pg/ml, P &#x26;lt; 0.001). Moreover, the plasma BNP level was significantly higher in the new-, than in the non-AF group (184.7 vs. 84.1 pg/ml, P &#x26;lt; 0.001). The optimal cutoff BNP level required to distinguish new-, from non-AF groups was 85.0 pg/ml, and the sensitivity and specificity was 83.3% and 76.2%, respectively. On multivariate logistic regression analysis, plasma BNP level &#x26;gt;85.0 pg/ml (odds ratio, 7.20; 95% confidence interval, 1.71 to 30.43, P = 0.007) was an independent factor associated with new-AF. CONCLUSION: High plasma BNP level should be a strong predictor of delayed AF after ischaemic stroke or TIA.</p>        <p>PMID: 19845751 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19687749&#x26;dopt=Abstract\">S-Nitrosylation of cardiac ion channels.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0160-2446&#x26;amp;volume=54&#x26;amp;issue=3&#x26;amp;spage=188"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.lwwonline.com-pt-pt-core-template-journal-lwwgateway-images-pmlogo.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19687749">Related Articles</a></td></tr></table>        <p><b>S-Nitrosylation of cardiac ion channels.</b></p>        <p>J Cardiovasc Pharmacol. 2009 Sep;54(3):188-95</p>        <p>Authors:  Gonzalez DR, Treuer A, Sun QA, Stamler JS, Hare JM</p>        <p>Nitric oxide (NO) exerts ubiquitous signaling via posttranslational modification of cysteine residues, a reaction termed S-nitrosylation. Important substrates of S-nitrosylation that influence cardiac function include receptors, enzymes, ion channels, transcription factors, and structural proteins. Cardiac ion channels subserving excitation-contraction coupling are potentially regulated by S-nitrosylation. Specificity is achieved in part by spatial colocalization of ion channels with nitric oxide synthases (NOSs), enzymatic sources of NO in biologic systems, and by coupling of NOS activity to localized calcium/second messenger concentrations. Ion channels regulate cardiac excitability and contractility in millisecond timescales, raising the possibility that NO-related species modulate heart function on a beat-to-beat basis. This review focuses on recent advances in understanding of NO regulation of the cardiac action potential and of the calcium release channel ryanodine receptor, which is crucial for the generation of force. S-Nitrosylation signaling is disrupted in pathological states in which the redox state of the cell is dysregulated, including ischemia, heart failure, and atrial fibrillation.</p>        <p>PMID: 19687749 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('</ul>');
document.write('</div>');
document.write('<div class=\"rss_feed\">');
document.write('<div class=\"rss_feed_title\">pubmed: "atrial fibrillation...</div>');
document.write('<ul class=\"rss_item_list\">');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20605835&#x26;dopt=Abstract\">Obstructive sleep apnea is a risk factor for stroke and atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www.chestjournal.org/cgi/pmidlookup?view=long&#x26;amp;pmid=20605835"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--highwire.stanford.edu-icons-externalservices-pubmed-standard-chest_final.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20605835">Related Articles</a></td></tr></table>        <p><b>Obstructive sleep apnea is a risk factor for stroke and atrial fibrillation.</b></p>        <p>Chest. 2010 Jul;138(1):239; author reply 239-40</p>        <p>Authors:  Johnson KG, Johnson DC</p>        <p></p>        <p>PMID: 20605835 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20598971&#x26;dopt=Abstract\">The MOnitoring Resynchronization dEvices and CARdiac patiEnts (MORE-CARE) study: rationale and design.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0002-8703(10)00330-3"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20598971">Related Articles</a></td></tr></table>        <p><b>The MOnitoring Resynchronization dEvices and CARdiac patiEnts (MORE-CARE) study: rationale and design.</b></p>        <p>Am Heart J. 2010 Jul;160(1):42-8</p>        <p>Authors:  Burri H, Quesada A, Ricci RP, Boriani G, Davinelli M, Favale S, Da Costa A, Kautzner J, Moser R, Navarro X, Santini M</p>        <p>BACKGROUND: With the advent of remote monitoring, current models of implantable cardioverter defibrillators (ICDs) have the possibility of sending automatic alert messages that allow early diagnosis of events such as lung fluid overload, atrial fibrillation and device integrity issues. Timely treatment of these events has the potential to improve patient outcome, but this has not as yet been proven. METHODS: The MORE-CARE study is a multicenter randomized controlled trial evaluating the efficacy of advanced device diagnostics and remote monitoring in improving the outcome of patients with biventricular ICDs. Up to 1720 patients with a standard indication for a biventricular ICD will be randomized to standard in-office follow-up, or to a remote monitoring strategy using the CareLink network and involving automatic alerts for lung fluid overload, atrial fibrillation, and device integrity issues. The first phase aims at evaluating the delay between an alert event, and clinical action to the event. The second phase of the study will evaluate whether the remote monitoring strategy results in a significant reduction of a combined end point of total mortality or cardiovascular and device-related hospitalization. The duration of the study will be event-driven due to its sequential design. CONCLUSION: MORE-CARE will evaluate the efficacy of remote monitoring for improving patient outcome in patients implanted with a biventricular ICD.</p>        <p>PMID: 20598971 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20598970&#x26;dopt=Abstract\">Cryptogenic Stroke and underlying Atrial Fibrillation (CRYSTAL AF): design and rationale.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0002-8703(10)00268-1"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20598970">Related Articles</a></td></tr></table>        <p><b>Cryptogenic Stroke and underlying Atrial Fibrillation (CRYSTAL AF): design and rationale.</b></p>        <p>Am Heart J. 2010 Jul;160(1):36-41.e1</p>        <p>Authors:  Sinha AM, Diener HC, Morillo CA, Sanna T, Bernstein RA, Di Lazzaro V, Passman R, Beckers F, Brachmann J</p>        <p>BACKGROUND: Patients with atrial fibrillation (AF) are at increased risk for ischemic stroke. In patients who have suffered a stroke, screening for AF is routinely performed only for a short period after the stroke as part of the evaluation for possible causes. If AF is detected after an ischemic stroke, oral anticoagulation therapy is recommended for secondary stroke prevention. In 25% to 30% of stroke patients, the stroke mechanism cannot be determined (cryptogenic stroke). The incidence of paroxysmal AF undetected by short-term monitoring in patients with cryptogenic stroke is unknown, but has important therapeutic implications on patient care. The optimum monitoring duration and method of AF detection after stroke are unknown. The purpose of this study is to evaluate the incidence of AF and time to AF detection in patients with cryptogenic stroke using an insertable cardiac monitor. STUDY DESIGN: The CRYSTAL AF trial is a randomized prospective study to evaluate a novel approach to long-term monitoring for AF detection in patients with cryptogenic stroke. Four hundred fifty cryptogenic stroke patients (by definition, without a history of AF) will be enrolled at approximately 50 sites in Europe, Canada, and the United States. Patients will be randomized in a 1:1 fashion to standard arrhythmia monitoring (control arm) or implantation of the subcutaneous cardiac monitor (Reveal XT; Medtronic, Inc, Minneapolis, MN) (continuous monitoring arm). OUTCOMES: The primary end point is time to detection of AF within 6 months after stroke. The clinical follow-up period will be at least 12 months. Study completion is expected at the end of 2012.</p>        <p>PMID: 20598970 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20558140&#x26;dopt=Abstract\">Functional dominant-negative mutation of sodium channel subunit gene SCN3B associated with atrial fibrillation in a Chinese GeneID population.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0006-291X(10)01152-6"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20558140">Related Articles</a></td></tr></table>        <p><b>Functional dominant-negative mutation of sodium channel subunit gene SCN3B associated with atrial fibrillation in a Chinese GeneID population.</b></p>        <p>Biochem Biophys Res Commun. 2010 Jul 16;398(1):98-104</p>        <p>Authors:  Wang P, Yang Q, Wu X, Yang Y, Shi L, Wang C, Wu G, Xia Y, Yang B, Zhang R, Xu C, Cheng X, Li S, Zhao Y, Fu F, Liao Y, Fang F, Chen Q, Tu X, Wang QK</p>        <p>Atrial fibrillation (AF) is the most common cardiac arrhythmia in the clinic, and accounts for more than 15% of strokes. Mutations in cardiac sodium channel alpha, beta1 and beta2 subunit genes (SCN5A, SCN1B, and SCN2B) have been identified in AF patients. We hypothesize that mutations in the sodium channel beta3 subunit gene SCN3B are also associated with AF. To test this hypothesis, we carried out a large scale sequencing analysis of all coding exons and exon-intron boundaries of SCN3B in 477 AF patients (28.5% lone AF) from the GeneID Chinese Han population. A novel A130V mutation was identified in a 46-year-old patient with lone AF, and the mutation was absent in 500 controls. Mutation A130V dramatically decreased the cardiac sodium current density when expressed in HEK293/Na(v)1.5 stable cell line, but did not have significant effect on kinetics of activation, inactivation, and channel recovery from inactivation. When co-expressed with wild type SCN3B, the A130V mutant SCN3B negated the function of wild type SCN3B, suggesting that A130V acts by a dominant negative mechanism. Western blot analysis with biotinylated plasma membrane protein extracts revealed that A130V did not affect cell surface expression of Na(v)1.5 or SCN3B, suggesting that mutant A130V SCN3B may not inhibit sodium channel trafficking, instead may affect conduction of sodium ions due to its malfunction as an integral component of the channel complex. This study identifies the first AF-associated mutation in SCN3B, and suggests that mutations in SCN3B may be a new pathogenic cause of AF.</p>        <p>PMID: 20558140 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20193182&#x26;dopt=Abstract\">[Chronic outcome of patients with paroxysmal atrial fibrillation post catheter ablation]</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20193182">Related Articles</a></td></tr></table>        <p><b>[Chronic outcome of patients with paroxysmal atrial fibrillation post catheter ablation]</b></p>        <p>Zhonghua Xin Xue Guan Bing Za Zhi. 2009 Dec;37(12):1101-4</p>        <p>Authors:  Lin YB, Xia YL, Gao LJ, Chu ZL, Cong PX, Chang D, Yin XM, Zhang SL, Yang DH, Yang YZ</p>        <p>OBJECTIVE: High short-term successful rate was reported for catheter ablation in patients with paroxysmal atrial fibrillation (AF), we analyzed the long-term outcome (success rate, anticoagulation therapy and embolism event, anti-arrhythmic therapy and death post procedure) of catheter ablation for paroxysmal AF in this study. METHODS: From January 2000 to December 2004, 106 consecutive patients with drug-refractory paroxysmal AF underwent catheter ablation and were followed-up for (60.7 + or - 11.8) months. Segmental pulmonary vein isolation (SPVI) was routinely performed by radiofrequency energy under the guidance of circular mapping catheter. The patients were followed up with 24 h-holter, ECG, telephone or letter. Data on recurrence of AF, the anticoagulation medication and the incidence of embolism, anti-arrhythmic therapy were obtained. RESULTS: There were 9 patients lost to follow up. In the remaining 97 patients [65 males, (54.8 + or - 11.2) years old], 3 cases died from cancer, sinus rhythm was maintained in 68 patients (Group S, 72.3%) and AF recurrence evidenced in 26 patients (Group R, 27.7%). In Group S, 56 patients (82.4%) discontinued anticoagulation medication, and 12 patients continued to take aspirin. There was no embolism event in Group S during follow-up. In Group R, 1 patient continued to take warfarin; 11 patients continued to take aspirin and 2 patients suffered from cerebral embolism. Anticoagulation medication was discontinued in 14 patients (53.8%) and 1 patient suffered form cerebral embolism. The incidence of embolism event in Group R is significantly higher than in Group S (P &#x26;lt; 0.01). More patients discontinued anti-arrhythmic medication in Group S than in Group R (80.9% vs. 56.0%, P &#x26;lt; 0.05). CONCLUSION: Catheter ablation is associated with satisfactory long-term success rate, reduced anti-arrhythmia medication, improved quality of life in patients with paroxysmal AF.</p>        <p>PMID: 20193182 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19923144&#x26;dopt=Abstract\">Outcome of atrial fibrillation among patients with end-stage renal disease.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://ndt.oxfordjournals.org/cgi/pmidlookup?view=long&#x26;amp;pmid=19923144"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--highwire.stanford.edu-icons-externalservices-pubmed-custom-oxfordjournals_final.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19923144">Related Articles</a></td></tr></table>        <p><b>Outcome of atrial fibrillation among patients with end-stage renal disease.</b></p>        <p>Nephrol Dial Transplant. 2010 Apr;25(4):1225-30</p>        <p>Authors:  Chou CY, Kuo HL, Wang SM, Liu JH, Lin HH, Liu YL, Huang CC</p>        <p>BACKGROUND: End-stage renal disease (ESRD) patients are more at risk for atrial fibrillation (AF) than the general population. However, the prognosis in ESRD patients with paroxysmal AF (PaAF), permanent AF (PAF) and paroxysmal AF transformed to permanent AF (TAF) is unknown. METHODS: In this retrospective longitudinal study, all ESRD patients with PaAF, PAF and TAF between January 2001 and December 2007 were reviewed. The development of thromboembolic events (TEE) was analyzed using Kaplan-Meier analysis and Cox regression. RESULTS: A total of 81 patients with PaAF, 49 patients with PAF and 89 patients with TAF were reviewed. Seventy-two (32.9%) patients developed TEE, and 63 (28.8%) patients died in 36.9 +/- 21.9 months. Patient survival was not significantly different between patients with different types of AF (P = 0.728). Patients with PaAF had a significantly lower TEE-free survival compared to patients with PAF (P = 0.036). In multivariate Cox regression, patients with paroxysmal AF were more at risk for TEE (P = 0.045) with a hazard ratio of 1.61 (95% confidence interval: 1.01-2.58). PaAF and congestive heart failure, hypertension, age older than 75 years, diabetes, and previous stroke or transient ischemic stroke (CHADS(2)) score were independently associated with an increase in TEE risk (P = 0.028 and P = 0.03). CONCLUSION: Patient survival is not different in patients with paroxysmal and permanent atrial fibrillation. However, patients with paroxysmal AF are more at risk for the development of TEE than those with permanent AF.</p>        <p>PMID: 19923144 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19845751&#x26;dopt=Abstract\">Brain natriuretic peptide as a predictor of delayed atrial fibrillation after ischaemic stroke and transient ischaemic attack.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www3.interscience.wiley.com/resolve/openurl?genre=article&#x26;amp;sid=nlm:pubmed&#x26;amp;issn=1351-5101&#x26;amp;date=2010&#x26;amp;volume=17&#x26;amp;issue=2&#x26;amp;spage=326"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www3.interscience.wiley.com-aboutus-images-wiley_interscience_pubmed_logo_120x27.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19845751">Related Articles</a></td></tr></table>        <p><b>Brain natriuretic peptide as a predictor of delayed atrial fibrillation after ischaemic stroke and transient ischaemic attack.</b></p>        <p>Eur J Neurol. 2010 Feb;17(2):326-31</p>        <p>Authors:  Okada Y, Shibazaki K, Kimura K, Iguchi Y, Miki T</p>        <p>BACKGROUND AND PURPOSE: We investigated whether the brain natriuretic peptide (BNP) level can serve as a predictive biological marker of delayed atrial fibrillation (AF). METHODS: Two hundred and thirty seven consecutive patients admitted to our institution with acute ischaemic stroke or transient ischaemic attack (TIA) within 24 h of onset were enrolled. The patients were classified according to the presence or absence of AF upon admission [AF and sinus rhythm (SR) groups]. The SR group was subdivided based on the development of AF after admission (new- and non-AF groups). We compared the characteristics between the AF and SR groups, and between the new- and non-AF groups. The factors associated with new-AF were investigated by multivariate logistic regression analysis. RESULTS: Amongst the enrolled patients, 72 (30.4%) had AF upon admission (AF group), and 13 (5.5%) developed AF thereafter (new-AF group). The plasma BNP level was significantly higher in the AF, than in the SR group (401.7 vs. 92.1 pg/ml, P &#x26;lt; 0.001). Moreover, the plasma BNP level was significantly higher in the new-, than in the non-AF group (184.7 vs. 84.1 pg/ml, P &#x26;lt; 0.001). The optimal cutoff BNP level required to distinguish new-, from non-AF groups was 85.0 pg/ml, and the sensitivity and specificity was 83.3% and 76.2%, respectively. On multivariate logistic regression analysis, plasma BNP level &#x26;gt;85.0 pg/ml (odds ratio, 7.20; 95% confidence interval, 1.71 to 30.43, P = 0.007) was an independent factor associated with new-AF. CONCLUSION: High plasma BNP level should be a strong predictor of delayed AF after ischaemic stroke or TIA.</p>        <p>PMID: 19845751 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19687749&#x26;dopt=Abstract\">S-Nitrosylation of cardiac ion channels.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0160-2446&#x26;amp;volume=54&#x26;amp;issue=3&#x26;amp;spage=188"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.lwwonline.com-pt-pt-core-template-journal-lwwgateway-images-pmlogo.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19687749">Related Articles</a></td></tr></table>        <p><b>S-Nitrosylation of cardiac ion channels.</b></p>        <p>J Cardiovasc Pharmacol. 2009 Sep;54(3):188-95</p>        <p>Authors:  Gonzalez DR, Treuer A, Sun QA, Stamler JS, Hare JM</p>        <p>Nitric oxide (NO) exerts ubiquitous signaling via posttranslational modification of cysteine residues, a reaction termed S-nitrosylation. Important substrates of S-nitrosylation that influence cardiac function include receptors, enzymes, ion channels, transcription factors, and structural proteins. Cardiac ion channels subserving excitation-contraction coupling are potentially regulated by S-nitrosylation. Specificity is achieved in part by spatial colocalization of ion channels with nitric oxide synthases (NOSs), enzymatic sources of NO in biologic systems, and by coupling of NOS activity to localized calcium/second messenger concentrations. Ion channels regulate cardiac excitability and contractility in millisecond timescales, raising the possibility that NO-related species modulate heart function on a beat-to-beat basis. This review focuses on recent advances in understanding of NO regulation of the cardiac action potential and of the calcium release channel ryanodine receptor, which is crucial for the generation of force. S-Nitrosylation signaling is disrupted in pathological states in which the redox state of the cell is dysregulated, including ischemia, heart failure, and atrial fibrillation.</p>        <p>PMID: 19687749 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('</ul>');
document.write('</div>');
document.write('<div class=\"rss_feed\">');
document.write('<div class=\"rss_feed_title\">pubmed: "atrial fibrillation...</div>');
document.write('<ul class=\"rss_item_list\">');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20605835&#x26;dopt=Abstract\">Obstructive sleep apnea is a risk factor for stroke and atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www.chestjournal.org/cgi/pmidlookup?view=long&#x26;amp;pmid=20605835"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--highwire.stanford.edu-icons-externalservices-pubmed-standard-chest_final.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20605835">Related Articles</a></td></tr></table>        <p><b>Obstructive sleep apnea is a risk factor for stroke and atrial fibrillation.</b></p>        <p>Chest. 2010 Jul;138(1):239; author reply 239-40</p>        <p>Authors:  Johnson KG, Johnson DC</p>        <p></p>        <p>PMID: 20605835 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20598971&#x26;dopt=Abstract\">The MOnitoring Resynchronization dEvices and CARdiac patiEnts (MORE-CARE) study: rationale and design.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0002-8703(10)00330-3"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20598971">Related Articles</a></td></tr></table>        <p><b>The MOnitoring Resynchronization dEvices and CARdiac patiEnts (MORE-CARE) study: rationale and design.</b></p>        <p>Am Heart J. 2010 Jul;160(1):42-8</p>        <p>Authors:  Burri H, Quesada A, Ricci RP, Boriani G, Davinelli M, Favale S, Da Costa A, Kautzner J, Moser R, Navarro X, Santini M</p>        <p>BACKGROUND: With the advent of remote monitoring, current models of implantable cardioverter defibrillators (ICDs) have the possibility of sending automatic alert messages that allow early diagnosis of events such as lung fluid overload, atrial fibrillation and device integrity issues. Timely treatment of these events has the potential to improve patient outcome, but this has not as yet been proven. METHODS: The MORE-CARE study is a multicenter randomized controlled trial evaluating the efficacy of advanced device diagnostics and remote monitoring in improving the outcome of patients with biventricular ICDs. Up to 1720 patients with a standard indication for a biventricular ICD will be randomized to standard in-office follow-up, or to a remote monitoring strategy using the CareLink network and involving automatic alerts for lung fluid overload, atrial fibrillation, and device integrity issues. The first phase aims at evaluating the delay between an alert event, and clinical action to the event. The second phase of the study will evaluate whether the remote monitoring strategy results in a significant reduction of a combined end point of total mortality or cardiovascular and device-related hospitalization. The duration of the study will be event-driven due to its sequential design. CONCLUSION: MORE-CARE will evaluate the efficacy of remote monitoring for improving patient outcome in patients implanted with a biventricular ICD.</p>        <p>PMID: 20598971 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20598970&#x26;dopt=Abstract\">Cryptogenic Stroke and underlying Atrial Fibrillation (CRYSTAL AF): design and rationale.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0002-8703(10)00268-1"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20598970">Related Articles</a></td></tr></table>        <p><b>Cryptogenic Stroke and underlying Atrial Fibrillation (CRYSTAL AF): design and rationale.</b></p>        <p>Am Heart J. 2010 Jul;160(1):36-41.e1</p>        <p>Authors:  Sinha AM, Diener HC, Morillo CA, Sanna T, Bernstein RA, Di Lazzaro V, Passman R, Beckers F, Brachmann J</p>        <p>BACKGROUND: Patients with atrial fibrillation (AF) are at increased risk for ischemic stroke. In patients who have suffered a stroke, screening for AF is routinely performed only for a short period after the stroke as part of the evaluation for possible causes. If AF is detected after an ischemic stroke, oral anticoagulation therapy is recommended for secondary stroke prevention. In 25% to 30% of stroke patients, the stroke mechanism cannot be determined (cryptogenic stroke). The incidence of paroxysmal AF undetected by short-term monitoring in patients with cryptogenic stroke is unknown, but has important therapeutic implications on patient care. The optimum monitoring duration and method of AF detection after stroke are unknown. The purpose of this study is to evaluate the incidence of AF and time to AF detection in patients with cryptogenic stroke using an insertable cardiac monitor. STUDY DESIGN: The CRYSTAL AF trial is a randomized prospective study to evaluate a novel approach to long-term monitoring for AF detection in patients with cryptogenic stroke. Four hundred fifty cryptogenic stroke patients (by definition, without a history of AF) will be enrolled at approximately 50 sites in Europe, Canada, and the United States. Patients will be randomized in a 1:1 fashion to standard arrhythmia monitoring (control arm) or implantation of the subcutaneous cardiac monitor (Reveal XT; Medtronic, Inc, Minneapolis, MN) (continuous monitoring arm). OUTCOMES: The primary end point is time to detection of AF within 6 months after stroke. The clinical follow-up period will be at least 12 months. Study completion is expected at the end of 2012.</p>        <p>PMID: 20598970 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20558140&#x26;dopt=Abstract\">Functional dominant-negative mutation of sodium channel subunit gene SCN3B associated with atrial fibrillation in a Chinese GeneID population.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0006-291X(10)01152-6"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20558140">Related Articles</a></td></tr></table>        <p><b>Functional dominant-negative mutation of sodium channel subunit gene SCN3B associated with atrial fibrillation in a Chinese GeneID population.</b></p>        <p>Biochem Biophys Res Commun. 2010 Jul 16;398(1):98-104</p>        <p>Authors:  Wang P, Yang Q, Wu X, Yang Y, Shi L, Wang C, Wu G, Xia Y, Yang B, Zhang R, Xu C, Cheng X, Li S, Zhao Y, Fu F, Liao Y, Fang F, Chen Q, Tu X, Wang QK</p>        <p>Atrial fibrillation (AF) is the most common cardiac arrhythmia in the clinic, and accounts for more than 15% of strokes. Mutations in cardiac sodium channel alpha, beta1 and beta2 subunit genes (SCN5A, SCN1B, and SCN2B) have been identified in AF patients. We hypothesize that mutations in the sodium channel beta3 subunit gene SCN3B are also associated with AF. To test this hypothesis, we carried out a large scale sequencing analysis of all coding exons and exon-intron boundaries of SCN3B in 477 AF patients (28.5% lone AF) from the GeneID Chinese Han population. A novel A130V mutation was identified in a 46-year-old patient with lone AF, and the mutation was absent in 500 controls. Mutation A130V dramatically decreased the cardiac sodium current density when expressed in HEK293/Na(v)1.5 stable cell line, but did not have significant effect on kinetics of activation, inactivation, and channel recovery from inactivation. When co-expressed with wild type SCN3B, the A130V mutant SCN3B negated the function of wild type SCN3B, suggesting that A130V acts by a dominant negative mechanism. Western blot analysis with biotinylated plasma membrane protein extracts revealed that A130V did not affect cell surface expression of Na(v)1.5 or SCN3B, suggesting that mutant A130V SCN3B may not inhibit sodium channel trafficking, instead may affect conduction of sodium ions due to its malfunction as an integral component of the channel complex. This study identifies the first AF-associated mutation in SCN3B, and suggests that mutations in SCN3B may be a new pathogenic cause of AF.</p>        <p>PMID: 20558140 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20193182&#x26;dopt=Abstract\">[Chronic outcome of patients with paroxysmal atrial fibrillation post catheter ablation]</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20193182">Related Articles</a></td></tr></table>        <p><b>[Chronic outcome of patients with paroxysmal atrial fibrillation post catheter ablation]</b></p>        <p>Zhonghua Xin Xue Guan Bing Za Zhi. 2009 Dec;37(12):1101-4</p>        <p>Authors:  Lin YB, Xia YL, Gao LJ, Chu ZL, Cong PX, Chang D, Yin XM, Zhang SL, Yang DH, Yang YZ</p>        <p>OBJECTIVE: High short-term successful rate was reported for catheter ablation in patients with paroxysmal atrial fibrillation (AF), we analyzed the long-term outcome (success rate, anticoagulation therapy and embolism event, anti-arrhythmic therapy and death post procedure) of catheter ablation for paroxysmal AF in this study. METHODS: From January 2000 to December 2004, 106 consecutive patients with drug-refractory paroxysmal AF underwent catheter ablation and were followed-up for (60.7 + or - 11.8) months. Segmental pulmonary vein isolation (SPVI) was routinely performed by radiofrequency energy under the guidance of circular mapping catheter. The patients were followed up with 24 h-holter, ECG, telephone or letter. Data on recurrence of AF, the anticoagulation medication and the incidence of embolism, anti-arrhythmic therapy were obtained. RESULTS: There were 9 patients lost to follow up. In the remaining 97 patients [65 males, (54.8 + or - 11.2) years old], 3 cases died from cancer, sinus rhythm was maintained in 68 patients (Group S, 72.3%) and AF recurrence evidenced in 26 patients (Group R, 27.7%). In Group S, 56 patients (82.4%) discontinued anticoagulation medication, and 12 patients continued to take aspirin. There was no embolism event in Group S during follow-up. In Group R, 1 patient continued to take warfarin; 11 patients continued to take aspirin and 2 patients suffered from cerebral embolism. Anticoagulation medication was discontinued in 14 patients (53.8%) and 1 patient suffered form cerebral embolism. The incidence of embolism event in Group R is significantly higher than in Group S (P &#x26;lt; 0.01). More patients discontinued anti-arrhythmic medication in Group S than in Group R (80.9% vs. 56.0%, P &#x26;lt; 0.05). CONCLUSION: Catheter ablation is associated with satisfactory long-term success rate, reduced anti-arrhythmia medication, improved quality of life in patients with paroxysmal AF.</p>        <p>PMID: 20193182 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19923144&#x26;dopt=Abstract\">Outcome of atrial fibrillation among patients with end-stage renal disease.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://ndt.oxfordjournals.org/cgi/pmidlookup?view=long&#x26;amp;pmid=19923144"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--highwire.stanford.edu-icons-externalservices-pubmed-custom-oxfordjournals_final.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19923144">Related Articles</a></td></tr></table>        <p><b>Outcome of atrial fibrillation among patients with end-stage renal disease.</b></p>        <p>Nephrol Dial Transplant. 2010 Apr;25(4):1225-30</p>        <p>Authors:  Chou CY, Kuo HL, Wang SM, Liu JH, Lin HH, Liu YL, Huang CC</p>        <p>BACKGROUND: End-stage renal disease (ESRD) patients are more at risk for atrial fibrillation (AF) than the general population. However, the prognosis in ESRD patients with paroxysmal AF (PaAF), permanent AF (PAF) and paroxysmal AF transformed to permanent AF (TAF) is unknown. METHODS: In this retrospective longitudinal study, all ESRD patients with PaAF, PAF and TAF between January 2001 and December 2007 were reviewed. The development of thromboembolic events (TEE) was analyzed using Kaplan-Meier analysis and Cox regression. RESULTS: A total of 81 patients with PaAF, 49 patients with PAF and 89 patients with TAF were reviewed. Seventy-two (32.9%) patients developed TEE, and 63 (28.8%) patients died in 36.9 +/- 21.9 months. Patient survival was not significantly different between patients with different types of AF (P = 0.728). Patients with PaAF had a significantly lower TEE-free survival compared to patients with PAF (P = 0.036). In multivariate Cox regression, patients with paroxysmal AF were more at risk for TEE (P = 0.045) with a hazard ratio of 1.61 (95% confidence interval: 1.01-2.58). PaAF and congestive heart failure, hypertension, age older than 75 years, diabetes, and previous stroke or transient ischemic stroke (CHADS(2)) score were independently associated with an increase in TEE risk (P = 0.028 and P = 0.03). CONCLUSION: Patient survival is not different in patients with paroxysmal and permanent atrial fibrillation. However, patients with paroxysmal AF are more at risk for the development of TEE than those with permanent AF.</p>        <p>PMID: 19923144 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19845751&#x26;dopt=Abstract\">Brain natriuretic peptide as a predictor of delayed atrial fibrillation after ischaemic stroke and transient ischaemic attack.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www3.interscience.wiley.com/resolve/openurl?genre=article&#x26;amp;sid=nlm:pubmed&#x26;amp;issn=1351-5101&#x26;amp;date=2010&#x26;amp;volume=17&#x26;amp;issue=2&#x26;amp;spage=326"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www3.interscience.wiley.com-aboutus-images-wiley_interscience_pubmed_logo_120x27.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19845751">Related Articles</a></td></tr></table>        <p><b>Brain natriuretic peptide as a predictor of delayed atrial fibrillation after ischaemic stroke and transient ischaemic attack.</b></p>        <p>Eur J Neurol. 2010 Feb;17(2):326-31</p>        <p>Authors:  Okada Y, Shibazaki K, Kimura K, Iguchi Y, Miki T</p>        <p>BACKGROUND AND PURPOSE: We investigated whether the brain natriuretic peptide (BNP) level can serve as a predictive biological marker of delayed atrial fibrillation (AF). METHODS: Two hundred and thirty seven consecutive patients admitted to our institution with acute ischaemic stroke or transient ischaemic attack (TIA) within 24 h of onset were enrolled. The patients were classified according to the presence or absence of AF upon admission [AF and sinus rhythm (SR) groups]. The SR group was subdivided based on the development of AF after admission (new- and non-AF groups). We compared the characteristics between the AF and SR groups, and between the new- and non-AF groups. The factors associated with new-AF were investigated by multivariate logistic regression analysis. RESULTS: Amongst the enrolled patients, 72 (30.4%) had AF upon admission (AF group), and 13 (5.5%) developed AF thereafter (new-AF group). The plasma BNP level was significantly higher in the AF, than in the SR group (401.7 vs. 92.1 pg/ml, P &#x26;lt; 0.001). Moreover, the plasma BNP level was significantly higher in the new-, than in the non-AF group (184.7 vs. 84.1 pg/ml, P &#x26;lt; 0.001). The optimal cutoff BNP level required to distinguish new-, from non-AF groups was 85.0 pg/ml, and the sensitivity and specificity was 83.3% and 76.2%, respectively. On multivariate logistic regression analysis, plasma BNP level &#x26;gt;85.0 pg/ml (odds ratio, 7.20; 95% confidence interval, 1.71 to 30.43, P = 0.007) was an independent factor associated with new-AF. CONCLUSION: High plasma BNP level should be a strong predictor of delayed AF after ischaemic stroke or TIA.</p>        <p>PMID: 19845751 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19687749&#x26;dopt=Abstract\">S-Nitrosylation of cardiac ion channels.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0160-2446&#x26;amp;volume=54&#x26;amp;issue=3&#x26;amp;spage=188"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.lwwonline.com-pt-pt-core-template-journal-lwwgateway-images-pmlogo.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19687749">Related Articles</a></td></tr></table>        <p><b>S-Nitrosylation of cardiac ion channels.</b></p>        <p>J Cardiovasc Pharmacol. 2009 Sep;54(3):188-95</p>        <p>Authors:  Gonzalez DR, Treuer A, Sun QA, Stamler JS, Hare JM</p>        <p>Nitric oxide (NO) exerts ubiquitous signaling via posttranslational modification of cysteine residues, a reaction termed S-nitrosylation. Important substrates of S-nitrosylation that influence cardiac function include receptors, enzymes, ion channels, transcription factors, and structural proteins. Cardiac ion channels subserving excitation-contraction coupling are potentially regulated by S-nitrosylation. Specificity is achieved in part by spatial colocalization of ion channels with nitric oxide synthases (NOSs), enzymatic sources of NO in biologic systems, and by coupling of NOS activity to localized calcium/second messenger concentrations. Ion channels regulate cardiac excitability and contractility in millisecond timescales, raising the possibility that NO-related species modulate heart function on a beat-to-beat basis. This review focuses on recent advances in understanding of NO regulation of the cardiac action potential and of the calcium release channel ryanodine receptor, which is crucial for the generation of force. S-Nitrosylation signaling is disrupted in pathological states in which the redox state of the cell is dysregulated, including ischemia, heart failure, and atrial fibrillation.</p>        <p>PMID: 19687749 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('</ul>');
document.write('</div>');
document.write('<div class=\"rss_feed\">');
document.write('<div class=\"rss_feed_title\">pubmed: "atrial fibrillation...</div>');
document.write('<ul class=\"rss_item_list\">');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20605835&#x26;dopt=Abstract\">Obstructive sleep apnea is a risk factor for stroke and atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www.chestjournal.org/cgi/pmidlookup?view=long&#x26;amp;pmid=20605835"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--highwire.stanford.edu-icons-externalservices-pubmed-standard-chest_final.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20605835">Related Articles</a></td></tr></table>        <p><b>Obstructive sleep apnea is a risk factor for stroke and atrial fibrillation.</b></p>        <p>Chest. 2010 Jul;138(1):239; author reply 239-40</p>        <p>Authors:  Johnson KG, Johnson DC</p>        <p></p>        <p>PMID: 20605835 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20598971&#x26;dopt=Abstract\">The MOnitoring Resynchronization dEvices and CARdiac patiEnts (MORE-CARE) study: rationale and design.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0002-8703(10)00330-3"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20598971">Related Articles</a></td></tr></table>        <p><b>The MOnitoring Resynchronization dEvices and CARdiac patiEnts (MORE-CARE) study: rationale and design.</b></p>        <p>Am Heart J. 2010 Jul;160(1):42-8</p>        <p>Authors:  Burri H, Quesada A, Ricci RP, Boriani G, Davinelli M, Favale S, Da Costa A, Kautzner J, Moser R, Navarro X, Santini M</p>        <p>BACKGROUND: With the advent of remote monitoring, current models of implantable cardioverter defibrillators (ICDs) have the possibility of sending automatic alert messages that allow early diagnosis of events such as lung fluid overload, atrial fibrillation and device integrity issues. Timely treatment of these events has the potential to improve patient outcome, but this has not as yet been proven. METHODS: The MORE-CARE study is a multicenter randomized controlled trial evaluating the efficacy of advanced device diagnostics and remote monitoring in improving the outcome of patients with biventricular ICDs. Up to 1720 patients with a standard indication for a biventricular ICD will be randomized to standard in-office follow-up, or to a remote monitoring strategy using the CareLink network and involving automatic alerts for lung fluid overload, atrial fibrillation, and device integrity issues. The first phase aims at evaluating the delay between an alert event, and clinical action to the event. The second phase of the study will evaluate whether the remote monitoring strategy results in a significant reduction of a combined end point of total mortality or cardiovascular and device-related hospitalization. The duration of the study will be event-driven due to its sequential design. CONCLUSION: MORE-CARE will evaluate the efficacy of remote monitoring for improving patient outcome in patients implanted with a biventricular ICD.</p>        <p>PMID: 20598971 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20598970&#x26;dopt=Abstract\">Cryptogenic Stroke and underlying Atrial Fibrillation (CRYSTAL AF): design and rationale.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0002-8703(10)00268-1"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20598970">Related Articles</a></td></tr></table>        <p><b>Cryptogenic Stroke and underlying Atrial Fibrillation (CRYSTAL AF): design and rationale.</b></p>        <p>Am Heart J. 2010 Jul;160(1):36-41.e1</p>        <p>Authors:  Sinha AM, Diener HC, Morillo CA, Sanna T, Bernstein RA, Di Lazzaro V, Passman R, Beckers F, Brachmann J</p>        <p>BACKGROUND: Patients with atrial fibrillation (AF) are at increased risk for ischemic stroke. In patients who have suffered a stroke, screening for AF is routinely performed only for a short period after the stroke as part of the evaluation for possible causes. If AF is detected after an ischemic stroke, oral anticoagulation therapy is recommended for secondary stroke prevention. In 25% to 30% of stroke patients, the stroke mechanism cannot be determined (cryptogenic stroke). The incidence of paroxysmal AF undetected by short-term monitoring in patients with cryptogenic stroke is unknown, but has important therapeutic implications on patient care. The optimum monitoring duration and method of AF detection after stroke are unknown. The purpose of this study is to evaluate the incidence of AF and time to AF detection in patients with cryptogenic stroke using an insertable cardiac monitor. STUDY DESIGN: The CRYSTAL AF trial is a randomized prospective study to evaluate a novel approach to long-term monitoring for AF detection in patients with cryptogenic stroke. Four hundred fifty cryptogenic stroke patients (by definition, without a history of AF) will be enrolled at approximately 50 sites in Europe, Canada, and the United States. Patients will be randomized in a 1:1 fashion to standard arrhythmia monitoring (control arm) or implantation of the subcutaneous cardiac monitor (Reveal XT; Medtronic, Inc, Minneapolis, MN) (continuous monitoring arm). OUTCOMES: The primary end point is time to detection of AF within 6 months after stroke. The clinical follow-up period will be at least 12 months. Study completion is expected at the end of 2012.</p>        <p>PMID: 20598970 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20558140&#x26;dopt=Abstract\">Functional dominant-negative mutation of sodium channel subunit gene SCN3B associated with atrial fibrillation in a Chinese GeneID population.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0006-291X(10)01152-6"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20558140">Related Articles</a></td></tr></table>        <p><b>Functional dominant-negative mutation of sodium channel subunit gene SCN3B associated with atrial fibrillation in a Chinese GeneID population.</b></p>        <p>Biochem Biophys Res Commun. 2010 Jul 16;398(1):98-104</p>        <p>Authors:  Wang P, Yang Q, Wu X, Yang Y, Shi L, Wang C, Wu G, Xia Y, Yang B, Zhang R, Xu C, Cheng X, Li S, Zhao Y, Fu F, Liao Y, Fang F, Chen Q, Tu X, Wang QK</p>        <p>Atrial fibrillation (AF) is the most common cardiac arrhythmia in the clinic, and accounts for more than 15% of strokes. Mutations in cardiac sodium channel alpha, beta1 and beta2 subunit genes (SCN5A, SCN1B, and SCN2B) have been identified in AF patients. We hypothesize that mutations in the sodium channel beta3 subunit gene SCN3B are also associated with AF. To test this hypothesis, we carried out a large scale sequencing analysis of all coding exons and exon-intron boundaries of SCN3B in 477 AF patients (28.5% lone AF) from the GeneID Chinese Han population. A novel A130V mutation was identified in a 46-year-old patient with lone AF, and the mutation was absent in 500 controls. Mutation A130V dramatically decreased the cardiac sodium current density when expressed in HEK293/Na(v)1.5 stable cell line, but did not have significant effect on kinetics of activation, inactivation, and channel recovery from inactivation. When co-expressed with wild type SCN3B, the A130V mutant SCN3B negated the function of wild type SCN3B, suggesting that A130V acts by a dominant negative mechanism. Western blot analysis with biotinylated plasma membrane protein extracts revealed that A130V did not affect cell surface expression of Na(v)1.5 or SCN3B, suggesting that mutant A130V SCN3B may not inhibit sodium channel trafficking, instead may affect conduction of sodium ions due to its malfunction as an integral component of the channel complex. This study identifies the first AF-associated mutation in SCN3B, and suggests that mutations in SCN3B may be a new pathogenic cause of AF.</p>        <p>PMID: 20558140 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20193182&#x26;dopt=Abstract\">[Chronic outcome of patients with paroxysmal atrial fibrillation post catheter ablation]</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20193182">Related Articles</a></td></tr></table>        <p><b>[Chronic outcome of patients with paroxysmal atrial fibrillation post catheter ablation]</b></p>        <p>Zhonghua Xin Xue Guan Bing Za Zhi. 2009 Dec;37(12):1101-4</p>        <p>Authors:  Lin YB, Xia YL, Gao LJ, Chu ZL, Cong PX, Chang D, Yin XM, Zhang SL, Yang DH, Yang YZ</p>        <p>OBJECTIVE: High short-term successful rate was reported for catheter ablation in patients with paroxysmal atrial fibrillation (AF), we analyzed the long-term outcome (success rate, anticoagulation therapy and embolism event, anti-arrhythmic therapy and death post procedure) of catheter ablation for paroxysmal AF in this study. METHODS: From January 2000 to December 2004, 106 consecutive patients with drug-refractory paroxysmal AF underwent catheter ablation and were followed-up for (60.7 + or - 11.8) months. Segmental pulmonary vein isolation (SPVI) was routinely performed by radiofrequency energy under the guidance of circular mapping catheter. The patients were followed up with 24 h-holter, ECG, telephone or letter. Data on recurrence of AF, the anticoagulation medication and the incidence of embolism, anti-arrhythmic therapy were obtained. RESULTS: There were 9 patients lost to follow up. In the remaining 97 patients [65 males, (54.8 + or - 11.2) years old], 3 cases died from cancer, sinus rhythm was maintained in 68 patients (Group S, 72.3%) and AF recurrence evidenced in 26 patients (Group R, 27.7%). In Group S, 56 patients (82.4%) discontinued anticoagulation medication, and 12 patients continued to take aspirin. There was no embolism event in Group S during follow-up. In Group R, 1 patient continued to take warfarin; 11 patients continued to take aspirin and 2 patients suffered from cerebral embolism. Anticoagulation medication was discontinued in 14 patients (53.8%) and 1 patient suffered form cerebral embolism. The incidence of embolism event in Group R is significantly higher than in Group S (P &#x26;lt; 0.01). More patients discontinued anti-arrhythmic medication in Group S than in Group R (80.9% vs. 56.0%, P &#x26;lt; 0.05). CONCLUSION: Catheter ablation is associated with satisfactory long-term success rate, reduced anti-arrhythmia medication, improved quality of life in patients with paroxysmal AF.</p>        <p>PMID: 20193182 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19923144&#x26;dopt=Abstract\">Outcome of atrial fibrillation among patients with end-stage renal disease.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://ndt.oxfordjournals.org/cgi/pmidlookup?view=long&#x26;amp;pmid=19923144"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--highwire.stanford.edu-icons-externalservices-pubmed-custom-oxfordjournals_final.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19923144">Related Articles</a></td></tr></table>        <p><b>Outcome of atrial fibrillation among patients with end-stage renal disease.</b></p>        <p>Nephrol Dial Transplant. 2010 Apr;25(4):1225-30</p>        <p>Authors:  Chou CY, Kuo HL, Wang SM, Liu JH, Lin HH, Liu YL, Huang CC</p>        <p>BACKGROUND: End-stage renal disease (ESRD) patients are more at risk for atrial fibrillation (AF) than the general population. However, the prognosis in ESRD patients with paroxysmal AF (PaAF), permanent AF (PAF) and paroxysmal AF transformed to permanent AF (TAF) is unknown. METHODS: In this retrospective longitudinal study, all ESRD patients with PaAF, PAF and TAF between January 2001 and December 2007 were reviewed. The development of thromboembolic events (TEE) was analyzed using Kaplan-Meier analysis and Cox regression. RESULTS: A total of 81 patients with PaAF, 49 patients with PAF and 89 patients with TAF were reviewed. Seventy-two (32.9%) patients developed TEE, and 63 (28.8%) patients died in 36.9 +/- 21.9 months. Patient survival was not significantly different between patients with different types of AF (P = 0.728). Patients with PaAF had a significantly lower TEE-free survival compared to patients with PAF (P = 0.036). In multivariate Cox regression, patients with paroxysmal AF were more at risk for TEE (P = 0.045) with a hazard ratio of 1.61 (95% confidence interval: 1.01-2.58). PaAF and congestive heart failure, hypertension, age older than 75 years, diabetes, and previous stroke or transient ischemic stroke (CHADS(2)) score were independently associated with an increase in TEE risk (P = 0.028 and P = 0.03). CONCLUSION: Patient survival is not different in patients with paroxysmal and permanent atrial fibrillation. However, patients with paroxysmal AF are more at risk for the development of TEE than those with permanent AF.</p>        <p>PMID: 19923144 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19845751&#x26;dopt=Abstract\">Brain natriuretic peptide as a predictor of delayed atrial fibrillation after ischaemic stroke and transient ischaemic attack.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www3.interscience.wiley.com/resolve/openurl?genre=article&#x26;amp;sid=nlm:pubmed&#x26;amp;issn=1351-5101&#x26;amp;date=2010&#x26;amp;volume=17&#x26;amp;issue=2&#x26;amp;spage=326"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www3.interscience.wiley.com-aboutus-images-wiley_interscience_pubmed_logo_120x27.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19845751">Related Articles</a></td></tr></table>        <p><b>Brain natriuretic peptide as a predictor of delayed atrial fibrillation after ischaemic stroke and transient ischaemic attack.</b></p>        <p>Eur J Neurol. 2010 Feb;17(2):326-31</p>        <p>Authors:  Okada Y, Shibazaki K, Kimura K, Iguchi Y, Miki T</p>        <p>BACKGROUND AND PURPOSE: We investigated whether the brain natriuretic peptide (BNP) level can serve as a predictive biological marker of delayed atrial fibrillation (AF). METHODS: Two hundred and thirty seven consecutive patients admitted to our institution with acute ischaemic stroke or transient ischaemic attack (TIA) within 24 h of onset were enrolled. The patients were classified according to the presence or absence of AF upon admission [AF and sinus rhythm (SR) groups]. The SR group was subdivided based on the development of AF after admission (new- and non-AF groups). We compared the characteristics between the AF and SR groups, and between the new- and non-AF groups. The factors associated with new-AF were investigated by multivariate logistic regression analysis. RESULTS: Amongst the enrolled patients, 72 (30.4%) had AF upon admission (AF group), and 13 (5.5%) developed AF thereafter (new-AF group). The plasma BNP level was significantly higher in the AF, than in the SR group (401.7 vs. 92.1 pg/ml, P &#x26;lt; 0.001). Moreover, the plasma BNP level was significantly higher in the new-, than in the non-AF group (184.7 vs. 84.1 pg/ml, P &#x26;lt; 0.001). The optimal cutoff BNP level required to distinguish new-, from non-AF groups was 85.0 pg/ml, and the sensitivity and specificity was 83.3% and 76.2%, respectively. On multivariate logistic regression analysis, plasma BNP level &#x26;gt;85.0 pg/ml (odds ratio, 7.20; 95% confidence interval, 1.71 to 30.43, P = 0.007) was an independent factor associated with new-AF. CONCLUSION: High plasma BNP level should be a strong predictor of delayed AF after ischaemic stroke or TIA.</p>        <p>PMID: 19845751 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19687749&#x26;dopt=Abstract\">S-Nitrosylation of cardiac ion channels.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0160-2446&#x26;amp;volume=54&#x26;amp;issue=3&#x26;amp;spage=188"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.lwwonline.com-pt-pt-core-template-journal-lwwgateway-images-pmlogo.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19687749">Related Articles</a></td></tr></table>        <p><b>S-Nitrosylation of cardiac ion channels.</b></p>        <p>J Cardiovasc Pharmacol. 2009 Sep;54(3):188-95</p>        <p>Authors:  Gonzalez DR, Treuer A, Sun QA, Stamler JS, Hare JM</p>        <p>Nitric oxide (NO) exerts ubiquitous signaling via posttranslational modification of cysteine residues, a reaction termed S-nitrosylation. Important substrates of S-nitrosylation that influence cardiac function include receptors, enzymes, ion channels, transcription factors, and structural proteins. Cardiac ion channels subserving excitation-contraction coupling are potentially regulated by S-nitrosylation. Specificity is achieved in part by spatial colocalization of ion channels with nitric oxide synthases (NOSs), enzymatic sources of NO in biologic systems, and by coupling of NOS activity to localized calcium/second messenger concentrations. Ion channels regulate cardiac excitability and contractility in millisecond timescales, raising the possibility that NO-related species modulate heart function on a beat-to-beat basis. This review focuses on recent advances in understanding of NO regulation of the cardiac action potential and of the calcium release channel ryanodine receptor, which is crucial for the generation of force. S-Nitrosylation signaling is disrupted in pathological states in which the redox state of the cell is dysregulated, including ischemia, heart failure, and atrial fibrillation.</p>        <p>PMID: 19687749 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('</ul>');
document.write('</div>');
document.write('<div class=\"rss_feed\">');
document.write('<div class=\"rss_feed_title\">pubmed: "atrial fibrillation...</div>');
document.write('<ul class=\"rss_item_list\">');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20605835&#x26;dopt=Abstract\">Obstructive sleep apnea is a risk factor for stroke and atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www.chestjournal.org/cgi/pmidlookup?view=long&#x26;amp;pmid=20605835"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--highwire.stanford.edu-icons-externalservices-pubmed-standard-chest_final.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20605835">Related Articles</a></td></tr></table>        <p><b>Obstructive sleep apnea is a risk factor for stroke and atrial fibrillation.</b></p>        <p>Chest. 2010 Jul;138(1):239; author reply 239-40</p>        <p>Authors:  Johnson KG, Johnson DC</p>        <p></p>        <p>PMID: 20605835 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20598971&#x26;dopt=Abstract\">The MOnitoring Resynchronization dEvices and CARdiac patiEnts (MORE-CARE) study: rationale and design.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0002-8703(10)00330-3"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20598971">Related Articles</a></td></tr></table>        <p><b>The MOnitoring Resynchronization dEvices and CARdiac patiEnts (MORE-CARE) study: rationale and design.</b></p>        <p>Am Heart J. 2010 Jul;160(1):42-8</p>        <p>Authors:  Burri H, Quesada A, Ricci RP, Boriani G, Davinelli M, Favale S, Da Costa A, Kautzner J, Moser R, Navarro X, Santini M</p>        <p>BACKGROUND: With the advent of remote monitoring, current models of implantable cardioverter defibrillators (ICDs) have the possibility of sending automatic alert messages that allow early diagnosis of events such as lung fluid overload, atrial fibrillation and device integrity issues. Timely treatment of these events has the potential to improve patient outcome, but this has not as yet been proven. METHODS: The MORE-CARE study is a multicenter randomized controlled trial evaluating the efficacy of advanced device diagnostics and remote monitoring in improving the outcome of patients with biventricular ICDs. Up to 1720 patients with a standard indication for a biventricular ICD will be randomized to standard in-office follow-up, or to a remote monitoring strategy using the CareLink network and involving automatic alerts for lung fluid overload, atrial fibrillation, and device integrity issues. The first phase aims at evaluating the delay between an alert event, and clinical action to the event. The second phase of the study will evaluate whether the remote monitoring strategy results in a significant reduction of a combined end point of total mortality or cardiovascular and device-related hospitalization. The duration of the study will be event-driven due to its sequential design. CONCLUSION: MORE-CARE will evaluate the efficacy of remote monitoring for improving patient outcome in patients implanted with a biventricular ICD.</p>        <p>PMID: 20598971 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20598970&#x26;dopt=Abstract\">Cryptogenic Stroke and underlying Atrial Fibrillation (CRYSTAL AF): design and rationale.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0002-8703(10)00268-1"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20598970">Related Articles</a></td></tr></table>        <p><b>Cryptogenic Stroke and underlying Atrial Fibrillation (CRYSTAL AF): design and rationale.</b></p>        <p>Am Heart J. 2010 Jul;160(1):36-41.e1</p>        <p>Authors:  Sinha AM, Diener HC, Morillo CA, Sanna T, Bernstein RA, Di Lazzaro V, Passman R, Beckers F, Brachmann J</p>        <p>BACKGROUND: Patients with atrial fibrillation (AF) are at increased risk for ischemic stroke. In patients who have suffered a stroke, screening for AF is routinely performed only for a short period after the stroke as part of the evaluation for possible causes. If AF is detected after an ischemic stroke, oral anticoagulation therapy is recommended for secondary stroke prevention. In 25% to 30% of stroke patients, the stroke mechanism cannot be determined (cryptogenic stroke). The incidence of paroxysmal AF undetected by short-term monitoring in patients with cryptogenic stroke is unknown, but has important therapeutic implications on patient care. The optimum monitoring duration and method of AF detection after stroke are unknown. The purpose of this study is to evaluate the incidence of AF and time to AF detection in patients with cryptogenic stroke using an insertable cardiac monitor. STUDY DESIGN: The CRYSTAL AF trial is a randomized prospective study to evaluate a novel approach to long-term monitoring for AF detection in patients with cryptogenic stroke. Four hundred fifty cryptogenic stroke patients (by definition, without a history of AF) will be enrolled at approximately 50 sites in Europe, Canada, and the United States. Patients will be randomized in a 1:1 fashion to standard arrhythmia monitoring (control arm) or implantation of the subcutaneous cardiac monitor (Reveal XT; Medtronic, Inc, Minneapolis, MN) (continuous monitoring arm). OUTCOMES: The primary end point is time to detection of AF within 6 months after stroke. The clinical follow-up period will be at least 12 months. Study completion is expected at the end of 2012.</p>        <p>PMID: 20598970 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20558140&#x26;dopt=Abstract\">Functional dominant-negative mutation of sodium channel subunit gene SCN3B associated with atrial fibrillation in a Chinese GeneID population.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0006-291X(10)01152-6"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20558140">Related Articles</a></td></tr></table>        <p><b>Functional dominant-negative mutation of sodium channel subunit gene SCN3B associated with atrial fibrillation in a Chinese GeneID population.</b></p>        <p>Biochem Biophys Res Commun. 2010 Jul 16;398(1):98-104</p>        <p>Authors:  Wang P, Yang Q, Wu X, Yang Y, Shi L, Wang C, Wu G, Xia Y, Yang B, Zhang R, Xu C, Cheng X, Li S, Zhao Y, Fu F, Liao Y, Fang F, Chen Q, Tu X, Wang QK</p>        <p>Atrial fibrillation (AF) is the most common cardiac arrhythmia in the clinic, and accounts for more than 15% of strokes. Mutations in cardiac sodium channel alpha, beta1 and beta2 subunit genes (SCN5A, SCN1B, and SCN2B) have been identified in AF patients. We hypothesize that mutations in the sodium channel beta3 subunit gene SCN3B are also associated with AF. To test this hypothesis, we carried out a large scale sequencing analysis of all coding exons and exon-intron boundaries of SCN3B in 477 AF patients (28.5% lone AF) from the GeneID Chinese Han population. A novel A130V mutation was identified in a 46-year-old patient with lone AF, and the mutation was absent in 500 controls. Mutation A130V dramatically decreased the cardiac sodium current density when expressed in HEK293/Na(v)1.5 stable cell line, but did not have significant effect on kinetics of activation, inactivation, and channel recovery from inactivation. When co-expressed with wild type SCN3B, the A130V mutant SCN3B negated the function of wild type SCN3B, suggesting that A130V acts by a dominant negative mechanism. Western blot analysis with biotinylated plasma membrane protein extracts revealed that A130V did not affect cell surface expression of Na(v)1.5 or SCN3B, suggesting that mutant A130V SCN3B may not inhibit sodium channel trafficking, instead may affect conduction of sodium ions due to its malfunction as an integral component of the channel complex. This study identifies the first AF-associated mutation in SCN3B, and suggests that mutations in SCN3B may be a new pathogenic cause of AF.</p>        <p>PMID: 20558140 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20193182&#x26;dopt=Abstract\">[Chronic outcome of patients with paroxysmal atrial fibrillation post catheter ablation]</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20193182">Related Articles</a></td></tr></table>        <p><b>[Chronic outcome of patients with paroxysmal atrial fibrillation post catheter ablation]</b></p>        <p>Zhonghua Xin Xue Guan Bing Za Zhi. 2009 Dec;37(12):1101-4</p>        <p>Authors:  Lin YB, Xia YL, Gao LJ, Chu ZL, Cong PX, Chang D, Yin XM, Zhang SL, Yang DH, Yang YZ</p>        <p>OBJECTIVE: High short-term successful rate was reported for catheter ablation in patients with paroxysmal atrial fibrillation (AF), we analyzed the long-term outcome (success rate, anticoagulation therapy and embolism event, anti-arrhythmic therapy and death post procedure) of catheter ablation for paroxysmal AF in this study. METHODS: From January 2000 to December 2004, 106 consecutive patients with drug-refractory paroxysmal AF underwent catheter ablation and were followed-up for (60.7 + or - 11.8) months. Segmental pulmonary vein isolation (SPVI) was routinely performed by radiofrequency energy under the guidance of circular mapping catheter. The patients were followed up with 24 h-holter, ECG, telephone or letter. Data on recurrence of AF, the anticoagulation medication and the incidence of embolism, anti-arrhythmic therapy were obtained. RESULTS: There were 9 patients lost to follow up. In the remaining 97 patients [65 males, (54.8 + or - 11.2) years old], 3 cases died from cancer, sinus rhythm was maintained in 68 patients (Group S, 72.3%) and AF recurrence evidenced in 26 patients (Group R, 27.7%). In Group S, 56 patients (82.4%) discontinued anticoagulation medication, and 12 patients continued to take aspirin. There was no embolism event in Group S during follow-up. In Group R, 1 patient continued to take warfarin; 11 patients continued to take aspirin and 2 patients suffered from cerebral embolism. Anticoagulation medication was discontinued in 14 patients (53.8%) and 1 patient suffered form cerebral embolism. The incidence of embolism event in Group R is significantly higher than in Group S (P &#x26;lt; 0.01). More patients discontinued anti-arrhythmic medication in Group S than in Group R (80.9% vs. 56.0%, P &#x26;lt; 0.05). CONCLUSION: Catheter ablation is associated with satisfactory long-term success rate, reduced anti-arrhythmia medication, improved quality of life in patients with paroxysmal AF.</p>        <p>PMID: 20193182 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19923144&#x26;dopt=Abstract\">Outcome of atrial fibrillation among patients with end-stage renal disease.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://ndt.oxfordjournals.org/cgi/pmidlookup?view=long&#x26;amp;pmid=19923144"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--highwire.stanford.edu-icons-externalservices-pubmed-custom-oxfordjournals_final.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19923144">Related Articles</a></td></tr></table>        <p><b>Outcome of atrial fibrillation among patients with end-stage renal disease.</b></p>        <p>Nephrol Dial Transplant. 2010 Apr;25(4):1225-30</p>        <p>Authors:  Chou CY, Kuo HL, Wang SM, Liu JH, Lin HH, Liu YL, Huang CC</p>        <p>BACKGROUND: End-stage renal disease (ESRD) patients are more at risk for atrial fibrillation (AF) than the general population. However, the prognosis in ESRD patients with paroxysmal AF (PaAF), permanent AF (PAF) and paroxysmal AF transformed to permanent AF (TAF) is unknown. METHODS: In this retrospective longitudinal study, all ESRD patients with PaAF, PAF and TAF between January 2001 and December 2007 were reviewed. The development of thromboembolic events (TEE) was analyzed using Kaplan-Meier analysis and Cox regression. RESULTS: A total of 81 patients with PaAF, 49 patients with PAF and 89 patients with TAF were reviewed. Seventy-two (32.9%) patients developed TEE, and 63 (28.8%) patients died in 36.9 +/- 21.9 months. Patient survival was not significantly different between patients with different types of AF (P = 0.728). Patients with PaAF had a significantly lower TEE-free survival compared to patients with PAF (P = 0.036). In multivariate Cox regression, patients with paroxysmal AF were more at risk for TEE (P = 0.045) with a hazard ratio of 1.61 (95% confidence interval: 1.01-2.58). PaAF and congestive heart failure, hypertension, age older than 75 years, diabetes, and previous stroke or transient ischemic stroke (CHADS(2)) score were independently associated with an increase in TEE risk (P = 0.028 and P = 0.03). CONCLUSION: Patient survival is not different in patients with paroxysmal and permanent atrial fibrillation. However, patients with paroxysmal AF are more at risk for the development of TEE than those with permanent AF.</p>        <p>PMID: 19923144 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19845751&#x26;dopt=Abstract\">Brain natriuretic peptide as a predictor of delayed atrial fibrillation after ischaemic stroke and transient ischaemic attack.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www3.interscience.wiley.com/resolve/openurl?genre=article&#x26;amp;sid=nlm:pubmed&#x26;amp;issn=1351-5101&#x26;amp;date=2010&#x26;amp;volume=17&#x26;amp;issue=2&#x26;amp;spage=326"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www3.interscience.wiley.com-aboutus-images-wiley_interscience_pubmed_logo_120x27.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19845751">Related Articles</a></td></tr></table>        <p><b>Brain natriuretic peptide as a predictor of delayed atrial fibrillation after ischaemic stroke and transient ischaemic attack.</b></p>        <p>Eur J Neurol. 2010 Feb;17(2):326-31</p>        <p>Authors:  Okada Y, Shibazaki K, Kimura K, Iguchi Y, Miki T</p>        <p>BACKGROUND AND PURPOSE: We investigated whether the brain natriuretic peptide (BNP) level can serve as a predictive biological marker of delayed atrial fibrillation (AF). METHODS: Two hundred and thirty seven consecutive patients admitted to our institution with acute ischaemic stroke or transient ischaemic attack (TIA) within 24 h of onset were enrolled. The patients were classified according to the presence or absence of AF upon admission [AF and sinus rhythm (SR) groups]. The SR group was subdivided based on the development of AF after admission (new- and non-AF groups). We compared the characteristics between the AF and SR groups, and between the new- and non-AF groups. The factors associated with new-AF were investigated by multivariate logistic regression analysis. RESULTS: Amongst the enrolled patients, 72 (30.4%) had AF upon admission (AF group), and 13 (5.5%) developed AF thereafter (new-AF group). The plasma BNP level was significantly higher in the AF, than in the SR group (401.7 vs. 92.1 pg/ml, P &#x26;lt; 0.001). Moreover, the plasma BNP level was significantly higher in the new-, than in the non-AF group (184.7 vs. 84.1 pg/ml, P &#x26;lt; 0.001). The optimal cutoff BNP level required to distinguish new-, from non-AF groups was 85.0 pg/ml, and the sensitivity and specificity was 83.3% and 76.2%, respectively. On multivariate logistic regression analysis, plasma BNP level &#x26;gt;85.0 pg/ml (odds ratio, 7.20; 95% confidence interval, 1.71 to 30.43, P = 0.007) was an independent factor associated with new-AF. CONCLUSION: High plasma BNP level should be a strong predictor of delayed AF after ischaemic stroke or TIA.</p>        <p>PMID: 19845751 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19687749&#x26;dopt=Abstract\">S-Nitrosylation of cardiac ion channels.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0160-2446&#x26;amp;volume=54&#x26;amp;issue=3&#x26;amp;spage=188"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.lwwonline.com-pt-pt-core-template-journal-lwwgateway-images-pmlogo.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19687749">Related Articles</a></td></tr></table>        <p><b>S-Nitrosylation of cardiac ion channels.</b></p>        <p>J Cardiovasc Pharmacol. 2009 Sep;54(3):188-95</p>        <p>Authors:  Gonzalez DR, Treuer A, Sun QA, Stamler JS, Hare JM</p>        <p>Nitric oxide (NO) exerts ubiquitous signaling via posttranslational modification of cysteine residues, a reaction termed S-nitrosylation. Important substrates of S-nitrosylation that influence cardiac function include receptors, enzymes, ion channels, transcription factors, and structural proteins. Cardiac ion channels subserving excitation-contraction coupling are potentially regulated by S-nitrosylation. Specificity is achieved in part by spatial colocalization of ion channels with nitric oxide synthases (NOSs), enzymatic sources of NO in biologic systems, and by coupling of NOS activity to localized calcium/second messenger concentrations. Ion channels regulate cardiac excitability and contractility in millisecond timescales, raising the possibility that NO-related species modulate heart function on a beat-to-beat basis. This review focuses on recent advances in understanding of NO regulation of the cardiac action potential and of the calcium release channel ryanodine receptor, which is crucial for the generation of force. S-Nitrosylation signaling is disrupted in pathological states in which the redox state of the cell is dysregulated, including ischemia, heart failure, and atrial fibrillation.</p>        <p>PMID: 19687749 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('</ul>');
document.write('</div>');
document.write('<div class=\"rss_feed\">');
document.write('<div class=\"rss_feed_title\">pubmed: "atrial fibrillation...</div>');
document.write('<ul class=\"rss_item_list\">');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20605835&#x26;dopt=Abstract\">Obstructive sleep apnea is a risk factor for stroke and atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www.chestjournal.org/cgi/pmidlookup?view=long&#x26;amp;pmid=20605835"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--highwire.stanford.edu-icons-externalservices-pubmed-standard-chest_final.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20605835">Related Articles</a></td></tr></table>        <p><b>Obstructive sleep apnea is a risk factor for stroke and atrial fibrillation.</b></p>        <p>Chest. 2010 Jul;138(1):239; author reply 239-40</p>        <p>Authors:  Johnson KG, Johnson DC</p>        <p></p>        <p>PMID: 20605835 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20598971&#x26;dopt=Abstract\">The MOnitoring Resynchronization dEvices and CARdiac patiEnts (MORE-CARE) study: rationale and design.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0002-8703(10)00330-3"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20598971">Related Articles</a></td></tr></table>        <p><b>The MOnitoring Resynchronization dEvices and CARdiac patiEnts (MORE-CARE) study: rationale and design.</b></p>        <p>Am Heart J. 2010 Jul;160(1):42-8</p>        <p>Authors:  Burri H, Quesada A, Ricci RP, Boriani G, Davinelli M, Favale S, Da Costa A, Kautzner J, Moser R, Navarro X, Santini M</p>        <p>BACKGROUND: With the advent of remote monitoring, current models of implantable cardioverter defibrillators (ICDs) have the possibility of sending automatic alert messages that allow early diagnosis of events such as lung fluid overload, atrial fibrillation and device integrity issues. Timely treatment of these events has the potential to improve patient outcome, but this has not as yet been proven. METHODS: The MORE-CARE study is a multicenter randomized controlled trial evaluating the efficacy of advanced device diagnostics and remote monitoring in improving the outcome of patients with biventricular ICDs. Up to 1720 patients with a standard indication for a biventricular ICD will be randomized to standard in-office follow-up, or to a remote monitoring strategy using the CareLink network and involving automatic alerts for lung fluid overload, atrial fibrillation, and device integrity issues. The first phase aims at evaluating the delay between an alert event, and clinical action to the event. The second phase of the study will evaluate whether the remote monitoring strategy results in a significant reduction of a combined end point of total mortality or cardiovascular and device-related hospitalization. The duration of the study will be event-driven due to its sequential design. CONCLUSION: MORE-CARE will evaluate the efficacy of remote monitoring for improving patient outcome in patients implanted with a biventricular ICD.</p>        <p>PMID: 20598971 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20598970&#x26;dopt=Abstract\">Cryptogenic Stroke and underlying Atrial Fibrillation (CRYSTAL AF): design and rationale.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0002-8703(10)00268-1"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20598970">Related Articles</a></td></tr></table>        <p><b>Cryptogenic Stroke and underlying Atrial Fibrillation (CRYSTAL AF): design and rationale.</b></p>        <p>Am Heart J. 2010 Jul;160(1):36-41.e1</p>        <p>Authors:  Sinha AM, Diener HC, Morillo CA, Sanna T, Bernstein RA, Di Lazzaro V, Passman R, Beckers F, Brachmann J</p>        <p>BACKGROUND: Patients with atrial fibrillation (AF) are at increased risk for ischemic stroke. In patients who have suffered a stroke, screening for AF is routinely performed only for a short period after the stroke as part of the evaluation for possible causes. If AF is detected after an ischemic stroke, oral anticoagulation therapy is recommended for secondary stroke prevention. In 25% to 30% of stroke patients, the stroke mechanism cannot be determined (cryptogenic stroke). The incidence of paroxysmal AF undetected by short-term monitoring in patients with cryptogenic stroke is unknown, but has important therapeutic implications on patient care. The optimum monitoring duration and method of AF detection after stroke are unknown. The purpose of this study is to evaluate the incidence of AF and time to AF detection in patients with cryptogenic stroke using an insertable cardiac monitor. STUDY DESIGN: The CRYSTAL AF trial is a randomized prospective study to evaluate a novel approach to long-term monitoring for AF detection in patients with cryptogenic stroke. Four hundred fifty cryptogenic stroke patients (by definition, without a history of AF) will be enrolled at approximately 50 sites in Europe, Canada, and the United States. Patients will be randomized in a 1:1 fashion to standard arrhythmia monitoring (control arm) or implantation of the subcutaneous cardiac monitor (Reveal XT; Medtronic, Inc, Minneapolis, MN) (continuous monitoring arm). OUTCOMES: The primary end point is time to detection of AF within 6 months after stroke. The clinical follow-up period will be at least 12 months. Study completion is expected at the end of 2012.</p>        <p>PMID: 20598970 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20558140&#x26;dopt=Abstract\">Functional dominant-negative mutation of sodium channel subunit gene SCN3B associated with atrial fibrillation in a Chinese GeneID population.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0006-291X(10)01152-6"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20558140">Related Articles</a></td></tr></table>        <p><b>Functional dominant-negative mutation of sodium channel subunit gene SCN3B associated with atrial fibrillation in a Chinese GeneID population.</b></p>        <p>Biochem Biophys Res Commun. 2010 Jul 16;398(1):98-104</p>        <p>Authors:  Wang P, Yang Q, Wu X, Yang Y, Shi L, Wang C, Wu G, Xia Y, Yang B, Zhang R, Xu C, Cheng X, Li S, Zhao Y, Fu F, Liao Y, Fang F, Chen Q, Tu X, Wang QK</p>        <p>Atrial fibrillation (AF) is the most common cardiac arrhythmia in the clinic, and accounts for more than 15% of strokes. Mutations in cardiac sodium channel alpha, beta1 and beta2 subunit genes (SCN5A, SCN1B, and SCN2B) have been identified in AF patients. We hypothesize that mutations in the sodium channel beta3 subunit gene SCN3B are also associated with AF. To test this hypothesis, we carried out a large scale sequencing analysis of all coding exons and exon-intron boundaries of SCN3B in 477 AF patients (28.5% lone AF) from the GeneID Chinese Han population. A novel A130V mutation was identified in a 46-year-old patient with lone AF, and the mutation was absent in 500 controls. Mutation A130V dramatically decreased the cardiac sodium current density when expressed in HEK293/Na(v)1.5 stable cell line, but did not have significant effect on kinetics of activation, inactivation, and channel recovery from inactivation. When co-expressed with wild type SCN3B, the A130V mutant SCN3B negated the function of wild type SCN3B, suggesting that A130V acts by a dominant negative mechanism. Western blot analysis with biotinylated plasma membrane protein extracts revealed that A130V did not affect cell surface expression of Na(v)1.5 or SCN3B, suggesting that mutant A130V SCN3B may not inhibit sodium channel trafficking, instead may affect conduction of sodium ions due to its malfunction as an integral component of the channel complex. This study identifies the first AF-associated mutation in SCN3B, and suggests that mutations in SCN3B may be a new pathogenic cause of AF.</p>        <p>PMID: 20558140 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20193182&#x26;dopt=Abstract\">[Chronic outcome of patients with paroxysmal atrial fibrillation post catheter ablation]</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20193182">Related Articles</a></td></tr></table>        <p><b>[Chronic outcome of patients with paroxysmal atrial fibrillation post catheter ablation]</b></p>        <p>Zhonghua Xin Xue Guan Bing Za Zhi. 2009 Dec;37(12):1101-4</p>        <p>Authors:  Lin YB, Xia YL, Gao LJ, Chu ZL, Cong PX, Chang D, Yin XM, Zhang SL, Yang DH, Yang YZ</p>        <p>OBJECTIVE: High short-term successful rate was reported for catheter ablation in patients with paroxysmal atrial fibrillation (AF), we analyzed the long-term outcome (success rate, anticoagulation therapy and embolism event, anti-arrhythmic therapy and death post procedure) of catheter ablation for paroxysmal AF in this study. METHODS: From January 2000 to December 2004, 106 consecutive patients with drug-refractory paroxysmal AF underwent catheter ablation and were followed-up for (60.7 + or - 11.8) months. Segmental pulmonary vein isolation (SPVI) was routinely performed by radiofrequency energy under the guidance of circular mapping catheter. The patients were followed up with 24 h-holter, ECG, telephone or letter. Data on recurrence of AF, the anticoagulation medication and the incidence of embolism, anti-arrhythmic therapy were obtained. RESULTS: There were 9 patients lost to follow up. In the remaining 97 patients [65 males, (54.8 + or - 11.2) years old], 3 cases died from cancer, sinus rhythm was maintained in 68 patients (Group S, 72.3%) and AF recurrence evidenced in 26 patients (Group R, 27.7%). In Group S, 56 patients (82.4%) discontinued anticoagulation medication, and 12 patients continued to take aspirin. There was no embolism event in Group S during follow-up. In Group R, 1 patient continued to take warfarin; 11 patients continued to take aspirin and 2 patients suffered from cerebral embolism. Anticoagulation medication was discontinued in 14 patients (53.8%) and 1 patient suffered form cerebral embolism. The incidence of embolism event in Group R is significantly higher than in Group S (P &#x26;lt; 0.01). More patients discontinued anti-arrhythmic medication in Group S than in Group R (80.9% vs. 56.0%, P &#x26;lt; 0.05). CONCLUSION: Catheter ablation is associated with satisfactory long-term success rate, reduced anti-arrhythmia medication, improved quality of life in patients with paroxysmal AF.</p>        <p>PMID: 20193182 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19923144&#x26;dopt=Abstract\">Outcome of atrial fibrillation among patients with end-stage renal disease.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://ndt.oxfordjournals.org/cgi/pmidlookup?view=long&#x26;amp;pmid=19923144"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--highwire.stanford.edu-icons-externalservices-pubmed-custom-oxfordjournals_final.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19923144">Related Articles</a></td></tr></table>        <p><b>Outcome of atrial fibrillation among patients with end-stage renal disease.</b></p>        <p>Nephrol Dial Transplant. 2010 Apr;25(4):1225-30</p>        <p>Authors:  Chou CY, Kuo HL, Wang SM, Liu JH, Lin HH, Liu YL, Huang CC</p>        <p>BACKGROUND: End-stage renal disease (ESRD) patients are more at risk for atrial fibrillation (AF) than the general population. However, the prognosis in ESRD patients with paroxysmal AF (PaAF), permanent AF (PAF) and paroxysmal AF transformed to permanent AF (TAF) is unknown. METHODS: In this retrospective longitudinal study, all ESRD patients with PaAF, PAF and TAF between January 2001 and December 2007 were reviewed. The development of thromboembolic events (TEE) was analyzed using Kaplan-Meier analysis and Cox regression. RESULTS: A total of 81 patients with PaAF, 49 patients with PAF and 89 patients with TAF were reviewed. Seventy-two (32.9%) patients developed TEE, and 63 (28.8%) patients died in 36.9 +/- 21.9 months. Patient survival was not significantly different between patients with different types of AF (P = 0.728). Patients with PaAF had a significantly lower TEE-free survival compared to patients with PAF (P = 0.036). In multivariate Cox regression, patients with paroxysmal AF were more at risk for TEE (P = 0.045) with a hazard ratio of 1.61 (95% confidence interval: 1.01-2.58). PaAF and congestive heart failure, hypertension, age older than 75 years, diabetes, and previous stroke or transient ischemic stroke (CHADS(2)) score were independently associated with an increase in TEE risk (P = 0.028 and P = 0.03). CONCLUSION: Patient survival is not different in patients with paroxysmal and permanent atrial fibrillation. However, patients with paroxysmal AF are more at risk for the development of TEE than those with permanent AF.</p>        <p>PMID: 19923144 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19845751&#x26;dopt=Abstract\">Brain natriuretic peptide as a predictor of delayed atrial fibrillation after ischaemic stroke and transient ischaemic attack.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www3.interscience.wiley.com/resolve/openurl?genre=article&#x26;amp;sid=nlm:pubmed&#x26;amp;issn=1351-5101&#x26;amp;date=2010&#x26;amp;volume=17&#x26;amp;issue=2&#x26;amp;spage=326"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www3.interscience.wiley.com-aboutus-images-wiley_interscience_pubmed_logo_120x27.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19845751">Related Articles</a></td></tr></table>        <p><b>Brain natriuretic peptide as a predictor of delayed atrial fibrillation after ischaemic stroke and transient ischaemic attack.</b></p>        <p>Eur J Neurol. 2010 Feb;17(2):326-31</p>        <p>Authors:  Okada Y, Shibazaki K, Kimura K, Iguchi Y, Miki T</p>        <p>BACKGROUND AND PURPOSE: We investigated whether the brain natriuretic peptide (BNP) level can serve as a predictive biological marker of delayed atrial fibrillation (AF). METHODS: Two hundred and thirty seven consecutive patients admitted to our institution with acute ischaemic stroke or transient ischaemic attack (TIA) within 24 h of onset were enrolled. The patients were classified according to the presence or absence of AF upon admission [AF and sinus rhythm (SR) groups]. The SR group was subdivided based on the development of AF after admission (new- and non-AF groups). We compared the characteristics between the AF and SR groups, and between the new- and non-AF groups. The factors associated with new-AF were investigated by multivariate logistic regression analysis. RESULTS: Amongst the enrolled patients, 72 (30.4%) had AF upon admission (AF group), and 13 (5.5%) developed AF thereafter (new-AF group). The plasma BNP level was significantly higher in the AF, than in the SR group (401.7 vs. 92.1 pg/ml, P &#x26;lt; 0.001). Moreover, the plasma BNP level was significantly higher in the new-, than in the non-AF group (184.7 vs. 84.1 pg/ml, P &#x26;lt; 0.001). The optimal cutoff BNP level required to distinguish new-, from non-AF groups was 85.0 pg/ml, and the sensitivity and specificity was 83.3% and 76.2%, respectively. On multivariate logistic regression analysis, plasma BNP level &#x26;gt;85.0 pg/ml (odds ratio, 7.20; 95% confidence interval, 1.71 to 30.43, P = 0.007) was an independent factor associated with new-AF. CONCLUSION: High plasma BNP level should be a strong predictor of delayed AF after ischaemic stroke or TIA.</p>        <p>PMID: 19845751 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19687749&#x26;dopt=Abstract\">S-Nitrosylation of cardiac ion channels.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0160-2446&#x26;amp;volume=54&#x26;amp;issue=3&#x26;amp;spage=188"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.lwwonline.com-pt-pt-core-template-journal-lwwgateway-images-pmlogo.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19687749">Related Articles</a></td></tr></table>        <p><b>S-Nitrosylation of cardiac ion channels.</b></p>        <p>J Cardiovasc Pharmacol. 2009 Sep;54(3):188-95</p>        <p>Authors:  Gonzalez DR, Treuer A, Sun QA, Stamler JS, Hare JM</p>        <p>Nitric oxide (NO) exerts ubiquitous signaling via posttranslational modification of cysteine residues, a reaction termed S-nitrosylation. Important substrates of S-nitrosylation that influence cardiac function include receptors, enzymes, ion channels, transcription factors, and structural proteins. Cardiac ion channels subserving excitation-contraction coupling are potentially regulated by S-nitrosylation. Specificity is achieved in part by spatial colocalization of ion channels with nitric oxide synthases (NOSs), enzymatic sources of NO in biologic systems, and by coupling of NOS activity to localized calcium/second messenger concentrations. Ion channels regulate cardiac excitability and contractility in millisecond timescales, raising the possibility that NO-related species modulate heart function on a beat-to-beat basis. This review focuses on recent advances in understanding of NO regulation of the cardiac action potential and of the calcium release channel ryanodine receptor, which is crucial for the generation of force. S-Nitrosylation signaling is disrupted in pathological states in which the redox state of the cell is dysregulated, including ischemia, heart failure, and atrial fibrillation.</p>        <p>PMID: 19687749 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('</ul>');
document.write('</div>');
document.write('<div class=\"rss_feed\">');
document.write('<div class=\"rss_feed_title\">pubmed: "atrial fibrillation...</div>');
document.write('<ul class=\"rss_item_list\">');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20639234&#x26;dopt=Abstract\">Atrial tachyarrhythmias and cardiac resynchronisation therapy: clinical and therapeutic implications.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://heart.bmj.com/cgi/pmidlookup?view=long&#x26;amp;pmid=20639234"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--highwire.stanford.edu-icons-externalservices-pubmed-custom-bmjjournals_final.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20639234">Related Articles</a></td></tr></table>        <p><b>Atrial tachyarrhythmias and cardiac resynchronisation therapy: clinical and therapeutic implications.</b></p>        <p>Heart. 2010 Aug;96(15):1174-8</p>        <p>Authors:  Lavalle C, Ricci RP, Santini M</p>        <p>Atrial fibrillation (AF) represents one of the most important comorbidities in patients with heart failure (HF). This report highlights the available evidence for the relationship between AF and cardiac resynchronisation therapy (CRT). Studies on the use of CRT in patients with HF and AF have demonstrated its effectiveness. It seems to reduce the AF burden and determines left atrial reverse remodelling. No definite data are available on AF ablation in patients with CRT but it might represent a therapeutic option. Furthermore, modern implantable pacemakers and cardioverter-defibrillators are provided with diagnostic algorithms which allow a better understanding of the AF burden.</p>        <p>PMID: 20639234 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20610459&#x26;dopt=Abstract\">Mitral valve replacement with or without a concomitant Maze procedure in patients with atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://heart.bmj.com/cgi/pmidlookup?view=long&#x26;amp;pmid=20610459"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--highwire.stanford.edu-icons-externalservices-pubmed-custom-bmjjournals_final.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20610459">Related Articles</a></td></tr></table>        <p><b>Mitral valve replacement with or without a concomitant Maze procedure in patients with atrial fibrillation.</b></p>        <p>Heart. 2010 Jul;96(14):1126-31</p>        <p>Authors:  Kim JB, Ju MH, Yun SC, Jung SH, Chung CH, Choo SJ, Lee TY, Song H, Lee JW</p>        <p>BACKGROUND: Although the Maze procedure is regarded as the most effective way to restore sinus rhythm in patients with chronic atrial fibrillation (AF), it remains unclear whether this procedure offers long-term clinical benefits in patients undergoing mechanical valve replacement. METHODS AND RESULTS: Between 1999 and 2007, 402 patients with AF-associated mitral valve (MV) disease underwent MV replacement with a mechanical prosthesis. Of these patients, 159 underwent valve replacement plus the Maze procedure, whereas 243 received valve replacement alone. The composite end points of cardiac death and cardiac-related morbidities were compared in these two groups using the inverse-probability-of-treatment-weighted method. At a median follow-up time of 63.1 months (range 0.2-123.9 months), patients who had undergone the Maze procedure were at significantly lower risk of thromboembolic events (hazard ratio (HR)=0.26, 95% confidence interval (CI) 0.07 to 0.95; p=0.041) and were at comparable risk of death (HR=0.96, 95% CI 0.44 to 2.07; p=0.907) and cardiac death (HR=1.26, 95% CI 0.53 to 3.01; p=0.598) compared with patients who underwent MV replacement alone. The composite risk of death or major events was lower in the Maze procedure group (HR=0.64, 95% CI 0.38 to 1.08; p=0.093). CONCLUSIONS: Compared with MV replacement alone, the addition of the Maze procedure was associated with a reduction in thromboembolic complications and better long-term event-free survival in patients with AF undergoing mechanical MV replacement. Prospective randomised data are necessary to confirm the findings of this study.</p>        <p>PMID: 20610459 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20572355&#x26;dopt=Abstract\">[Long-term pursuit of endurance sport: a new risk factor for atrial fibrillation?]</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20572355">Related Articles</a></td></tr></table>        <p><b>[Long-term pursuit of endurance sport: a new risk factor for atrial fibrillation?]</b></p>        <p>Rev Med Suisse. 2010 Jun 2;6(251):1122, 1124-6</p>        <p>Authors:  Park CI, Shah D</p>        <p>Long-term pursuit of endurance sport: a new risk factor for atrial fibrillation? Lone atrial fibrillation is a term used when the arrhythmia develops in patients under 60 years old without any underlying cardiovascular disease. The aetiology is currently unknown but some recent data suggest that there is an association between a life-long practice of the endurance sport and atrial fibrillation. Long-term structural changes in the left atrium and increased vagal tone related to high intensity training are the main hypothesized mechanisms. The best therapeutic approach is still unknown but radiofrequency catheter ablation can become the treatment of choice for this kind of patient.</p>        <p>PMID: 20572355 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('</ul>');
document.write('</div>');
document.write('<div class=\"rss_feed\">');
document.write('<div class=\"rss_feed_title\">pubmed: "atrial fibrillation...</div>');
document.write('<ul class=\"rss_item_list\">');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20639234&#x26;dopt=Abstract\">Atrial tachyarrhythmias and cardiac resynchronisation therapy: clinical and therapeutic implications.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://heart.bmj.com/cgi/pmidlookup?view=long&#x26;amp;pmid=20639234"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--highwire.stanford.edu-icons-externalservices-pubmed-custom-bmjjournals_final.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20639234">Related Articles</a></td></tr></table>        <p><b>Atrial tachyarrhythmias and cardiac resynchronisation therapy: clinical and therapeutic implications.</b></p>        <p>Heart. 2010 Aug;96(15):1174-8</p>        <p>Authors:  Lavalle C, Ricci RP, Santini M</p>        <p>Atrial fibrillation (AF) represents one of the most important comorbidities in patients with heart failure (HF). This report highlights the available evidence for the relationship between AF and cardiac resynchronisation therapy (CRT). Studies on the use of CRT in patients with HF and AF have demonstrated its effectiveness. It seems to reduce the AF burden and determines left atrial reverse remodelling. No definite data are available on AF ablation in patients with CRT but it might represent a therapeutic option. Furthermore, modern implantable pacemakers and cardioverter-defibrillators are provided with diagnostic algorithms which allow a better understanding of the AF burden.</p>        <p>PMID: 20639234 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20610459&#x26;dopt=Abstract\">Mitral valve replacement with or without a concomitant Maze procedure in patients with atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://heart.bmj.com/cgi/pmidlookup?view=long&#x26;amp;pmid=20610459"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--highwire.stanford.edu-icons-externalservices-pubmed-custom-bmjjournals_final.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20610459">Related Articles</a></td></tr></table>        <p><b>Mitral valve replacement with or without a concomitant Maze procedure in patients with atrial fibrillation.</b></p>        <p>Heart. 2010 Jul;96(14):1126-31</p>        <p>Authors:  Kim JB, Ju MH, Yun SC, Jung SH, Chung CH, Choo SJ, Lee TY, Song H, Lee JW</p>        <p>BACKGROUND: Although the Maze procedure is regarded as the most effective way to restore sinus rhythm in patients with chronic atrial fibrillation (AF), it remains unclear whether this procedure offers long-term clinical benefits in patients undergoing mechanical valve replacement. METHODS AND RESULTS: Between 1999 and 2007, 402 patients with AF-associated mitral valve (MV) disease underwent MV replacement with a mechanical prosthesis. Of these patients, 159 underwent valve replacement plus the Maze procedure, whereas 243 received valve replacement alone. The composite end points of cardiac death and cardiac-related morbidities were compared in these two groups using the inverse-probability-of-treatment-weighted method. At a median follow-up time of 63.1 months (range 0.2-123.9 months), patients who had undergone the Maze procedure were at significantly lower risk of thromboembolic events (hazard ratio (HR)=0.26, 95% confidence interval (CI) 0.07 to 0.95; p=0.041) and were at comparable risk of death (HR=0.96, 95% CI 0.44 to 2.07; p=0.907) and cardiac death (HR=1.26, 95% CI 0.53 to 3.01; p=0.598) compared with patients who underwent MV replacement alone. The composite risk of death or major events was lower in the Maze procedure group (HR=0.64, 95% CI 0.38 to 1.08; p=0.093). CONCLUSIONS: Compared with MV replacement alone, the addition of the Maze procedure was associated with a reduction in thromboembolic complications and better long-term event-free survival in patients with AF undergoing mechanical MV replacement. Prospective randomised data are necessary to confirm the findings of this study.</p>        <p>PMID: 20610459 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20572355&#x26;dopt=Abstract\">[Long-term pursuit of endurance sport: a new risk factor for atrial fibrillation?]</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20572355">Related Articles</a></td></tr></table>        <p><b>[Long-term pursuit of endurance sport: a new risk factor for atrial fibrillation?]</b></p>        <p>Rev Med Suisse. 2010 Jun 2;6(251):1122, 1124-6</p>        <p>Authors:  Park CI, Shah D</p>        <p>Long-term pursuit of endurance sport: a new risk factor for atrial fibrillation? Lone atrial fibrillation is a term used when the arrhythmia develops in patients under 60 years old without any underlying cardiovascular disease. The aetiology is currently unknown but some recent data suggest that there is an association between a life-long practice of the endurance sport and atrial fibrillation. Long-term structural changes in the left atrium and increased vagal tone related to high intensity training are the main hypothesized mechanisms. The best therapeutic approach is still unknown but radiofrequency catheter ablation can become the treatment of choice for this kind of patient.</p>        <p>PMID: 20572355 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('</ul>');
document.write('</div>');
document.write('<div class=\"rss_feed\">');
document.write('<div class=\"rss_feed_title\">pubmed: "atrial fibrillation...</div>');
document.write('<ul class=\"rss_item_list\">');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20671015&#x26;dopt=Abstract\">Dabigatran etexilate in people with atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www.bmj.com/cgi/pmidlookup?view=long&#x26;amp;pmid=20671015"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--highwire.stanford.edu-icons-externalservices-pubmed-custom-bmj_full.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20671015">Related Articles</a></td></tr></table>        <p><b>Dabigatran etexilate in people with atrial fibrillation.</b></p>        <p>BMJ. 2010;341:c3784</p>        <p>Authors:  Raju NC, Hankey GJ</p>        <p></p>        <p>PMID: 20671015 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20643247&#x26;dopt=Abstract\">Obesity and outcomes among patients with established atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0002-9149(10)00785-X"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20643247">Related Articles</a></td></tr></table>        <p><b>Obesity and outcomes among patients with established atrial fibrillation.</b></p>        <p>Am J Cardiol. 2010 Aug 1;106(3):369-73</p>        <p>Authors:  Ardestani A, Hoffman HJ, Cooper HA</p>        <p>Atrial fibrillation (AF) and obesity have reached epidemic proportions. The impact of obesity on clinical outcomes in patients with established AF is unknown. We analyzed 2,492 patients in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. Body mass index (BMI) was evaluated as a categorical variable (normal 18.5 to &#x26;lt;25 kg/m(2), overweight 25 to &#x26;lt;30 kg/m(2), obese &#x26;gt;or=30 kg/m(2)). Rate of death from any cause was higher in the normal BMI group (5.8 per 100 patient-years) than in the overweight and obese groups (3.9 and 3.7, respectively). Cardiovascular death rate was highest in the normal BMI group (3.1 per 100 patient-years), lowest in the overweight group (1.5 per 100 patient-years), and intermediate in the obese group (2.1 per 100 patient-years). After adjustment for baseline factors, differences in risk of death from any cause were no longer significant. However, overweight remained associated with a lower risk of cardiovascular death (hazard ratio 0.47, p = 0.002). Obese patients were more likely to have an uncontrolled heart rate at rest, but rhythm-control strategy success was similar across BMI categories. In each BMI category, risk of death from any cause was similar for patients randomized to a rhythm- or rate-control strategy. In conclusion, in patients with established AF, overweight and obesity do not adversely affect overall survival. Obesity does not appear to affect the relative benefit of a rate- or rhythm-control strategy.</p>        <p>PMID: 20643247 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20637405&#x26;dopt=Abstract\">Noninvasive positive pressure ventilation in procedural sedation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0735-6757(09)00555-5"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20637405">Related Articles</a></td></tr></table>        <p><b>Noninvasive positive pressure ventilation in procedural sedation.</b></p>        <p>Am J Emerg Med. 2010 Jul;28(6):750.e1-3</p>        <p>Authors:  Remick J, Sacchetti A, Bages G, Delagol K</p>        <p>Maintenance of spontaneous effective ventilations can present unique challenges to emergency physicians directing procedural sedation in patients with underlying anatomic or physiologic upper airway pathology. In a morbidly obese patient requiring electrical cradioversion, use of bilevel positive airway pressure facilitated deep sedation while averting any adverse respiratory complications. Noninvasive pressure support ventilation may present another emergency department adjunct for difficult procedural sedation cases.</p>        <p>PMID: 20637405 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20606116&#x26;dopt=Abstract\">Paradigm of genetic mosaicism and lone atrial fibrillation: physiological characterization of a connexin 43-deletion mutant identified from atrial tissue.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://circ.ahajournals.org/cgi/pmidlookup?view=long&#x26;amp;pmid=20606116"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--highwire.stanford.edu-icons-externalservices-pubmed-standard-circulationaha_final.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20606116">Related Articles</a></td></tr></table>        <p><b>Paradigm of genetic mosaicism and lone atrial fibrillation: physiological characterization of a connexin 43-deletion mutant identified from atrial tissue.</b></p>        <p>Circulation. 2010 Jul 20;122(3):236-44</p>        <p>Authors:  Thibodeau IL, Xu J, Li Q, Liu G, Lam K, Veinot JP, Birnie DH, Jones DL, Krahn AD, Lemery R, Nicholson BJ, Gollob MH</p>        <p>BACKGROUND: Atrial fibrillation (AF) is the most common sustained arrhythmia observed in otherwise healthy individuals. Most lone AF cases are nonfamilial, leading to the assumption that a primary genetic origin is unlikely. In this study, we provide data supporting a novel paradigm that atrial tissue-specific genetic defects may be associated with sporadic cases of lone AF. METHODS AND RESULTS: We sequenced the entire coding region of the connexin 43 (Cx43) gene (GJA1) from atrial tissue and lymphocytes of 10 unrelated subjects with nonfamilial, lone AF who had undergone surgical pulmonary vein isolation. In the atrial tissue of 1 patient, we identified a novel frameshift mutation caused by a single nucleotide deletion (c.932delC) that predicted 36 aberrant amino acids followed by a premature stop codon, leading to truncation of the C-terminal domain of Cx43. The mutation was absent from the lymphocyte DNA of the patient, indicating genetic mosaicism. Protein trafficking studies demonstrated intracellular retention of the mutant protein and a dominant-negative effect on gap junction formation of both wild-type Cx43 and Cx40. Electrophysiological studies revealed no electrical coupling of cells expressing the mutant protein alone and significant reductions in coupling when coexpressed with wild-type connexins. CONCLUSIONS: This study reports atrial tissue genetic mosaicism of a novel loss-of-function Cx43 mutation associated with lone AF. These findings implicate somatic genetic defects of Cx43 as a potential cause of AF and support the paradigm that sporadic, nonfamilial cases of lone AF may arise from genetic mosaicism that creates heterogeneous coupling patterns, predisposing the tissue to reentrant arrhythmias.</p>        <p>PMID: 20606116 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20552595&#x26;dopt=Abstract\">Association of age, gender, and weight on maintenance dose of intravenous unfractionated heparin.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://dx.doi.org/10.1002/ajh.21751"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www3.interscience.wiley.com-aboutus-images-wiley_interscience_pubmed_logo_120x27.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20552595">Related Articles</a></td></tr></table>        <p><b>Association of age, gender, and weight on maintenance dose of intravenous unfractionated heparin.</b></p>        <p>Am J Hematol. 2010 Aug;85(8):624-6</p>        <p>Authors:  Verma S, Kato S, Blum R, Shapira I, Friedmann P, Varma M</p>        <p></p>        <p>PMID: 20552595 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20482332&#x26;dopt=Abstract\">Atrial-esophageal fistula after atrial radiofrequency catheter ablation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20482332">Related Articles</a></td></tr></table>        <p><b>Atrial-esophageal fistula after atrial radiofrequency catheter ablation.</b></p>        <p>Clin Infect Dis. 2010 Jul 1;51(1):73-6</p>        <p>Authors:  Siegel MO, Parenti DM, Simon GL</p>        <p>Atrial-esophageal fistula is a rare but often fatal complication of catheter radiofrequency ablation. Patients occasionally have bacteremia and have been misdiagnosed with endocarditis. Infectious diseases specialists are often consulted and need to be aware of this complication. We report a case of atrial-esophageal fistula after radiofrequency ablation that illustrates the salient features of this illness.</p>        <p>PMID: 20482332 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20425289&#x26;dopt=Abstract\">The impact of depression in heart disease.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://dx.doi.org/10.1007/s11920-010-0116-8"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--production.springer.de-OnlineResources-Logos-springerlink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20425289">Related Articles</a></td></tr></table>        <p><b>The impact of depression in heart disease.</b></p>        <p>Curr Psychiatry Rep. 2010 Jun;12(3):255-64</p>        <p>Authors:  Sher Y, Lolak S, Maldonado JR</p>        <p>Depression and heart disease affect millions of people worldwide. Studies have shown that depression is a significant risk factor for new heart disease and that it increases morbidity and mortality in established heart disease. Many hypothesized and studied mechanisms have linked depression and heart disease, including serotonergic pathway and platelet dysfunction, inflammation, autonomic nervous system and hypothalamic-pituitary-adrenal axis imbalance, and psychosocial factors. Although the treatment of depression in cardiac patients has been shown to be safe and modestly efficacious, it has yet to translate into reduced cardiovascular morbidity and mortality. Understanding the impact and mechanisms behind the association of depression and heart disease may allow for the development of treatments aimed at altering the devastating consequences caused by these comorbid illnesses.</p>        <p>PMID: 20425289 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20407957&#x26;dopt=Abstract\">Cryoballoon ablation for pulmonary vein isolation in patients with paroxysmal atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20407957">Related Articles</a></td></tr></table>        <p><b>Cryoballoon ablation for pulmonary vein isolation in patients with paroxysmal atrial fibrillation.</b></p>        <p>Swiss Med Wkly. 2010 Apr 17;140(15-16):214-21</p>        <p>Authors:  K&#xC3;&#xBC;hne M, Schaer B, Ammann P, Suter Y, Osswald S, Sticherling C</p>        <p>Cryoballoon ablation has emerged as a novel treatment option for drug-refractory atrial fibrillation (AF). The purpose of this manuscript is to report the initial experience of a Swiss centre performing cryoballoon ablation, and to provide a critical review of the literature. Fourteen patients (age 59 +/- 10 years, LVEF 57 +/- 5%, left atrial size 41 +/- 3 mm) with paroxysmal AF were studied. After transseptal puncture, a 28 mm cryoballoon catheter was inserted into the left atrium. After balloon positioning at the antrum of each pulmonary vein (PV), cryoballoon ablation was performed (5 minutes/application). The endpoint of the ablation was pulmonary vein isolation (PVI). Eighty-four percent of all PVs could be isolated with the cryoballoon alone. There was no specific distribution of the PVs requiring additional non-balloon ablation. The mean procedure time was 199 +/- 56 minutes. One patient developed tamponade requiring drainage. No phrenic nerve palsies occurred. After a period of follow-up of 12 +/- 3 months, 10/14 patients (71%) were in sinus rhythm without antiarrhythmic drugs. A review of AF ablation procedures performed at our centre during a one-year period showed that documentation of persistent AF or other arrhythmias were the causes for not using the cryoballoon in 49% of patients because additional linear lesions may be required in these cases. Cryoballoon ablation is an interesting new tool for PVI. The success rate of 71% after a 1-year follow-up is not higher when compared to radiofrequency ablation. Furthermore, data on long-term outcomes are lacking. Randomised comparisons with radiofrequency catheter ablation are needed.</p>        <p>PMID: 20407957 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20385507&#x26;dopt=Abstract\">Prognosis of atrial fibrillation in patients with symptomatic peripheral arterial disease: data from the REduction of Atherothrombosis for Continued Health (REACH) Registry.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S1078-5884(10)00152-8"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20385507">Related Articles</a></td></tr></table>        <p><b>Prognosis of atrial fibrillation in patients with symptomatic peripheral arterial disease: data from the REduction of Atherothrombosis for Continued Health (REACH) Registry.</b></p>        <p>Eur J Vasc Endovasc Surg. 2010 Jul;40(1):9-16</p>        <p>Authors:  Winkel TA, Hoeks SE, Schouten O, Zeymer U, Limbourg T, Baumgartner I, Bhatt DL, Steg PG, Goto S, R&#xC3;&#xB6;ther J, Cacoub PP, Verhagen HJ, Bax JJ, Poldermans D</p>        <p>BACKGROUND: Atrial fibrillation (AF) is a significant risk factor for cardiovascular (CV) mortality. This study aims to evaluate the prognostic implication of AF in patients with peripheral arterial disease (PAD). METHODS: The International Reduction of Atherothrombosis for Continued Health (REACH) Registry included 23,542 outpatients in Europe with established coronary artery disease, cerebrovascular disease (CVD), PAD and/or &#x26;gt; or =3 risk factors. Of these, 3753 patients had symptomatic PAD. CV risk factors were determined at baseline. Study end point was a combination of cardiac death, non-fatal myocardial infarction (MI) and stroke (CV events) during 2 years of follow-up. Cox regression analysis adjusted for age, gender and other risk factors (i.e., congestive heart failure, coronary artery re-vascularisation, coronary artery bypass grafting (CABG), MI, hypertension, stroke, current smoking and diabetes) was used. RESULTS: Of 3753 PAD patients, 392 (10%) were known to have AF. Patients with AF were older and had a higher prevalence of CVD, diabetes and hypertension. Long-term CV mortality occurred in 5.6% of patients with AF and in 1.6% of those without AF (p&#x26;lt;0.001). Multivariable analyses showed that AF was an independent predictor of late CV events (hazard ratio (HR): 1.5; 95% confidence interval (CI): 1.09-2.0). CONCLUSION: AF is common in European patients with symptomatic PAD and is independently associated with a worse 2-year CV outcome.</p>        <p>PMID: 20385507 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20381820&#x26;dopt=Abstract\">Effect of statins on atrial fibrillation after cardiac surgery: a duration- and dose-response meta-analysis.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0022-5223(10)00226-6"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20381820">Related Articles</a></td></tr></table>        <p><b>Effect of statins on atrial fibrillation after cardiac surgery: a duration- and dose-response meta-analysis.</b></p>        <p>J Thorac Cardiovasc Surg. 2010 Aug;140(2):364-72</p>        <p>Authors:  Chen WT, Krishnan GM, Sood N, Kluger J, Coleman CI</p>        <p>OBJECTIVE: This meta-analysis of randomized, controlled trials evaluated effects of statins on postoperative atrial fibrillation risk after cardiac surgery. METHODS: Randomized, controlled trials evaluating statins in cardiac surgery were selected from MEDLINE (1996-August 2009), Cochrane CENTRAL Register, and manual review of references without any language restrictions. End points examined included postoperative atrial fibrillation, intensive care unit stay, and total hospital stay. Meta-regression analyses were conducted to determine whether statins&#x27; effects were duration or dose dependent. A random-effects model was used in all instances. RESULTS: Eight trials (n = 774) were identified and subjected to meta-analysis. Statins reduced postoperative atrial fibrillation risk (relative risk 0.57, 95% confidence interval 0.45-0.72, P &#x26;lt; .0001, risk difference -0.14, 95% confidence interval -0.20 to -0.08, P &#x26;lt; .0001, number needed to treat 8) and total hospital stay (weighted mean difference -0.66 days, 95% confidence interval -1.01 to -0.30 days, P = .0004) relative to placebo. Intensive care unit stay was also reduced (weighted mean difference -0.17 days, 95% confidence interval -0.37 to 0.03 days, P = .09) but did not meet prespecified criteria for statistical significance. Metaregression analysis revealed association between duration of preoperative statin prophylaxis and postoperative atrial fibrillation risk reduction (3% reduction per day, P = .008). No association was found between statin dose used and risk reduction (P = .47). CONCLUSIONS: Evidence suggests that statins are associated with reduced risk of postoperative atrial fibrillation and shorter hospital stay after cardiac surgery and that earlier therapy results in more profound benefit.</p>        <p>PMID: 20381820 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20381077&#x26;dopt=Abstract\">A randomized, controlled study of amiodarone for prevention of atrial fibrillation after transthoracic esophagectomy.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0022-5223(10)00102-9"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20381077">Related Articles</a></td></tr></table>        <p><b>A randomized, controlled study of amiodarone for prevention of atrial fibrillation after transthoracic esophagectomy.</b></p>        <p>J Thorac Cardiovasc Surg. 2010 Jul;140(1):45-51</p>        <p>Authors:  Tisdale JE, Wroblewski HA, Wall DS, Rieger KM, Hammoud ZT, Young JV, Kesler KA</p>        <p>OBJECTIVE: Atrial fibrillation is common after esophagectomy. The objective of this study was to determine the efficacy and safety of amiodarone for prevention of atrial fibrillation after transthoracic esophagectomy. METHODS: Eighty patients undergoing transthoracic esophagectomy were randomly, prospectively assigned to receive amiodarone (n = 40) or no prophylaxis (control group, n = 40). Amiodarone-treated patients received the drug by continuous infusion, initiated at the time of induction of anesthesia, at a rate of 0.73 mg/min (43.75 mg/h), and continued for 96 hours (total dose 4200 mg). The primary end point was atrial fibrillation requiring treatment. Secondary end points included any atrial fibrillation lasting longer than 30 seconds and postoperative hospital and intensive care unit stays. RESULTS: There were no significant differences between the amiodarone and control groups in demographic characteristics, comorbid conditions, or preoperative or postoperative use of beta-blockers or calcium-channel blockers. The incidence of atrial fibrillation requiring treatment was lower in the amiodarone group than in the control group (15% vs 40%, P = .02, relative risk reduction 62.5%). There were no significant differences between the amiodarone and control groups in median hospital stay (11 days vs 12 days, P = .31) or median intensive care unit stay (68 hours vs 77 hours, p = .097). There were no significant difference between the groups in the incidences of adverse effects. CONCLUSIONS: Amiodarone prophylaxis significantly reduced the incidence of atrial fibrillation after transthoracic esophagectomy.</p>        <p>PMID: 20381077 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20379004&#x26;dopt=Abstract\">Impact of drug alteration to maintain rhythm control in paroxysmal atrial fibrillation. - Subanalysis from J-RHYTHM study -.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://joi.jlc.jst.go.jp/JST.JSTAGE/circj/CJ-09-0643?from=PubMed"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkout.jstage.jst.go.jp-logo.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20379004">Related Articles</a></td></tr></table>        <p><b>Impact of drug alteration to maintain rhythm control in paroxysmal atrial fibrillation. - Subanalysis from J-RHYTHM study -.</b></p>        <p>Circ J. 2010;74(5):870-5</p>        <p>Authors:  Endo A, Kohsaka S, Suzuki S, Atarashi H, Kamakura S, Sakurai M, Nakaya H, Fukatani M, Mitamura H, Yamazaki T, Yamashita T, Ogawa S,  </p>        <p>BACKGROUND: The Japanese Rhythm Management Trial for Atrial Fibrillation (J-RHYTHM) study showed rhythm control was associated with fewer changes in the assigned treatment strategy compared to rate control in atrial fibrillation (AF). The aim was to describe how antiarrhythmics (AAs) were altered in the rhythm control arm and whether altering AAs would impact long-term outcomes. METHODS AND RESULTS: Of 390 enrolled patients, 23.5% altered their AAs (drug alteration [DA] group). The hard endpoint (HE) was defined as a composite of death, stroke, embolism, major bleeding or heart failure hospitalization; soft endpoint (SE) was defined physical/psychological disability requiring alteration of treatment strategy. The patients were followed for 1.7 years. No significant difference was noted in the occurrence of HE (4.0% vs 6.5%, P=0.31), but DA-group patients had higher rates of SE (9.3% vs 18.4%, P=0.017) compared to single AA patients. The DA group was also associated with the occurrence of SE after adjustment (HR 1.90, P=0.042). When the DA group was subdivided according to the use of class III drugs or change of drugs between classes, there were no differences in outcomes. CONCLUSIONS: The need to change AA was associated with physical/psychological disabilities that seemed not to be relieved simply by changing AAs, and this should be considered as a marker for refractory paroxysmal AF requiring other strategies.</p>        <p>PMID: 20379004 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20379003&#x26;dopt=Abstract\">Effect of bepridil in atrial fibrillation inducibility facilitated by vagal nerve stimulation. - Prevention of vagal nerve activation-induced shortening of the atrial action potential duration -.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://joi.jlc.jst.go.jp/JST.JSTAGE/circj/CJ-09-0716?from=PubMed"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkout.jstage.jst.go.jp-logo.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20379003">Related Articles</a></td></tr></table>        <p><b>Effect of bepridil in atrial fibrillation inducibility facilitated by vagal nerve stimulation. - Prevention of vagal nerve activation-induced shortening of the atrial action potential duration -.</b></p>        <p>Circ J. 2010;74(5):895-902</p>        <p>Authors:  Iijima K, Chinushi M, Izumi D, Ahara S, Furushima H, Komura S, Hosaka Y, Sanada A, Sato A, Aizawa Y</p>        <p>BACKGROUND: Because bepridil blocks multiple myocardial ionic channels, including the muscarinic acetylcholine receptor-operated potassium current (I(KAch)), bepridil is expected to suppress atrial fibrillation (AF) mediated by vagal nerve stimulation (VNS). METHODS AND RESULTS: The therapeutic effects of bepridil were studied with a special focus on heart rate variability (HRV) in a canine model of AF. During VNS, AF was induced in 9 of 9 experiments before, vs 3 of 9 experiments after administration of bepridil (P&#x26;lt;0.01). During 350 ms atrial pacing, VNS shortened the right and left atrial monophasic action potentials at 90% repolarization (MAP90) by -31+/-8% and -22+/-12%, respectively, vs -10+/-13% and -6+/-8%, respectively, after bepridil (P&#x26;lt;0.01, N=9). Bepridil prolonged the sinus cycle length, although it had no significant effect on the conduction time measured at 300 ms pacing. Statistically insignificant change was observed in the VNS-induced slowing of the sinus cycle length and in the VNS-induced increase in high frequency amplitude of HRV before (1.2+/-0.7 to 5.3+/-4.0 ms) vs after (1.7+/-0.8 to 5.4+/-2.3 ms) bepridil administration. CONCLUSIONS: Bepridil prevented the VNS-induced shortening of atrial MAP90 and suppressed the inducibility of AF during VNS in two-thirds of the experiments. As far as this study shows, it may be possible that inhibition of I(KAch) played a part in this antifibrillatory effect.</p>        <p>PMID: 20379003 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20379001&#x26;dopt=Abstract\">Effect of epicardial fat pad ablation on acute atrial electrical remodeling and inducibility of atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://joi.jlc.jst.go.jp/JST.JSTAGE/circj/CJ-09-0967?from=PubMed"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkout.jstage.jst.go.jp-logo.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20379001">Related Articles</a></td></tr></table>        <p><b>Effect of epicardial fat pad ablation on acute atrial electrical remodeling and inducibility of atrial fibrillation.</b></p>        <p>Circ J. 2010;74(5):885-94</p>        <p>Authors:  Chang D, Zhang S, Yang D, Gao L, Lin Y, Chu Z, Jiang X, Yin X, Zheng Z, Wei X, You D, Xiao X, Cong P, Bian X, Xia Y, Yang Y</p>        <p>BACKGROUND: Atrial electrical remodeling (AER) is the underlying mechanism of atrial fibrillation (AF). The present study investigated the impact of epicardial fat pad (FP) ablation on acute AER (AAER) and inducibility of AF. METHODS AND RESULTS: AAER was performed in 28 mongrel dogs through 4-h rapid atrial pacing (RAP). Before RAP, 14 dogs (ablation group) underwent FP ablation, and the other 14 (control group) underwent a sham procedure. The atrial effective refractory period (ERP) and vulnerability window (VW) of AF were measured with and without bilateral cervical vagosympathetic nerve stimulation (VNS) at the high right atrium, ostium of the coronary sinus (CS) and distal CS before and after every hour of RAP. In the control group, ERP was markedly shortened in the first 2 h of RAP and then stabilized. AF was only slightly induced. After RAP, the time course of ERP with and without VNS was similar. VNS significantly shortened ERP and increased VW before and after RAP. In the ablation group, ERP was significantly prolonged after FP ablation. Moreover, neither VNS nor RAP shortened the ERP or increased the VW. AF could not be induced (VW=0). CONCLUSIONS: RAP resulted in AAER, which may be mediated and aggravated by autonomic activity. Epicardial FP ablation generated denervation, which not only abolishes AF inducibility but also prevents RAP-mediated AAER.</p>        <p>PMID: 20379001 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20354335&#x26;dopt=Abstract\">Importance of morphological changes in T-U waves during bepridil therapy as a predictor of ventricular arrhythmic event.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://joi.jlc.jst.go.jp/JST.JSTAGE/circj/CJ-09-0937?from=PubMed"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkout.jstage.jst.go.jp-logo.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20354335">Related Articles</a></td></tr></table>        <p><b>Importance of morphological changes in T-U waves during bepridil therapy as a predictor of ventricular arrhythmic event.</b></p>        <p>Circ J. 2010;74(5):876-84</p>        <p>Authors:  Kurokawa S, Niwano S, Kiryu M, Murakami M, Ishikawa S, Yumoto Y, Moriguchi M, Niwano H, Kosukegawa T, Izumi T</p>        <p>BACKGROUND: Although bepridil is a useful anti-arrhythmic agent for atrial fibrillation, the appearance of serious ventricular arrhythmia, such as torsades de pointes, might be a problem. In this study, T-U wave morphology was evaluated during bepridil therapy and was examined as a predictor of ventricular arrhythmic events. METHODS AND RESULTS: The study population consisted of 113 patients on bepridil therapy. They were divided into 2 groups with and without ventricular arrhythmic events. Morphological changes in T-U waves were analyzed in leads V(2-5). During bepridil treatment, the QTc interval was prolonged from 0.45+/-0.01 to 0.49+/-0.01 s(1/2) in all patients (P&#x26;lt;0.0001) and any type of T-U wave change (fused U, slurred, bifid, biphasic or negative) appeared in 73% of event-free and 100% of event groups. In univariate analysis, QTc interval before bepridil (P=0.028), a wide QRS complex (P=0.042) before bepridil, biphasic (P=0.027) or negative (P=0.002) T-U waves in the stable phase, and the new appearance of biphasic (P=0.004) or negative (P&#x26;lt;0.0001) T-U waves exhibited significant differences. In multivariate analysis, only newly appeared negative T-U wave exhibited a significant difference (odds ratio 10.13, 95% confidence interval = 0.031-2.302, P=0.041). CONCLUSIONS: In patients with stable bepridil treatment, a change in T-U wave morphology might be a useful predictor of ventricular arrhythmia assisting the QT interval.</p>        <p>PMID: 20354335 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20333471&#x26;dopt=Abstract\">Factors associated with the development of atrial fibrillation in patients with rheumatic mitral stenosis.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://dx.doi.org/10.1007/s10554-010-9609-0"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--production.springer.de-OnlineResources-Logos-springerlink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20333471">Related Articles</a></td></tr></table>        <p><b>Factors associated with the development of atrial fibrillation in patients with rheumatic mitral stenosis.</b></p>        <p>Int J Cardiovasc Imaging. 2010 Jun;26(5):547-52</p>        <p>Authors:  Ozaydin M, Turker Y, Varol E, Alaca S, Erdogan D, Yilmaz N, Dogan A</p>        <p>The aim of this study was to evaluate the factors associated with the development of atrial fibrillation (AF) in patients with rheumatic mitral stenosis (MS). A total of 146 consecutive patients with rheumatic MS were screened. They were accepted to be in AF group and sinus rhythm group according to their rhythm in the baseline ECG. After screening, 38 patients were excluded due to hyperthyroidism (n = 13), chronic obstructive pulmonary disease (n = 22), malignancy (n = 2) and rheumatoid arthritis (n = 1). Therefore, remaining 108 patients, 74 of whom in sinus rhythm (MS-SR) and 34 of whom in AF (MS-AF) constituted study population. Fourty age- and gender-matched patients constituted control group. Factors associated with development of AF in multivariable analysis included High sensitivity C reactive protein (P = 0.005; odds ratio, 3.44; 95% confidence interval, 1.44-8.22), N-terminal of brain natriuretic peptide precursor (P &#x26;lt; 0.0001; odds ratio, 1.03; 95% confidence interval, 1.02-1.06) and left atrial diameter (P &#x26;lt; 0.0001; odds ratio, 1.68; 95% confidence interval, 1.32-2.14). Present study suggests that High sensitivity C reactive protein, N-terminal of brain natriuretic peptide precursor and left atrial diameter are associated with development AF in patients with MS.</p>        <p>PMID: 20333471 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20199386&#x26;dopt=Abstract\">Clinical development of selective anticoagulants: a state of the art.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20199386">Related Articles</a></td></tr></table>        <p><b>Clinical development of selective anticoagulants: a state of the art.</b></p>        <p>Rev Recent Clin Trials. 2010 May;5(2):85-93</p>        <p>Authors:  Capranzano P, Capodanno D, Tamburino C</p>        <p>Although standard anticoagulation, including heparins and vitamin K antagonists (VKA), is clinically beneficial, several unmet needs remain due to several pharmacokinetic and pharmacodymamic limitations. Selective anticoagulant agents have been developed to overcome the drawbacks associated with both heparins and VKA. Agents selectively targeting factor Xa, IXa and thrombin are alternative anticoagulants in the most advanced phases of clinical development. Compared to traditional anticoagulants these drugs have the potential to be more effective, safer and easier to use and to provide a more predictable dose response, without need for routine monitoring and dose adjustment. This review will summarize the current status of selective anticoagulant drugs, which are already licensed or being evaluated in advanced phases clinical studies for antithrombotic treatment in non-valvular atrial fibrillation, percutaneous coronary intervention and acute coronary syndromes, focusing on design and results of studies in these specific clinical settings.</p>        <p>PMID: 20199386 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20170505&#x26;dopt=Abstract\">Bisphosphonates and risk of atrial fibrillation: a meta-analysis.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://arthritis-research.com/content/12/1/R30"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.biomedcentral.com-graphics-pubmed-art-free.gif" border="0"/></a> <a href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&#x26;amp;pubmedid=20170505"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.pubmedcentral.nih.gov-corehtml-pmc-pmcgifs-pubmed-pmc.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20170505">Related Articles</a></td></tr></table>        <p><b>Bisphosphonates and risk of atrial fibrillation: a meta-analysis.</b></p>        <p>Arthritis Res Ther. 2010;12(1):R30</p>        <p>Authors:  Kim SY, Kim MJ, Cadarette SM, Solomon DH</p>        <p>INTRODUCTION: Bisphosphonates are the most commonly used drugs for the prevention and treatment of osteoporosis. Although a recent FDA review of the results of clinical trials reported no clear link between bisphosphonates and serious or non-serious atrial fibrillation (AF), some epidemiologic studies have suggested an association between AF and bisphosphonates. METHODS: We conducted a meta-analysis of non-experimental studies to evaluate the risk of AF associated with bisphosphonates. Studies were identified by searching MEDLINE and EMBASE using a combination of the Medical Subject Headings and keywords. Our search was limited to English language articles. The pooled estimates of odds ratios (OR) as a measure of effect size were calculated using a random effects model. RESULTS: Seven eligible studies with 266,761 patients were identified: three cohort, three case-control, and one self-controlled case series. Bisphosphonate exposure was not associated with an increased risk of AF [pooled multivariate OR 1.04, 95% confidence interval (CI) 0.92-1.16] after adjusting for known risk factors. Moderate heterogeneity was noted (I-squared score = 62.8%). Stratified analyses by study design, cohort versus case-control studies, yielded similar results. Egger&#x27;s and Begg&#x27;s tests did not suggest an evidence of publication bias (P = 0.90, 1.00 respectively). No clear asymmetry was observed in the funnel plot analysis. Few studies compared risk between bisphosphonates or by dosing. CONCLUSIONS: Our study did not find an association between bisphosphonate exposure and AF. This finding is consistent with the FDA&#x27;s statement.</p>        <p>PMID: 20170505 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20164089&#x26;dopt=Abstract\">Prognostic value of exercise echocardiography in patients with atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://ejechocard.oxfordjournals.org/cgi/pmidlookup?view=long&#x26;amp;pmid=20164089"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--highwire.stanford.edu-icons-externalservices-pubmed-custom-oxfordjournals_final.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20164089">Related Articles</a></td></tr></table>        <p><b>Prognostic value of exercise echocardiography in patients with atrial fibrillation.</b></p>        <p>Eur J Echocardiogr. 2010 May;11(4):346-51</p>        <p>Authors:  Bouzas-Mosquera A, Peteiro J, Broull&#xC3;&#xB3;n FJ, Alvarez-Garc&#xC3;&#xAD;a N, Mosquera VX, Rodr&#xC3;&#xAD;guez-Vilela A, Casas S, Castro-Beiras A</p>        <p>AIMS: Non-invasive imaging techniques for the detection of coronary artery disease (CAD) may have technical problems in patients with atrial fibrillation (AF). Although the prognostic value of exercise echocardiography (ExEcho) has been well established in several subgroups of patients, it has not yet been specifically evaluated in these patients. METHODS AND RESULTS: From a population of 8095 patients with known or suspected CAD referred for ExEcho, 419 had AF at the time of the tests. Ischaemia was defined as the development of new or worsening wall motion abnormalities with exercise. Endpoints were hard cardiac events (i.e. cardiac death or non-fatal myocardial infarction). Mean age was 68.4 +/- 8.5 years, and 256 patients (61.1%) were men. Ischaemia was detected in 92 patients (22%). Over a mean follow-up of 3.10 +/- 2.98 years, 59 hard cardiac events occurred. The 5-year hard cardiac event rate was 37.3% in patients with ischaemia, when compared with 14.5% in patients without ischaemia (P &#x26;lt; 0.001). In multivariate analysis, ischaemia on ExEcho remained an independent predictor of hard cardiac events (hazard ratio 1.99, 95% confidence interval 1.06-3.74, P = 0.03), and also provided incremental value over clinical, resting echocardiographic and treadmill exercise data for the prediction of hard cardiac events (P = 0.04). CONCLUSION: ExEcho provides significant prognostic information for predicting hard cardiac events in patients with AF.</p>        <p>PMID: 20164089 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20122702&#x26;dopt=Abstract\">Efficacy of a novel bipolar radiofrequency ablation device on the beating heart for atrial fibrillation ablation: a long-term porcine study.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0022-5223(09)01386-5"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20122702">Related Articles</a></td></tr></table>        <p><b>Efficacy of a novel bipolar radiofrequency ablation device on the beating heart for atrial fibrillation ablation: a long-term porcine study.</b></p>        <p>J Thorac Cardiovasc Surg. 2010 Jul;140(1):203-8</p>        <p>Authors:  Voeller RK, Zierer A, Lall SC, Sakamoto S, Schuessler RB, Damiano RJ</p>        <p>OBJECTIVE: Over recent years, a variety of energy sources have been used to replace the traditional incisions of the Cox maze procedure for the surgical treatment of atrial fibrillation. This study evaluated the safety and efficacy of a new bipolar radiofrequency ablation device for atrial ablation in a long-term porcine model. METHODS: Six pigs underwent a Cox maze IV procedure on a beating heart off cardiopulmonary bypass using the AtriCure Isolator II bipolar ablation device (AtriCure, Inc, Cincinnati, Ohio). In addition, 6 pigs underwent median sternotomy and pericardiotomy alone to serve as a control group. All animals were allowed to survive for 30 days. Each pig underwent induction of atrial fibrillation and was then humanely killed to remove the heart en bloc for histologic assessment. Magnetic resonance imaging scans were also obtained preoperatively and postoperatively to assess atrial and ventricular function, pulmonary vein anatomy, valve function, and coronary artery patency. RESULTS: All animals survived the operation. Electrical isolation of the left atrial appendage and the pulmonary veins was documented by pacing acutely and at 30 days in all animals. No animal that underwent the Cox maze IV procedure was able to be induced into atrial fibrillation at 30 days postoperatively, compared with all the sham animals. All 257 ablations examined were discrete, linear, and transmural, with a mean lesion width of 2.2 +/- 1.1 mm and a mean lesion depth of 5.3 +/- 3.0 mm. CONCLUSIONS: The AtriCure Isolator II device was able to create reliable long-term transmural lesions of the modified Cox maze procedure on a beating heart without cardiopulmonary bypass 100% of the time. There were no discernible effects on ventricular or valvular function.</p>        <p>PMID: 20122702 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20080265&#x26;dopt=Abstract\">Angiotensin II receptor type 1 is upregulated in atrial tissue of patients with rheumatic valvular disease with atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0022-5223(09)01400-7"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20080265">Related Articles</a></td></tr></table>        <p><b>Angiotensin II receptor type 1 is upregulated in atrial tissue of patients with rheumatic valvular disease with atrial fibrillation.</b></p>        <p>J Thorac Cardiovasc Surg. 2010 Aug;140(2):298-304</p>        <p>Authors:  Cong H, Li X, Ma L, Jiang H, Mao Y, Xu M</p>        <p>OBJECTIVE: The purpose of this study was to examine the changes in expression of angiotensin II receptor type 1/2 in left or right atrial tissue from patients with rheumatic valvular disease with or without atrial fibrillation. METHODS: Atrial tissue samples were obtained from 39 patients with rheumatic mitral valve disease during cardiac surgery. Among these patients, there were 25 with atrial fibrillation and 14 with sinus rhythm. The level of angiotensin II receptor type 1 or type 2 mRNA transcription was measured by means of a semiquantitative reverse transcription-polymerase chain reaction technique. Expression of angiotensin II receptor type 1 or type 2 protein was detected by means of immunohistochemistry assay and Western blot analysis. RESULTS: The inner diameter of the left atrium was clearly enlarged in the atrial fibrillation group in comparison with that seen in the sinus rhythm group. The expression levels of both angiotensin II receptor type 1 mRNA and protein in the left atrial tissue were significantly increased in the patients with atrial fibrillation compared with those seen in patients with sinus rhythm (P &#x26;lt; .05). Interestingly, the comparison of angiotensin II receptor type 2 expression levels in the left atrial tissue between these 2 groups is not statistically significant. In addition, the results of angiotensin II receptor type 1 or 2 expression in the right atrial tissue did not show any obvious change in the patients with atrial fibrillation versus those with sinus rhythm. CONCLUSIONS: Expression of angiotensin II receptor type 1 but not type 2 is highly upregulated only in the left atrial tissue of patients with rheumatic valvular disease with atrial fibrillation. This suggests that there is a possible pathophysiologic role of the renin-angiotensin system in patients with atrial fibrillation and that a series of effects mediated by the activation of angiotensin II receptor type 1 in the left atrial tissue might be one of the molecular mechanisms involved in the process of atrial remodeling in atrial fibrillation.</p>        <p>PMID: 20080265 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20025707&#x26;dopt=Abstract\">Persistent atrial fibrillation converts to common type atrial flutter during CFAE ablation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www3.interscience.wiley.com/resolve/openurl?genre=article&#x26;amp;sid=nlm:pubmed&#x26;amp;issn=0147-8389&#x26;amp;date=2010&#x26;amp;volume=33&#x26;amp;issue=3&#x26;amp;spage=304"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www3.interscience.wiley.com-aboutus-images-wiley_interscience_pubmed_logo_120x27.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20025707">Related Articles</a></td></tr></table>        <p><b>Persistent atrial fibrillation converts to common type atrial flutter during CFAE ablation.</b></p>        <p>Pacing Clin Electrophysiol. 2010 Mar;33(3):304-8</p>        <p>Authors:  Luik A, Merkel M, Riexinger T, Wondraschek R, Schmitt C</p>        <p>BACKGROUND: Catheter ablation of persistent and long-standing persistent atrial fibrillation (AF) is still challenging. So far different ablation techniques have been reported, including pulmonary vein isolation, additional linear lesions, ablation of complex fractionated atrial electrograms (CFAE), and combinations of these techniques. During ablation of CFAE, the occurrence of left atrial (LA) tachycardia is well known. The occurrence of right atrial flutter on the other hand is less well described. METHODS: Here, we report three patients who had been ablated because of symptomatic persistent atrial fibrillation. SUMMARY: In all patients, AF changed into a cavotricuspid isthmus = dependent right atrial flutter during ablation of CFAE in the LA.</p>        <p>PMID: 20025707 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20025702&#x26;dopt=Abstract\">Severe venous and lymphatic obstruction after single-chamber pacemaker implantation in a patient with chest radiation therapy.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www3.interscience.wiley.com/resolve/openurl?genre=article&#x26;amp;sid=nlm:pubmed&#x26;amp;issn=0147-8389&#x26;amp;date=2010&#x26;amp;volume=33&#x26;amp;issue=4&#x26;amp;spage=520"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www3.interscience.wiley.com-aboutus-images-wiley_interscience_pubmed_logo_120x27.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20025702">Related Articles</a></td></tr></table>        <p><b>Severe venous and lymphatic obstruction after single-chamber pacemaker implantation in a patient with chest radiation therapy.</b></p>        <p>Pacing Clin Electrophysiol. 2010 Apr;33(4):520-4</p>        <p>Authors:  Diamond JM, Kotloff RM, Liu CF, Cooper JM</p>        <p>A 73-year-old woman with a history of paroxysmal atrial fibrillation, sinus node dysfunction, bilateral breast cancer, and extensive chest radiation developed progressive edema, dyspnea, and recurrent pleural effusions soon after single-chamber pacemaker implantation. Thoracentesis yielded a diagnosis of chylothorax, and progressive refractory anasarca developed. A computed tomography angiogram suggested obstruction of the superior vena cava and left subclavian vein despite outpatient therapeutic anticoagulation. Autopsy confirmed venous thrombosis, along with mediastinal fibrosis. The presumed etiology of the chylothorax and anasarca was obstruction of the atretic central venous structures following pacemaker implantation, critically impairing the already tenuous venous and lymphatic drainage. (PACE 2010; 520-524).</p>        <p>PMID: 20025702 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20015130&#x26;dopt=Abstract\">Inappropriate biventricular implantable cardioverter defibrillator firing due to cryptogenic double counting.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www3.interscience.wiley.com/resolve/openurl?genre=article&#x26;amp;sid=nlm:pubmed&#x26;amp;issn=0147-8389&#x26;amp;date=2010&#x26;amp;volume=33&#x26;amp;issue=4&#x26;amp;spage=486"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www3.interscience.wiley.com-aboutus-images-wiley_interscience_pubmed_logo_120x27.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20015130">Related Articles</a></td></tr></table>        <p><b>Inappropriate biventricular implantable cardioverter defibrillator firing due to cryptogenic double counting.</b></p>        <p>Pacing Clin Electrophysiol. 2010 Apr;33(4):486-90</p>        <p>Authors:  Spragg DD, Marine JE</p>        <p></p>        <p>PMID: 20015130 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19954501&#x26;dopt=Abstract\">Effect of mitral isthmus block on development of atrial tachycardia following ablation for atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www3.interscience.wiley.com/resolve/openurl?genre=article&#x26;amp;sid=nlm:pubmed&#x26;amp;issn=0147-8389&#x26;amp;date=2010&#x26;amp;volume=33&#x26;amp;issue=4&#x26;amp;spage=460"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www3.interscience.wiley.com-aboutus-images-wiley_interscience_pubmed_logo_120x27.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19954501">Related Articles</a></td></tr></table>        <p><b>Effect of mitral isthmus block on development of atrial tachycardia following ablation for atrial fibrillation.</b></p>        <p>Pacing Clin Electrophysiol. 2010 Apr;33(4):460-8</p>        <p>Authors:  Anousheh R, Sawhney NS, Panutich M, Tate C, Chen WC, Feld GK</p>        <p>BACKGROUND: Successful mitral isthmus (MI) ablation may reduce recurrence of atrial fibrillation (AF) and macro-reentrant atrial tachycardia (AT) after pulmonary vein isolation (PVI) for AF. OBJECTIVE: To determine if achieving bidirectional MI conduction block (MIB) during circumferential pulmonary vein ablation (CPVA) plus left atrial linear ablation (LALA) affects development of AT. METHODS: Sixty consecutive patients with persistent (n = 25) or paroxysmal (n = 35) AF undergoing CPVA plus LALA at the MI and LA roof were evaluated in a prospective, nonrandomized study. RESULTS: PVI was achieved in all patients. Bidirectional MI block was achieved in 50 of 60 patients (83%). During 18 +/- 5 months follow-up, 12 patients (20%) developed recurrent AF and 15 (25%) developed AT. Patients in whom MIB was not achieved at initial ablation had four times higher risk of developing AT (P = 0.008, 95% confidence interval 1.43-11.48) versus patients with MIB. In 12 patients with AT undergoing repeat ablation, 22 ATs were identified, with reentry involving the MI in nine, the LA roof in six, and the ridge between the LA appendage and left PVs in seven. In patients with MIB at initial ablation, recovery of MI conduction was seen in eight of 13 undergoing repeat ablation. CONCLUSIONS: AT occurring after CPVA plus LALA is often due to incomplete MI ablation, but may also occur at the LA roof, and ridge between the LA appendage and left PVs. Failure to achieve MI block increases the risk of developing AT. Resumption of MI conduction may also be a mechanism for AT recurrence. (PACE 2010; 460-468).</p>        <p>PMID: 19954501 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19930105&#x26;dopt=Abstract\">Mapping and isolation of the pulmonary veins using the PVAC catheter.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www3.interscience.wiley.com/resolve/openurl?genre=article&#x26;amp;sid=nlm:pubmed&#x26;amp;issn=0147-8389&#x26;amp;date=2010&#x26;amp;volume=33&#x26;amp;issue=2&#x26;amp;spage=168"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www3.interscience.wiley.com-aboutus-images-wiley_interscience_pubmed_logo_120x27.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19930105">Related Articles</a></td></tr></table>        <p><b>Mapping and isolation of the pulmonary veins using the PVAC catheter.</b></p>        <p>Pacing Clin Electrophysiol. 2010 Feb;33(2):168-78</p>        <p>Authors:  Duytschaever M, Anne W, Papiashvili G, Vandekerckhove Y, Tavernier R</p>        <p>OBJECTIVES: We aimed to investigate the feasibility, efficacy, and safety of the pulmonary vein ablation catheter (PVAC) catheter (a novel multielectrode catheter using duty-cycled bipolar and unipolar radiofrequency energy, Medtronic, Minneapolis, MN, USA) to completely isolate the pulmonary veins (PVs). METHODS: Twenty-seven patients (60 +/- 8 years) with paroxysmal atrial fibrillation (AF) underwent PV isolation with the PVAC catheter. PVAC was used for both mapping and isolation of the PVs (PVAC-guided ablation). After PVAC ablation, presence/absence of PV potentials (PVP) was verified using a conventional circular mapping catheter. In case of residual PVP on the circular catheter, PVAC ablation was continued. RESULTS: After PVAC-guided ablation 99 of 106 PVs (93%) and 21 of 27 patients (78%) were proven to be isolated. Failure to isolate was due to a mapping failure in four right-sided PVs and a true ablation failure in three right-sided PVs. After continued PVAC ablation, 103 of 106 PVs (97%) and 25 of 27 patients (93%) were shown to be isolated. The total procedural time from femoral vein access to complete catheter withdrawal was 176 +/- 25 minutes. The actual dwelling-time of the PVAC within the left atrium was 102 +/- 37 minutes. Esophageal T degrees rise to &#x26;gt;38.5 degrees occurred in nine of 19 monitored patients (47%). CONCLUSIONS: (1) PVAC-guided ablation (i.e., mapping and ablation with a single catheter) results in isolation of all PVs in 73% of the patients. (2) An additional circular mapping catheter is required to increase complete isolation rate to 93% of the patients. (3) Given the esophageal T degrees rise in almost 50% of patients, safety precautions are needed.</p>        <p>PMID: 19930105 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19920409&#x26;dopt=Abstract\">Atrial fibrillation is a possible marker of frailty in hospitalized patients: results of the GIFA Study.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19920409">Related Articles</a></td></tr></table>        <p><b>Atrial fibrillation is a possible marker of frailty in hospitalized patients: results of the GIFA Study.</b></p>        <p>Aging Clin Exp Res. 2010 Apr;22(2):129-33</p>        <p>Authors:  Fumagalli S, Tarantini F, Guarducci L, Pozzi C, Pepe G, Boncinelli L, Valoti P, Baldasseroni S, Masotti G, Marchionni N,  </p>        <p>BACKGROUND AND AIMS: Atrial fibrillation (AF) is the most common arrhythmia in elderly people, who are particularly exposed to its most severe complications, such as stroke, worsening heart failure and dementia. Some studies demonstrate that AF is associated with increased mortality in home-dwelling subjects, but little is known about the clinical impact of the arrhythmia in hospitalized patients. We studied the clinical associations and effects of AF on the 23,174 hospitalized patients enrolled in the GIFA (Gruppo Italiano di Farmacoepidemiologia nell&#x27;Anziano) Study. METHODS: Patients were divided into three groups according to the absence or presence of AF (sinus rhythm, non_AF; AF as main diagnosis, AF_main; AF as comorbid condition, AF_associated) and stratified into four age-groups (&#x26;lt; or =60, 61-70, 71-80 and &#x26;gt;80 yrs). RESULTS: AF_associated patients were older, more frequently disabled, and characterized by greater comorbidity and longer in-hospital length of stay. Urea nitrogen concentration was higher, and total cholesterol was lower in AF_associated patients, compared with the other two groups. Overall mortality was 6.0%. Mortality was higher in AF_associated patients (non_AF: 6.0% vs AF_associated: 7.1% vs AF_main: 0%, p&#x26;lt;0.001). CONCLUSIONS: Our results suggest that, in hospitalized patients, AF as a comorbid condition is associated with worse metabolic profile and clinical outcomes, and thus, may represent a marker of frailty.</p>        <p>PMID: 19920409 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19889192&#x26;dopt=Abstract\">The effect of bipole tip-to-ring distance in atrial electrodes upon atrial tachyarrhythmia sensing capability in modern dual-chamber pacemakers.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www3.interscience.wiley.com/resolve/openurl?genre=article&#x26;amp;sid=nlm:pubmed&#x26;amp;issn=0147-8389&#x26;amp;date=2010&#x26;amp;volume=33&#x26;amp;issue=1&#x26;amp;spage=85"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www3.interscience.wiley.com-aboutus-images-wiley_interscience_pubmed_logo_120x27.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19889192">Related Articles</a></td></tr></table>        <p><b>The effect of bipole tip-to-ring distance in atrial electrodes upon atrial tachyarrhythmia sensing capability in modern dual-chamber pacemakers.</b></p>        <p>Pacing Clin Electrophysiol. 2010 Jan;33(1):85-93</p>        <p>Authors:  Silberbauer J, Arya A, Veasey RA, Boodhoo L, Kamalvand K, O&#x27;Nunain S, Hildick-Smith D, Paul V, Patel NR, Lloyd GW, Sulke N</p>        <p>INTRODUCTION: Accurate atrial arrhythmia discrimination is important for dual chamber pacemakers and defibrillators. The aim was to assess the accuracy of atrial arrhythmia recording using modern devices and relate this to atrial tip-to-ring (TTR) distance. METHODS: One hundred eighty-two patients (72 + or - 9 years, 55% male) with paroxysmal atrial fibrillation were enrolled and were included in the study if they had an atrial fibrillation (AF) burden of 1-50% during a monitoring phase. Seventy-nine patients fulfilled these criteria and were followed for at least 5 months. Electrodes were classified as having short (&#x26;lt;10 mm), medium (10-12), or long (13-18) atrial TTR spacing. RESULTS: Two thousand eight hundred eighty-three detailed onset reports were analyzed; 730 (25%) demonstrated aberrant sensing. Six percent were due to farfield R wave oversensing (FFRWO) and 19% due to undersensing, sometimes occurring in the same patient and study phase. FFRWO was significantly reduced with short TTR electrodes (P &#x26;lt; 0.05). Undersensing due to sensitivity fallout was 18% (short), 24% (medium), and 17% (long) (P = ns). Undersensing due to pacemaker blanking was 11% (short), 11% (medium), and 12% (long) (P = ns). Active fixation electrodes did not show any difference from passive fixation. CONCLUSION: Atrial electrodes with a short TTR (&#x26;lt;10 mm) significantly reduce FFRWO without increasing undersensing and should be used routinely in patients with paroxysmal atrial tachyarrhythmias. However, 20% of atrial tachyarrythmia episodes were incorrectly classified as terminated by these modern devices due to undersensing. Clinicians should be wary of using device-derived endpoints that rely on AF episode number or duration as these may be falsely increased or reduced, respectively.</p>        <p>PMID: 19889192 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19889183&#x26;dopt=Abstract\">Transseptal catheterization: considerations and caveats.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www3.interscience.wiley.com/resolve/openurl?genre=article&#x26;amp;sid=nlm:pubmed&#x26;amp;issn=0147-8389&#x26;amp;date=2010&#x26;amp;volume=33&#x26;amp;issue=2&#x26;amp;spage=231"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www3.interscience.wiley.com-aboutus-images-wiley_interscience_pubmed_logo_120x27.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19889183">Related Articles</a></td></tr></table>        <p><b>Transseptal catheterization: considerations and caveats.</b></p>        <p>Pacing Clin Electrophysiol. 2010 Feb;33(2):231-42</p>        <p>Authors:  Tzeis S, Andrikopoulos G, Deisenhofer I, Ho SY, Theodorakis G</p>        <p>Transseptal catheterization is used by interventional cardiologists to gain access in the left atrium. This technique was initially introduced for left-sided pressure measurements and has been integrated in a variety of procedures including left atrial ablations and percutaneous mitral valvuloplasties. The establishment of catheter ablation of atrial fibrillation as an effective treatment strategy has brought transseptal catheterization back to the limelight. Technique refinements, introduction of adjunctive imaging tools, and enrichment of available technical equipment have simplified the procedure. In the present article we review the technique of transseptal catheterization, presenting tips and caveats that could be of value for safe and successful transseptal punctures.</p>        <p>PMID: 19889183 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19889181&#x26;dopt=Abstract\">Long-term clinical efficacy and risk of catheter ablation for atrial fibrillation in octogenarians.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www3.interscience.wiley.com/resolve/openurl?genre=article&#x26;amp;sid=nlm:pubmed&#x26;amp;issn=0147-8389&#x26;amp;date=2010&#x26;amp;volume=33&#x26;amp;issue=2&#x26;amp;spage=146"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www3.interscience.wiley.com-aboutus-images-wiley_interscience_pubmed_logo_120x27.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19889181">Related Articles</a></td></tr></table>        <p><b>Long-term clinical efficacy and risk of catheter ablation for atrial fibrillation in octogenarians.</b></p>        <p>Pacing Clin Electrophysiol. 2010 Feb;33(2):146-52</p>        <p>Authors:  Bunch TJ, Weiss JP, Crandall BG, May HT, Bair TL, Osborn JS, Anderson JL, Lappe DL, Muhlestein JB, Nelson J, Day JD</p>        <p>BACKGROUND: Radiofrequency ablation is an effective treatment for atrial fibrillation (AF). With improved safety, the therapy has been offered to increasingly older populations. Arrhythmia mechanisms, medical comorbidities, and safety may vary in the very elderly population. METHODS: Patients presenting for AF ablation were divided into two groups [&#x26;gt; or =80 years (n = 35), &#x26;lt;80 years (n = 717)]. AF ablation consisted of pulmonary vein antral isolation with or without additional linear lesions. A successful outcome was defined as no further AF and off all antiarrhythmic medications &#x26;gt;3 months following 1 + ablation procedures. RESULTS: The type of AF was similar in both groups (paroxysmal: 46% in the older group vs 54% in the younger, P = 0.33). Older patients were more likely to have a higher CHADS2 score, coronary artery disease, and less likely to have had a prior ablation. The hospital stay on average was longer in the older cohort (2.9 +/- 7.7 vs 2.1 +/- 1.1 days, P = 0.001). There was no increased risk of peri-procedural complications. One-year survival free of AF or flutter was 78% in those &#x26;gt;80 and 75% in those younger (P = 0.78). There was no difference between groups if the AF was paroxysmal (P = 0.44) or persistent/chronic (P = 0.74). Over a 3-year follow-up period, five patients died and four strokes occurred all in the younger cohort. CONCLUSION: Octogenarian patients, despite more coexistent cardiovascular diseases, have favorable outcomes after AF ablation measured by successful rhythm management. On an average their hospital stay is longer, but no significant increase in short- or long-term complications was observed. These data support AF ablation in select octogenarians.</p>        <p>PMID: 19889181 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19875908&#x26;dopt=Abstract\">A case of myotonic dystrophy presenting with ventricular tachycardia and atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19875908">Related Articles</a></td></tr></table>        <p><b>A case of myotonic dystrophy presenting with ventricular tachycardia and atrial fibrillation.</b></p>        <p>Turk Kardiyol Dern Ars. 2009 Jul;37(5):337-40</p>        <p>Authors:  Ero&#xC4;&#x9F;lu S, Ozin B, Ozbi&#xC3;&#xA7;er S, M&#xC3;&#xBC;derriso&#xC4;&#x9F;lu H</p>        <p>Myotonic dystrophy type 1 (MD1) is an autosomal dominant disorder characterized by myotonia, progressive muscular weakness, cataract, and cardiac involvement. Cardiac involvement is common and includes conduction system abnormalities, supraventricular and ventricular arrhythmias, and less frequently, myocardial dysfunction and ischemic heart disease. A 54-year-old woman with a previous diagnosis of MD1 was admitted with palpitation, blood pressure of 157/118 mmHg, and a heart rate of 220 beats/min. Electrocardiography (ECG) showed ventricular tachycardia. Within minutes, hemodynamic collapse developed and electrical cardioversion was performed. Immediately following cardioversion, ECG showed atrial fibrillation, a slightly prolonged QT interval, and intraventricular conduction delay. After intravenous infusion of amiodarone, the rhythm converted to sinus. Transthoracic echocardiography showed significantly depressed left ventricular function, an ejection fraction of 25%, and normal coronary arteries. During electrophysiological study, atrium-His interval and His-ventricle interval were 120 msec was 54 msec, respectively, and monomorphic ventricular flutter was induced. An implantable cardioverter-defibrillator was placed. She was discharged in sinus rhythm.</p>        <p>PMID: 19875908 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19875905&#x26;dopt=Abstract\">[Mid-term results of surgical radiofrequency ablation for permanent atrial fibrillation]</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19875905">Related Articles</a></td></tr></table>        <p><b>[Mid-term results of surgical radiofrequency ablation for permanent atrial fibrillation]</b></p>        <p>Turk Kardiyol Dern Ars. 2009 Jul;37(5):321-7</p>        <p>Authors:  Mataraci I, Polat A, Mert B, Aks&#xC3;&#xBC;t M, Kirali K</p>        <p>OBJECTIVES: Atrial fibrillation (AF) is a common problem in cardiac surgery patients. We evaluated the mid-term results of patients who underwent open heart surgery and radiofrequency ablation (RFA). STUDY DESIGN: The study included 79 patients (53 females, 26 males; mean age 53+/-11 years; range 32 to 76 years) who underwent concomitant RFA for AF during open heart surgery under cardiopulmonary bypass. The majority of patients were in NYHA class III (n=68, 86.1%) and had (n=67, 84.8%) rheumatic heart disease. The mean preoperative AF duration was 47+/-41 months. The most frequent procedure involved the mitral valve (64 replacements, 11 reconstructions). A unipolar probe was used in 60 patients (76%) and a bipolar probe in 19 patients (24.1%). The mean follow-up period was 20.8+/-14.7 months (range 1 to 59 months). RESULTS: The mean perfusion and cross-clamp times were 102.4+/-15.7 min (range 48 to 171 min) and 76.1+/-25.0 min (range 27 to 145 min), respectively. In-hospital mortality occurred in two patients (2.5%) and late mortality occurred in three patients (3.8%). One patient (1.3%) required implantation of a permanent pacemaker. During discharge, 58 patients (73.4%) were in sinus rhythm, of which nine (15.3%) developed recurrent AF within a mean of 5.3+/-4.4 months (range 2 to 12 months). Transient atrial flutter was seen in three patients (3.8%). Logistic regression analysis showed no risk factor to significantly affect early or late AF recurrence. Six- and 12-month rates of AF-free rhythm were 94.3+/-3.9% and 87.6+/-5.9% for operations performed by the year 2006 and 95.2+/-3.3% and 92.2+/-4.4% afterwards, respectively (p=0.0001). There was no significant difference with respect to survival between patients discharged with AF and in sinus rhythm (p&#x26;gt;0.05). CONCLUSION: Radiofrequency ablation is increasingly performed for the treatment of AF, yielding more successful results.</p>        <p>PMID: 19875905 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19843312&#x26;dopt=Abstract\">Cavotricuspid isthmus: anatomy, electrophysiology, and long-term outcome of radiofrequency ablation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www3.interscience.wiley.com/resolve/openurl?genre=article&#x26;amp;sid=nlm:pubmed&#x26;amp;issn=0147-8389&#x26;amp;date=2009&#x26;amp;volume=32&#x26;amp;issue=12&#x26;amp;spage=1591"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www3.interscience.wiley.com-aboutus-images-wiley_interscience_pubmed_logo_120x27.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19843312">Related Articles</a></td></tr></table>        <p><b>Cavotricuspid isthmus: anatomy, electrophysiology, and long-term outcome of radiofrequency ablation.</b></p>        <p>Pacing Clin Electrophysiol. 2009 Dec;32(12):1591-5</p>        <p>Authors:  Tai CT, Chen SA</p>        <p>The cavotricuspid isthmus (CTI) had a complex architecture with an anisotropic conduction property. An incremental pacing from the low right atrial isthmus produced a conduction delay and block, and initiated atrial flutter. Radiofrequency catheter ablation of the CTI was very effective in eliminating the typical atrial flutter. However, atrial fibrillation often occurred after ablation of the isthmus and needs further treatment.</p>        <p>PMID: 19843312 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19825009&#x26;dopt=Abstract\">Impact of right ventricular pacing sites on exercise capacity during ventricular rate regularization in patients with permanent atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www3.interscience.wiley.com/resolve/openurl?genre=article&#x26;amp;sid=nlm:pubmed&#x26;amp;issn=0147-8389&#x26;amp;date=2009&#x26;amp;volume=32&#x26;amp;issue=12&#x26;amp;spage=1536"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www3.interscience.wiley.com-aboutus-images-wiley_interscience_pubmed_logo_120x27.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19825009">Related Articles</a></td></tr></table>        <p><b>Impact of right ventricular pacing sites on exercise capacity during ventricular rate regularization in patients with permanent atrial fibrillation.</b></p>        <p>Pacing Clin Electrophysiol. 2009 Dec;32(12):1536-42</p>        <p>Authors:  Tse HF, Siu CW, Lau CP</p>        <p>BACKGROUND: The deleterious effects of right ventricular apical (RVA) pacing may offset the potential benefit of ventricular rate (VR) regularization and rate adaptation during an exercise in patient&#x27;s atrial fibrillation (AF). METHODS: We studied 30 patients with permanent AF and symptomatic bradycardia who receive pacemaker implantation with RVA (n = 15) or right ventricular septal (RVS, n = 15) pacing. All the patients underwent an acute cardiopulmonary exercise testing using VVI-mode (VVI-OFF) and VVI-mode with VR regularization (VRR) algorithm on (VVI-ON). RESULTS: There were no significant differences in the baseline characteristics between the two groups, except pacing QRS duration was significantly shorter during RVS pacing than RVA pacing (138.9 +/- 5 vs 158.4 +/- 6.1 ms, P = 0.035). Overall, VVI-ON mode increased the peak exercise VR, exercise time, metabolic equivalents (METs), and peak oxygen consumption (VO(2)max), and decreased the VR variability compared with VVI-OFF mode during exercise (P &#x26;lt; 0.05), suggesting that VRR pacing improved exercise capacity during exercise. However, further analysis on the impact of VRR pacing with different pacing sites revealed that only patients with RVS pacing but not patients with RVA pacing had significant increased exercise time, METs, and VO(2)max during VVI-ON compared with VVI-OFF, despite similar changes in peaked exercise VR and VR variability. CONCLUSION: In patients with permanent AF, VRR pacing at RVS, but not at RVA, improved exercise capacity during exercise.</p>        <p>PMID: 19825009 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19824941&#x26;dopt=Abstract\">Superior vena cava stenosis after radiofrequency catheter ablation for electrical isolation of the superior vena cava.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www3.interscience.wiley.com/resolve/openurl?genre=article&#x26;amp;sid=nlm:pubmed&#x26;amp;issn=0147-8389&#x26;amp;date=2010&#x26;amp;volume=33&#x26;amp;issue=4&#x26;amp;spage=e36"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www3.interscience.wiley.com-aboutus-images-wiley_interscience_pubmed_logo_120x27.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19824941">Related Articles</a></td></tr></table>        <p><b>Superior vena cava stenosis after radiofrequency catheter ablation for electrical isolation of the superior vena cava.</b></p>        <p>Pacing Clin Electrophysiol. 2010 Apr;33(4):e36-8</p>        <p>Authors:  K&#xC3;&#xBC;hne M, Schaer B, Osswald S, Sticherling C</p>        <p>Ectopic beats originating from the superior vena cava (SVC) may initiate atrial fibrillation. This report describes a patient undergoing radiofrequency catheter ablation for electrical isolation of the SVC resulting in SVC stenosis. Noncircumferential lesion sets for SVC isolation to reduce ablation times may be preferred. (PACE 2010; e36-e38).</p>        <p>PMID: 19824941 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19821942&#x26;dopt=Abstract\">Use of an angioplasty wire to perforate the interatrial septum for a difficult transseptal puncture.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www3.interscience.wiley.com/resolve/openurl?genre=article&#x26;amp;sid=nlm:pubmed&#x26;amp;issn=0147-8389&#x26;amp;date=2010&#x26;amp;volume=33&#x26;amp;issue=2&#x26;amp;spage=243"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www3.interscience.wiley.com-aboutus-images-wiley_interscience_pubmed_logo_120x27.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19821942">Related Articles</a></td></tr></table>        <p><b>Use of an angioplasty wire to perforate the interatrial septum for a difficult transseptal puncture.</b></p>        <p>Pacing Clin Electrophysiol. 2010 Feb;33(2):243-5</p>        <p>Authors:  Ahsan SY, Wright S, Lambiase PD, McCready JW, Chow AW</p>        <p>With the expansion in catheter-based treatments for atrial fibrillation the number of transseptal punctures being performed by cardiac electrophysiologists has increased significantly. Although in general transseptal puncture is successful, in a small percentage of cases it cannot be achieved due to complex intraatrial anatomy. We report the case of a difficult transseptal puncture (TSP), performed where the conventional approach using a Brockenbrough needle sheath was unable to perforate the septum. TSP was only achieved using a novel technique assisted by an angioplasty wire.</p>        <p>PMID: 19821942 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19793371&#x26;dopt=Abstract\">Primary prevention of atrial fibrillation: does the atrial lead position influence the incidence of atrial arrhythmias in patients with sinus node dysfunction? Results from the PASTA Trial.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www3.interscience.wiley.com/resolve/openurl?genre=article&#x26;amp;sid=nlm:pubmed&#x26;amp;issn=0147-8389&#x26;amp;date=2009&#x26;amp;volume=32&#x26;amp;issue=12&#x26;amp;spage=1553"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www3.interscience.wiley.com-aboutus-images-wiley_interscience_pubmed_logo_120x27.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19793371">Related Articles</a></td></tr></table>        <p><b>Primary prevention of atrial fibrillation: does the atrial lead position influence the incidence of atrial arrhythmias in patients with sinus node dysfunction? Results from the PASTA Trial.</b></p>        <p>Pacing Clin Electrophysiol. 2009 Dec;32(12):1553-61</p>        <p>Authors:  Spitzer SG, Wacker P, Gazarek S, Malinowski K, Schibgilla V,  </p>        <p>INTRODUCTION: PASTA (pacing of the atria in sinus node disease) is a prospective and randomized trial, assessing the effect of different atrial lead positions on the atrial fibrillation (AF) incidence in patients with sinus node disease (SND). METHOD: The atrial lead position is randomized to: (a) free right atrial wall, (b) right atrial appendage (RAA), (c) coronary sinus ostium (CS-Os), or (d) dual site right atrial pacing (CS-Os + RAA). The pacemakers (Vitatron Selection 9000 or Prevent AF, Vitatron B.V., Arnhem, The Netherlands) are programmed in DDDR 70 mode and the total follow-up duration is 24 months. To describe the atrial rhythm state, pacemaker-derived data (arrhythmia counter) were assessed for AF episodes. AF was considered as evident, if the AF burden (time in AF related to follow-up interval) was &#x26;gt;1% (i.e., 15 min/d). Follow-up data after 24 months were evaluated. RESULTS: The analysis evaluates 142 patients (77 male, 74.5 +/- 7.8 years). There was no statistical significant difference with respect to the occurrence of AF between the four groups after 24 months (A: 36%; B: 38%, C: 32%, D: 48%). The percentage of atrial/ventricular pacing was in A: 78/76%, in B: 84/81%, in C: 70/65%, and in D: 79/69%. These differences were not significant. CONCLUSION: The evaluation of the AF burden &#x26;gt;1% and the total AF burden after 24 months did not show differences in the incidence of AF in patients with dual chamber pacemaker therapy for SND. We were not able to demonstrate a significant influence of right atrial lead position on the incidence of AF recurrence.</p>        <p>PMID: 19793371 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19793367&#x26;dopt=Abstract\">Effects of rosuvastatin on asymmetric dimethylarginine levels and early atrial fibrillation recurrence after electrical cardioversion.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www3.interscience.wiley.com/resolve/openurl?genre=article&#x26;amp;sid=nlm:pubmed&#x26;amp;issn=0147-8389&#x26;amp;date=2009&#x26;amp;volume=32&#x26;amp;issue=12&#x26;amp;spage=1562"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www3.interscience.wiley.com-aboutus-images-wiley_interscience_pubmed_logo_120x27.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19793367">Related Articles</a></td></tr></table>        <p><b>Effects of rosuvastatin on asymmetric dimethylarginine levels and early atrial fibrillation recurrence after electrical cardioversion.</b></p>        <p>Pacing Clin Electrophysiol. 2009 Dec;32(12):1562-6</p>        <p>Authors:  Xia W, Yin Z, Li J, Song Y, Qu X</p>        <p>BACKGROUND: High levels of asymmetric dimethylarginine (ADMA) are associated with an increased risk of early recurrence of atrial fibrillation (AF) after electrical cardioversion. We aimed to investigate the effects of rosuvastatin on serum ADMA levels and early recurrence of AF following successful electrical cardioversion. METHODS: A total of 64 patients with persistent AF, but without known heart disease, who underwent elective electrical cardioversion were randomized to the rosuvastatin (group I, n = 32) and control (group II, n = 32) groups. The end point was the recurrence of AF during the 3 months of follow-up. RESULTS: The baseline ADMA levels were not different between the two groups. At the end of follow-up, serum ADMA levels in group I decreased compared with the baseline levels, whereas no significant change occurred in group II. During the follow-up, five patients in group I (15.6%) and 13 in group II (40.6%) had AF recurrence (P &#x26;lt; 0.05, log-rank test). With the Cox proportional model, the predictors of recurrence included age &#x26;gt; or =65 years, left atrial diameter &#x26;gt;45 mm, and baseline ADMA levels &#x26;gt; or =2.0 micromol/l. Rosuvastatin was associated with a reduced risk of AF recurrence (relative risk 0.35, 95% confidence interval 0.12-0.96, P &#x26;lt; 0.05). CONCLUSIONS: Rosuvastatin decreased the early recurrence of AF following successful electrical cardioversion with reduced ADMA levels.</p>        <p>PMID: 19793367 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19761504&#x26;dopt=Abstract\">ATP revealed extra pulmonary vein source of atrial fibrillation after circumferential pulmonary vein isolation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www3.interscience.wiley.com/resolve/openurl?genre=article&#x26;amp;sid=nlm:pubmed&#x26;amp;issn=0147-8389&#x26;amp;date=2010&#x26;amp;volume=33&#x26;amp;issue=2&#x26;amp;spage=248"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www3.interscience.wiley.com-aboutus-images-wiley_interscience_pubmed_logo_120x27.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19761504">Related Articles</a></td></tr></table>        <p><b>ATP revealed extra pulmonary vein source of atrial fibrillation after circumferential pulmonary vein isolation.</b></p>        <p>Pacing Clin Electrophysiol. 2010 Feb;33(2):248-51</p>        <p>Authors:  Jiang CY, Jiang RH, Matsuo S, Fu GS</p>        <p>Noninducibility of atrial fibrillation (AF) by additional electrograms-guided ablation may benefit the clinical outcome. This report illustrates the effect of adenosine triphosphate (ATP) injection on AF inducibility after pulmonary vein (PV) isolation. AF was triggered twice by ATP without PV reconnection. Meanwhile, complex fractionated atrial electrograms (CFAEs) were observed, and ablation targets on these sites appeared to be essential to the AF elimination. It suggests that CFAEs may contribute to the initiation of some AF. ATP may be useful to induce AF after proven PV isolation, and further ablation might be necessary to ensure efficacy after circumferential PV isolation.</p>        <p>PMID: 19761504 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19732360&#x26;dopt=Abstract\">Linear radiofrequency microcatheter ablation guided by phased array intracardiac echocardiography combined with temperature decay.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www3.interscience.wiley.com/resolve/openurl?genre=article&#x26;amp;sid=nlm:pubmed&#x26;amp;issn=0147-8389&#x26;amp;date=2009&#x26;amp;volume=32&#x26;amp;issue=12&#x26;amp;spage=1543"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www3.interscience.wiley.com-aboutus-images-wiley_interscience_pubmed_logo_120x27.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19732360">Related Articles</a></td></tr></table>        <p><b>Linear radiofrequency microcatheter ablation guided by phased array intracardiac echocardiography combined with temperature decay.</b></p>        <p>Pacing Clin Electrophysiol. 2009 Dec;32(12):1543-52</p>        <p>Authors:  Keane D, Hynes B, Lamkin R, Houghtaling C, Zhou L, Aretz T, Ruskin J</p>        <p>BACKGROUND: Fluoroscopy-guided catheter placement is limited in its ability to determine electrode-endocardial contact and involves radiation exposure. We hypothesized that (1) intracardiac echocardiography (ICE) would provide superior assessment of linear electrode contact compared to fluoroscopy and (2) slow temperature decay upon discontinuation of the radiofrequency current (time for temperature to fall 90% after a 10-second test application of the radiofrequency current T90) would indicate optimal electrode-myocardial contact. METHODS: Sixty endocardial lesions were created in the atria and ventricles of six goats by simultaneous delivery of the radiofrequency current through two linear electrodes of a microcatheter with a central interelectrode thermocouple. Catheter placement was guided by fluoroscopy. A 7.5-MHz ICE transducer in the right atrium or ventricle assessed electrode contact. T90 and previously reported parameters of electrode contact and lesion formation were recorded. Histomorphometry was performed on the lesions. RESULTS: T90 was 4.27 +/- 4.98 seconds. Lesion depth significantly correlated with ICE assessment of electrode contact (r = 0.56, P = 0.001); T90 upon radiofrequency current offset (r = 0.48, P = 0.008), impedance fall upon radiofrequency current onset (r = 0.37, P = 0.008), bipolar pacing threshold preablation (r =-0.56, P = 0.001), bipolar electrogram amplitude preablation (r = 0.43, P = 0.02), but not with fluoroscopic assessment of the electrode contact (r = 0.18, n.s.). For the prediction of achieving a lesion depth of &#x26;gt;2 mm, a T90 of &#x26;gt;4.0 seconds yielded a specificity of 86% and a sensitivity of 52%, ICE yielded a specificity and sensitivity of 58% and 68%, respectively, while the specificity and sensitivity of fluoroscopy were 26% and 68%, respectively. Both ICE and T90 provide additional clinical relevance during guidance of cardiac microcatheter ablation.</p>        <p>PMID: 19732360 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19595214&#x26;dopt=Abstract\">[Intraoperative treatment for atrial fibrillation using bi-polar radiofrequency ablation system: a clinical report of 91 cases]</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19595214">Related Articles</a></td></tr></table>        <p><b>[Intraoperative treatment for atrial fibrillation using bi-polar radiofrequency ablation system: a clinical report of 91 cases]</b></p>        <p>Zhonghua Wai Ke Za Zhi. 2009 Apr 1;47(7):533-6</p>        <p>Authors:  Cui YQ, Meng X, Li Y, Wang JG, Zeng W, Gao F, Xu CL</p>        <p>OBJECTIVE: To observe the short and mid-term therapeutic effects of Bi-polar ablation systems for intraoperative treatment of atrial fibrillation (AF). METHODS: From March 2005 to January 2007, 91 patients received intraoperative treatment of atrial fibrillation with Bi-polar ablation systems, including 5 cases of paroxysmal atrial fibrillation and 86 persistent/permanent cases. The main concomitant heart diseases were rheumatic mitral valve diseases. Atricure Dry Ablation System was used for 37 cases and Cardioblate Irrigated Ablation System for 54 cases. The ablation lesion patterns included Cox-maze III, Modified Cox Mini-maze and Left-sided Maze. RESULTS: Mean ablation time was (14.1+/-6.7) min. No ablation-related complications occurred. Three patients died perioperatively. Two patients had permanent pacemaker implantation 3 months after operation. One case suffered from stroke and lower limb thrombosis 2.5 years after operation. Follow-up lasted for 6 to 29 months. The none-AF rhythm were 62.5%, 85.2%, 79.0% and 74.5% at discharge, 3 months, 6 months, and&#x26;gt;or=12 months respectively. Compared to Uni-polar Ablation therapy group, the restoration of sinus rhythm in Bi-polar group were significantly higher at 6 months and&#x26;gt;or=12 months postoperatively. The latest follow-up results indicated that 100% of preoperative paroxysmal atrial fibrillation patients restored sinus rhythm and 75.3% of persistent/permanent patients were free from atrial fibrillation. The none-AF rhythm of Atricure group (81.1%) showed no difference from the Cardioblate (77.5%). Meanwhile there were no significant differences among the three ablation lesion groups. CONCLUSION: Intraoperative radiofrequency ablation with Bi-polar systems is a feasible, safe and highly effective surgical option compared to the Uni-polar ablation technique.</p>        <p>PMID: 19595214 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=19211271&#x26;dopt=Abstract\">Atrial expression of endothelial nitric oxide synthase in patients with and without atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S1054-8807(09)00003-9"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=19211271">Related Articles</a></td></tr></table>        <p><b>Atrial expression of endothelial nitric oxide synthase in patients with and without atrial fibrillation.</b></p>        <p>Cardiovasc Pathol. 2010 May-Jun;19(3):e51-60</p>        <p>Authors:  Bukowska A, R&#xC3;&#xB6;cken C, Erxleben M, R&#xC3;&#xB6;hl FW, Hammw&#xC3;&#xB6;hner M, Huth C, Ebert MP, Lendeckel U, Goette A</p>        <p>BACKGROUND: Atrial fibrillation (AF) is associated with oxidative stress within the fibrillating atrial myocardium. Experimental studies suggest that reduced levels of nitric oxide (NO) caused by down-regulation of the NO synthase (eNOS) contribute to the development of prothrombotic endocardial remodeling in AF. This study was designed to determine the endocardial expression of eNOS in atrial tissue samples from patients with and without AF. METHODS: Tissue microarrays were used to analyze right atrial tissue specimens obtained from 234 patients (38 with AF; 196 with sinus rhythm) for differences in atrial eNOS expression. In selected patients, immunohistological results were confirmed by Western blotting. RESULTS: Immunohistochemical analyses showed that eNOS is expressed by endocardial cells and myocytes. However, endocardial expression of eNOS was not independently related to AF per se. There was no difference between paroxysmal and persistent AF. Clinical factors like gender (P=.05) and coronary artery disease (P=.06) were associated with down-regulation of eNOS. Interestingly, diabetes mellitus (P=.02) was associated with an up-regulation of endocardial eNOS, whereas other risk factors for thromboembolic events did not influence eNOS levels. Multivariable analysis showed that eNOS expression is influenced by interactions between diabetes mellitus and AF (P=.09) as well as by interactions between gender and AF (P=.04). Lowest levels of eNOS were found in women with AF. CONCLUSION: AF does not independently effect atrial eNOS expression in humans. Due to the nonuniform regulation of endocardial eNOS expression, it appears unlikely that down-regulation of eNOS is a final common pathway for the development of prothrombotic endocardial remodeling, since classical risk factors for thromboembolic events do not reduce endocardial eNOS protein.</p>        <p>PMID: 19211271 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('</ul>');
document.write('</div>');
document.write('<div class=\"rss_feed\">');
document.write('<div class=\"rss_feed_title\">pubmed: "atrial fibrillation...</div>');
document.write('<ul class=\"rss_item_list\">');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20499771&#x26;dopt=Abstract\">Very late recurrences of atrial fibrillation after pulmonary vein isolation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20499771">Related Articles</a></td></tr></table>        <p><b>Very late recurrences of atrial fibrillation after pulmonary vein isolation.</b></p>        <p>Hosp Pract (Minneap). 2010 Jun;38(3):40-4</p>        <p>Authors:  Klein EM, Steinberg JS</p>        <p>Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, accounting for approximately one-third of all hospitalizations from cardiac rhythm disturbances. Over the past decade, catheter ablation (predominantly in the form of pulmonary vein isolation [PVI]) has become an important therapy in the treatment of patients with symptomatic, drug-refractory AF. Despite the improvements in technology, operator experience, and advances in methodology that have led to higher success rates and a reduction in complications, the recurrence rate of AF after PVI is still relatively high. Published studies suggest that approximately 33% to 86% of patients undergoing catheter ablation of AF have freedom from recurrent AF, with 30% to 40% requiring a second procedure. Although most studies looking at the efficacy of PVI are limited by relatively short follow-up, recent data suggest that patients with an initially favorable procedural response may have very late recurrences of AF, even years after PVI. It is likely that the mechanism behind very late recurrences of AF is multifactorial, involving both recurrent pulmonary vein triggers and progressive remodeling of left atrial substrate over time, making it more vulnerable to triggering. These recurrences have important clinical implications in the care of patients, specifically with regard to the increased risk of stroke associated with AF.</p>        <p>PMID: 20499771 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20677363&#x26;dopt=Abstract\">Lenient versus strict rate control in atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20677363">Related Articles</a></td></tr></table>        <p><b>Lenient versus strict rate control in atrial fibrillation.</b></p>        <p>N Engl J Med. 2010 Jul 22;363(4):393; author reply 393-4</p>        <p>Authors:  Bhaskar E</p>        <p></p>        <p>PMID: 20677363 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20677362&#x26;dopt=Abstract\">Lenient versus strict rate control in atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20677362">Related Articles</a></td></tr></table>        <p><b>Lenient versus strict rate control in atrial fibrillation.</b></p>        <p>N Engl J Med. 2010 Jul 22;363(4):392-3; author reply 393-4</p>        <p>Authors:  Grimsley EW, Patel R, Persed P</p>        <p></p>        <p>PMID: 20677362 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20660409&#x26;dopt=Abstract\">Lenient versus strict rate control in atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20660409">Related Articles</a></td></tr></table>        <p><b>Lenient versus strict rate control in atrial fibrillation.</b></p>        <p>N Engl J Med. 2010 Jul 22;363(4):392; author reply 393-4</p>        <p>Authors:  Marine JE</p>        <p></p>        <p>PMID: 20660409 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20620710&#x26;dopt=Abstract\">Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry&#x27;s PINNACLE (Practice Innovation And Clinical Excellence) program.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(10)01744-4"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20620710">Related Articles</a></td></tr></table>        <p><b>Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry&#x27;s PINNACLE (Practice Innovation And Clinical Excellence) program.</b></p>        <p>J Am Coll Cardiol. 2010 Jun 29;56(1):8-14</p>        <p>Authors:  Chan PS, Oetgen WJ, Buchanan D, Mitchell K, Fiocchi FF, Tang F, Jones PG, Breeding T, Thrutchley D, Rumsfeld JS, Spertus JA</p>        <p>OBJECTIVES: We examined compliance with performance measures for 14,464 patients enrolled from July 2008 through June 2009 into the American College of Cardiology&#x27;s PINNACLE (Practice Innovation And Clinical Excellence) program to provide initial insights into the quality of outpatient cardiac care. BACKGROUND: Little is known about the quality of care of outpatients with coronary artery disease (CAD), heart failure, and atrial fibrillation, and whether sex and racial disparities exist in the treatment of outpatients. METHODS: The PINNACLE program is the first, national, prospective office-based quality improvement program of cardiac patients designed, in part, to capture, report, and improve outpatient performance measure compliance. We examined the proportion of patients whose care was compliant with established American College of Cardiology, American Heart Association, and American Medical Association-Physician Consortium for Performance Improvement (ACC/AHA/PCPI) performance measures for CAD, heart failure, and atrial fibrillation. RESULTS: There were 14,464 unique patients enrolled from 27 U.S. practices, accounting for 18,021 clinical visits. Of these, 8,132 (56.4%) had CAD, 5,012 (34.7%) had heart failure, and 2,786 (19.3%) had nonvalvular atrial fibrillation. Data from the PINNACLE program were feasibly collected for 24 of 25 ACC/AHA/PCPI performance measures. Compliance with performance measures ranged from being very low (e.g., 13.3% of CAD patients screened for diabetes mellitus) to very high (e.g., 96.7% of heart failure patients with blood pressure assessments), with moderate (70% to 90%) compliance observed for most performance measures. For 3 performance measures, there were small differences in compliance rates by race or sex. CONCLUSIONS: For more than 14,000 patients enrolled from 27 practices in the outpatient PINNACLE program, we found that compliance with performance measures was variable, even after accounting for exclusion criteria, suggesting an important opportunity to improve the quality of outpatient care.</p>        <p>PMID: 20620710 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20568394&#x26;dopt=Abstract\">[Atrial fibrillation before and after pacemaker implantation (WI and DDD) in patients with complete atrioventricular block]</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20568394">Related Articles</a></td></tr></table>        <p><b>[Atrial fibrillation before and after pacemaker implantation (WI and DDD) in patients with complete atrioventricular block]</b></p>        <p>Pol Merkur Lekarski. 2010 May;28(167):345-9</p>        <p>Authors:  Matusik P, Woznica N, Lelakowsk J</p>        <p>Atrial fibrillation (AF) is a frequent problem of patients with pacemakers, and depends not only on disease but also on stimulation method. The aim of the study was to estimate the prevalence of AF before and after pacemaker implantation as well as to assess the influence of VVI and DDD cardiac pacing on onset of AF in patients with complete atrioventricularblock (AVB). MATERIAL AND METHODS: We included 155 patients controlled between 2000 and 2008 in Pacemaker Clinic because of AVB III degree, treated with VVI or DDD pacemaker implantation. Information about the health status of the patients was gathered from medical documentation and analysis of clinical ambulatory electrocardiograms. RESULTS: The study group comprised of 68 women and 87 men, mean age 68.7 +/- 13.9 years during implantation. 69% of patients had VVI pacemaker. There were 72.3% of patients with sinus rhythm before pacemaker implantation. During follow-up 4 +/- 2.8 years in 19.6% cases onset of atrial fibrillation de novo was diagnosed (in 31.3% in VVI mode vs. 2.2% in DDD mode; p = 0.00014). Mean time to AF since implantation was approximately 2.5 years. In VVI group (21 persons) amounted 32.1 months, while in 1 patient with DDD pacemaker 18 months. Between group with AF after implantation and with sinus rhythm preserved there was no statistically significant difference in age or gender (p = 0.89512 and p = 0.1253, respectively). Prevalence of atrial fibrillation after pacemaker implantation increased to 40%. CONCLUSIONS: Atrial fibrillation is frequent in patients before and after pacemaker implantation, especially in patients stimulated in VVI mode. Major possibility of atrial fibrillation onset after pacemaker implantation should result in more attention during routine ECG examination.</p>        <p>PMID: 20568394 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20517485&#x26;dopt=Abstract\">Antithrombotic therapy in very elderly patients with atrial fibrillation: is it enough to assess thromboembolic risk?</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&#x26;amp;pubmedid=20517485"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.pubmedcentral.nih.gov-corehtml-pmc-pmcgifs-pubmed-pmc.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20517485">Related Articles</a></td></tr></table>        <p><b>Antithrombotic therapy in very elderly patients with atrial fibrillation: is it enough to assess thromboembolic risk?</b></p>        <p>Clin Interv Aging. 2010;5:157-62</p>        <p>Authors:  Guo Y, Wu Q, Zhang L, Yang T, Zhu P, Gao W, Zhao Y, Gao M</p>        <p>Although attention has been given to thromboprophylaxis for atrial fibrillation (AF) in present treatment guidelines, practical, clinical antithrombotic therapy is poorly developed for very elderly patients. We reviewed the records of 105 consecutive patients with AF of mean age 85 years, to determine how the greatest benefits from antithrombotic therapy could be obtained in this group. The mean CHADS2 score in these patients was 3.1 +/- 1.5. Before antithrombotic therapy, 21.0% of the patients had diseases with a risk of hemorrhage, 26.7% had diseases with a risk of thrombosis, and 8.6% had diseases with a risk of both hemorrhage and thrombosis. Moreover, 89 patients (84.8%) were receiving a single antiplatelet drug, 10 (9.5%) used aspirin plus clopidogrel, and six (5.7%) were taking an oral anticoagulant (OAC). Additionally, dual antiplatelet therapy was more commonly given to patients with permanent AF (paroxysmal and persistent versus permanent, 6.3% and 12.5% versus 30%, respectively, Chi-square = 8.4, P = 0.010). The incidence of adverse events was 25.7%, with thromboembolic events in 20.0% and hemorrhage in 5.7% of patients. There were no thromboembolic events in those patients taking OACs, but 33% of patients who took OACs had bleeding complications. It is difficult to choose appropriate antithrombotic strategies in very elderly patients. Both the thrombotic risk and the bleeding risk should be considered for helping such patients derive optimal benefit from thromboprophylaxis for AF.</p>        <p>PMID: 20517485 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20436706&#x26;dopt=Abstract\">Characteristics of P wave in patients with sinus rhythm after maze operation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://jkms.org/DOIx.php?id=10.3346/jkms.2010.25.5.712"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--jkms.org-image-jkmslogo2.jpg" border="0"/></a> <a href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&#x26;amp;pubmedid=20436706"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.pubmedcentral.nih.gov-corehtml-pmc-pmcgifs-pubmed-pmc.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20436706">Related Articles</a></td></tr></table>        <p><b>Characteristics of P wave in patients with sinus rhythm after maze operation.</b></p>        <p>J Korean Med Sci. 2010 May;25(5):712-5</p>        <p>Authors:  Park HE, Kim KH, Kim KB, Ahn H, Choi YS, Oh S</p>        <p>Maze operation could alter P wave morphology in electrocardiogram (ECG), which might prevent exact diagnosis of the cardiac rhythm of patients. However, characteristics of P wave in patients with sinus rhythm after the operation have not been elucidated systematically. Consecutive patients who underwent the modified Cox Maze operation from January to December 2007 were enrolled. The standard 12-lead ECG and echocardiography were evaluated in patients who had sinus rhythm at 6 months after the operation. The average axis of P wave was 65+/-30 degrees. The average amplitude of P wave was less than 0.1 mV in all 12-leads, with highest amplitude in V(1). The most common morphology of P wave was monophasic with positive polarity (49%), except aVR lead, which was different from those in patients with enlarged left atrium, characterized by large P-terminal force in the lead V(1). There were no significant differences in P-wave characteristics and echocardiographic parameters between patients with LA activity (30.6%) versus without LA activity (69.4%) at 6 months after the operation. In conclusion, the morphology of P wave in patients after Maze operation shows loss of typical ECG pattern of P mitrale: P wave morphology is small in amplitude, monophasic and with positive polarity.</p>        <p>PMID: 20436706 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('</ul>');
document.write('</div>');
document.write('<div class=\"rss_feed\">');
document.write('<div class=\"rss_feed_title\">pubmed: "atrial fibrillation...</div>');
document.write('<ul class=\"rss_item_list\">');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20499771&#x26;dopt=Abstract\">Very late recurrences of atrial fibrillation after pulmonary vein isolation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20499771">Related Articles</a></td></tr></table>        <p><b>Very late recurrences of atrial fibrillation after pulmonary vein isolation.</b></p>        <p>Hosp Pract (Minneap). 2010 Jun;38(3):40-4</p>        <p>Authors:  Klein EM, Steinberg JS</p>        <p>Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, accounting for approximately one-third of all hospitalizations from cardiac rhythm disturbances. Over the past decade, catheter ablation (predominantly in the form of pulmonary vein isolation [PVI]) has become an important therapy in the treatment of patients with symptomatic, drug-refractory AF. Despite the improvements in technology, operator experience, and advances in methodology that have led to higher success rates and a reduction in complications, the recurrence rate of AF after PVI is still relatively high. Published studies suggest that approximately 33% to 86% of patients undergoing catheter ablation of AF have freedom from recurrent AF, with 30% to 40% requiring a second procedure. Although most studies looking at the efficacy of PVI are limited by relatively short follow-up, recent data suggest that patients with an initially favorable procedural response may have very late recurrences of AF, even years after PVI. It is likely that the mechanism behind very late recurrences of AF is multifactorial, involving both recurrent pulmonary vein triggers and progressive remodeling of left atrial substrate over time, making it more vulnerable to triggering. These recurrences have important clinical implications in the care of patients, specifically with regard to the increased risk of stroke associated with AF.</p>        <p>PMID: 20499771 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20677363&#x26;dopt=Abstract\">Lenient versus strict rate control in atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20677363">Related Articles</a></td></tr></table>        <p><b>Lenient versus strict rate control in atrial fibrillation.</b></p>        <p>N Engl J Med. 2010 Jul 22;363(4):393; author reply 393-4</p>        <p>Authors:  Bhaskar E</p>        <p></p>        <p>PMID: 20677363 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20677362&#x26;dopt=Abstract\">Lenient versus strict rate control in atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20677362">Related Articles</a></td></tr></table>        <p><b>Lenient versus strict rate control in atrial fibrillation.</b></p>        <p>N Engl J Med. 2010 Jul 22;363(4):392-3; author reply 393-4</p>        <p>Authors:  Grimsley EW, Patel R, Persed P</p>        <p></p>        <p>PMID: 20677362 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20660409&#x26;dopt=Abstract\">Lenient versus strict rate control in atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20660409">Related Articles</a></td></tr></table>        <p><b>Lenient versus strict rate control in atrial fibrillation.</b></p>        <p>N Engl J Med. 2010 Jul 22;363(4):392; author reply 393-4</p>        <p>Authors:  Marine JE</p>        <p></p>        <p>PMID: 20660409 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20620710&#x26;dopt=Abstract\">Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry&#x27;s PINNACLE (Practice Innovation And Clinical Excellence) program.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(10)01744-4"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20620710">Related Articles</a></td></tr></table>        <p><b>Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry&#x27;s PINNACLE (Practice Innovation And Clinical Excellence) program.</b></p>        <p>J Am Coll Cardiol. 2010 Jun 29;56(1):8-14</p>        <p>Authors:  Chan PS, Oetgen WJ, Buchanan D, Mitchell K, Fiocchi FF, Tang F, Jones PG, Breeding T, Thrutchley D, Rumsfeld JS, Spertus JA</p>        <p>OBJECTIVES: We examined compliance with performance measures for 14,464 patients enrolled from July 2008 through June 2009 into the American College of Cardiology&#x27;s PINNACLE (Practice Innovation And Clinical Excellence) program to provide initial insights into the quality of outpatient cardiac care. BACKGROUND: Little is known about the quality of care of outpatients with coronary artery disease (CAD), heart failure, and atrial fibrillation, and whether sex and racial disparities exist in the treatment of outpatients. METHODS: The PINNACLE program is the first, national, prospective office-based quality improvement program of cardiac patients designed, in part, to capture, report, and improve outpatient performance measure compliance. We examined the proportion of patients whose care was compliant with established American College of Cardiology, American Heart Association, and American Medical Association-Physician Consortium for Performance Improvement (ACC/AHA/PCPI) performance measures for CAD, heart failure, and atrial fibrillation. RESULTS: There were 14,464 unique patients enrolled from 27 U.S. practices, accounting for 18,021 clinical visits. Of these, 8,132 (56.4%) had CAD, 5,012 (34.7%) had heart failure, and 2,786 (19.3%) had nonvalvular atrial fibrillation. Data from the PINNACLE program were feasibly collected for 24 of 25 ACC/AHA/PCPI performance measures. Compliance with performance measures ranged from being very low (e.g., 13.3% of CAD patients screened for diabetes mellitus) to very high (e.g., 96.7% of heart failure patients with blood pressure assessments), with moderate (70% to 90%) compliance observed for most performance measures. For 3 performance measures, there were small differences in compliance rates by race or sex. CONCLUSIONS: For more than 14,000 patients enrolled from 27 practices in the outpatient PINNACLE program, we found that compliance with performance measures was variable, even after accounting for exclusion criteria, suggesting an important opportunity to improve the quality of outpatient care.</p>        <p>PMID: 20620710 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20568394&#x26;dopt=Abstract\">[Atrial fibrillation before and after pacemaker implantation (WI and DDD) in patients with complete atrioventricular block]</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20568394">Related Articles</a></td></tr></table>        <p><b>[Atrial fibrillation before and after pacemaker implantation (WI and DDD) in patients with complete atrioventricular block]</b></p>        <p>Pol Merkur Lekarski. 2010 May;28(167):345-9</p>        <p>Authors:  Matusik P, Woznica N, Lelakowsk J</p>        <p>Atrial fibrillation (AF) is a frequent problem of patients with pacemakers, and depends not only on disease but also on stimulation method. The aim of the study was to estimate the prevalence of AF before and after pacemaker implantation as well as to assess the influence of VVI and DDD cardiac pacing on onset of AF in patients with complete atrioventricularblock (AVB). MATERIAL AND METHODS: We included 155 patients controlled between 2000 and 2008 in Pacemaker Clinic because of AVB III degree, treated with VVI or DDD pacemaker implantation. Information about the health status of the patients was gathered from medical documentation and analysis of clinical ambulatory electrocardiograms. RESULTS: The study group comprised of 68 women and 87 men, mean age 68.7 +/- 13.9 years during implantation. 69% of patients had VVI pacemaker. There were 72.3% of patients with sinus rhythm before pacemaker implantation. During follow-up 4 +/- 2.8 years in 19.6% cases onset of atrial fibrillation de novo was diagnosed (in 31.3% in VVI mode vs. 2.2% in DDD mode; p = 0.00014). Mean time to AF since implantation was approximately 2.5 years. In VVI group (21 persons) amounted 32.1 months, while in 1 patient with DDD pacemaker 18 months. Between group with AF after implantation and with sinus rhythm preserved there was no statistically significant difference in age or gender (p = 0.89512 and p = 0.1253, respectively). Prevalence of atrial fibrillation after pacemaker implantation increased to 40%. CONCLUSIONS: Atrial fibrillation is frequent in patients before and after pacemaker implantation, especially in patients stimulated in VVI mode. Major possibility of atrial fibrillation onset after pacemaker implantation should result in more attention during routine ECG examination.</p>        <p>PMID: 20568394 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20517485&#x26;dopt=Abstract\">Antithrombotic therapy in very elderly patients with atrial fibrillation: is it enough to assess thromboembolic risk?</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&#x26;amp;pubmedid=20517485"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.pubmedcentral.nih.gov-corehtml-pmc-pmcgifs-pubmed-pmc.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20517485">Related Articles</a></td></tr></table>        <p><b>Antithrombotic therapy in very elderly patients with atrial fibrillation: is it enough to assess thromboembolic risk?</b></p>        <p>Clin Interv Aging. 2010;5:157-62</p>        <p>Authors:  Guo Y, Wu Q, Zhang L, Yang T, Zhu P, Gao W, Zhao Y, Gao M</p>        <p>Although attention has been given to thromboprophylaxis for atrial fibrillation (AF) in present treatment guidelines, practical, clinical antithrombotic therapy is poorly developed for very elderly patients. We reviewed the records of 105 consecutive patients with AF of mean age 85 years, to determine how the greatest benefits from antithrombotic therapy could be obtained in this group. The mean CHADS2 score in these patients was 3.1 +/- 1.5. Before antithrombotic therapy, 21.0% of the patients had diseases with a risk of hemorrhage, 26.7% had diseases with a risk of thrombosis, and 8.6% had diseases with a risk of both hemorrhage and thrombosis. Moreover, 89 patients (84.8%) were receiving a single antiplatelet drug, 10 (9.5%) used aspirin plus clopidogrel, and six (5.7%) were taking an oral anticoagulant (OAC). Additionally, dual antiplatelet therapy was more commonly given to patients with permanent AF (paroxysmal and persistent versus permanent, 6.3% and 12.5% versus 30%, respectively, Chi-square = 8.4, P = 0.010). The incidence of adverse events was 25.7%, with thromboembolic events in 20.0% and hemorrhage in 5.7% of patients. There were no thromboembolic events in those patients taking OACs, but 33% of patients who took OACs had bleeding complications. It is difficult to choose appropriate antithrombotic strategies in very elderly patients. Both the thrombotic risk and the bleeding risk should be considered for helping such patients derive optimal benefit from thromboprophylaxis for AF.</p>        <p>PMID: 20517485 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20436706&#x26;dopt=Abstract\">Characteristics of P wave in patients with sinus rhythm after maze operation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://jkms.org/DOIx.php?id=10.3346/jkms.2010.25.5.712"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--jkms.org-image-jkmslogo2.jpg" border="0"/></a> <a href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&#x26;amp;pubmedid=20436706"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.pubmedcentral.nih.gov-corehtml-pmc-pmcgifs-pubmed-pmc.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20436706">Related Articles</a></td></tr></table>        <p><b>Characteristics of P wave in patients with sinus rhythm after maze operation.</b></p>        <p>J Korean Med Sci. 2010 May;25(5):712-5</p>        <p>Authors:  Park HE, Kim KH, Kim KB, Ahn H, Choi YS, Oh S</p>        <p>Maze operation could alter P wave morphology in electrocardiogram (ECG), which might prevent exact diagnosis of the cardiac rhythm of patients. However, characteristics of P wave in patients with sinus rhythm after the operation have not been elucidated systematically. Consecutive patients who underwent the modified Cox Maze operation from January to December 2007 were enrolled. The standard 12-lead ECG and echocardiography were evaluated in patients who had sinus rhythm at 6 months after the operation. The average axis of P wave was 65+/-30 degrees. The average amplitude of P wave was less than 0.1 mV in all 12-leads, with highest amplitude in V(1). The most common morphology of P wave was monophasic with positive polarity (49%), except aVR lead, which was different from those in patients with enlarged left atrium, characterized by large P-terminal force in the lead V(1). There were no significant differences in P-wave characteristics and echocardiographic parameters between patients with LA activity (30.6%) versus without LA activity (69.4%) at 6 months after the operation. In conclusion, the morphology of P wave in patients after Maze operation shows loss of typical ECG pattern of P mitrale: P wave morphology is small in amplitude, monophasic and with positive polarity.</p>        <p>PMID: 20436706 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('</ul>');
document.write('</div>');
document.write('<div class=\"rss_feed\">');
document.write('<div class=\"rss_feed_title\">pubmed: "atrial fibrillation...</div>');
document.write('<ul class=\"rss_item_list\">');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20499771&#x26;dopt=Abstract\">Very late recurrences of atrial fibrillation after pulmonary vein isolation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20499771">Related Articles</a></td></tr></table>        <p><b>Very late recurrences of atrial fibrillation after pulmonary vein isolation.</b></p>        <p>Hosp Pract (Minneap). 2010 Jun;38(3):40-4</p>        <p>Authors:  Klein EM, Steinberg JS</p>        <p>Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, accounting for approximately one-third of all hospitalizations from cardiac rhythm disturbances. Over the past decade, catheter ablation (predominantly in the form of pulmonary vein isolation [PVI]) has become an important therapy in the treatment of patients with symptomatic, drug-refractory AF. Despite the improvements in technology, operator experience, and advances in methodology that have led to higher success rates and a reduction in complications, the recurrence rate of AF after PVI is still relatively high. Published studies suggest that approximately 33% to 86% of patients undergoing catheter ablation of AF have freedom from recurrent AF, with 30% to 40% requiring a second procedure. Although most studies looking at the efficacy of PVI are limited by relatively short follow-up, recent data suggest that patients with an initially favorable procedural response may have very late recurrences of AF, even years after PVI. It is likely that the mechanism behind very late recurrences of AF is multifactorial, involving both recurrent pulmonary vein triggers and progressive remodeling of left atrial substrate over time, making it more vulnerable to triggering. These recurrences have important clinical implications in the care of patients, specifically with regard to the increased risk of stroke associated with AF.</p>        <p>PMID: 20499771 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20677363&#x26;dopt=Abstract\">Lenient versus strict rate control in atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20677363">Related Articles</a></td></tr></table>        <p><b>Lenient versus strict rate control in atrial fibrillation.</b></p>        <p>N Engl J Med. 2010 Jul 22;363(4):393; author reply 393-4</p>        <p>Authors:  Bhaskar E</p>        <p></p>        <p>PMID: 20677363 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20677362&#x26;dopt=Abstract\">Lenient versus strict rate control in atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20677362">Related Articles</a></td></tr></table>        <p><b>Lenient versus strict rate control in atrial fibrillation.</b></p>        <p>N Engl J Med. 2010 Jul 22;363(4):392-3; author reply 393-4</p>        <p>Authors:  Grimsley EW, Patel R, Persed P</p>        <p></p>        <p>PMID: 20677362 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20660409&#x26;dopt=Abstract\">Lenient versus strict rate control in atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20660409">Related Articles</a></td></tr></table>        <p><b>Lenient versus strict rate control in atrial fibrillation.</b></p>        <p>N Engl J Med. 2010 Jul 22;363(4):392; author reply 393-4</p>        <p>Authors:  Marine JE</p>        <p></p>        <p>PMID: 20660409 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20620710&#x26;dopt=Abstract\">Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry&#x27;s PINNACLE (Practice Innovation And Clinical Excellence) program.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(10)01744-4"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20620710">Related Articles</a></td></tr></table>        <p><b>Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry&#x27;s PINNACLE (Practice Innovation And Clinical Excellence) program.</b></p>        <p>J Am Coll Cardiol. 2010 Jun 29;56(1):8-14</p>        <p>Authors:  Chan PS, Oetgen WJ, Buchanan D, Mitchell K, Fiocchi FF, Tang F, Jones PG, Breeding T, Thrutchley D, Rumsfeld JS, Spertus JA</p>        <p>OBJECTIVES: We examined compliance with performance measures for 14,464 patients enrolled from July 2008 through June 2009 into the American College of Cardiology&#x27;s PINNACLE (Practice Innovation And Clinical Excellence) program to provide initial insights into the quality of outpatient cardiac care. BACKGROUND: Little is known about the quality of care of outpatients with coronary artery disease (CAD), heart failure, and atrial fibrillation, and whether sex and racial disparities exist in the treatment of outpatients. METHODS: The PINNACLE program is the first, national, prospective office-based quality improvement program of cardiac patients designed, in part, to capture, report, and improve outpatient performance measure compliance. We examined the proportion of patients whose care was compliant with established American College of Cardiology, American Heart Association, and American Medical Association-Physician Consortium for Performance Improvement (ACC/AHA/PCPI) performance measures for CAD, heart failure, and atrial fibrillation. RESULTS: There were 14,464 unique patients enrolled from 27 U.S. practices, accounting for 18,021 clinical visits. Of these, 8,132 (56.4%) had CAD, 5,012 (34.7%) had heart failure, and 2,786 (19.3%) had nonvalvular atrial fibrillation. Data from the PINNACLE program were feasibly collected for 24 of 25 ACC/AHA/PCPI performance measures. Compliance with performance measures ranged from being very low (e.g., 13.3% of CAD patients screened for diabetes mellitus) to very high (e.g., 96.7% of heart failure patients with blood pressure assessments), with moderate (70% to 90%) compliance observed for most performance measures. For 3 performance measures, there were small differences in compliance rates by race or sex. CONCLUSIONS: For more than 14,000 patients enrolled from 27 practices in the outpatient PINNACLE program, we found that compliance with performance measures was variable, even after accounting for exclusion criteria, suggesting an important opportunity to improve the quality of outpatient care.</p>        <p>PMID: 20620710 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20568394&#x26;dopt=Abstract\">[Atrial fibrillation before and after pacemaker implantation (WI and DDD) in patients with complete atrioventricular block]</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20568394">Related Articles</a></td></tr></table>        <p><b>[Atrial fibrillation before and after pacemaker implantation (WI and DDD) in patients with complete atrioventricular block]</b></p>        <p>Pol Merkur Lekarski. 2010 May;28(167):345-9</p>        <p>Authors:  Matusik P, Woznica N, Lelakowsk J</p>        <p>Atrial fibrillation (AF) is a frequent problem of patients with pacemakers, and depends not only on disease but also on stimulation method. The aim of the study was to estimate the prevalence of AF before and after pacemaker implantation as well as to assess the influence of VVI and DDD cardiac pacing on onset of AF in patients with complete atrioventricularblock (AVB). MATERIAL AND METHODS: We included 155 patients controlled between 2000 and 2008 in Pacemaker Clinic because of AVB III degree, treated with VVI or DDD pacemaker implantation. Information about the health status of the patients was gathered from medical documentation and analysis of clinical ambulatory electrocardiograms. RESULTS: The study group comprised of 68 women and 87 men, mean age 68.7 +/- 13.9 years during implantation. 69% of patients had VVI pacemaker. There were 72.3% of patients with sinus rhythm before pacemaker implantation. During follow-up 4 +/- 2.8 years in 19.6% cases onset of atrial fibrillation de novo was diagnosed (in 31.3% in VVI mode vs. 2.2% in DDD mode; p = 0.00014). Mean time to AF since implantation was approximately 2.5 years. In VVI group (21 persons) amounted 32.1 months, while in 1 patient with DDD pacemaker 18 months. Between group with AF after implantation and with sinus rhythm preserved there was no statistically significant difference in age or gender (p = 0.89512 and p = 0.1253, respectively). Prevalence of atrial fibrillation after pacemaker implantation increased to 40%. CONCLUSIONS: Atrial fibrillation is frequent in patients before and after pacemaker implantation, especially in patients stimulated in VVI mode. Major possibility of atrial fibrillation onset after pacemaker implantation should result in more attention during routine ECG examination.</p>        <p>PMID: 20568394 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20517485&#x26;dopt=Abstract\">Antithrombotic therapy in very elderly patients with atrial fibrillation: is it enough to assess thromboembolic risk?</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&#x26;amp;pubmedid=20517485"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.pubmedcentral.nih.gov-corehtml-pmc-pmcgifs-pubmed-pmc.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20517485">Related Articles</a></td></tr></table>        <p><b>Antithrombotic therapy in very elderly patients with atrial fibrillation: is it enough to assess thromboembolic risk?</b></p>        <p>Clin Interv Aging. 2010;5:157-62</p>        <p>Authors:  Guo Y, Wu Q, Zhang L, Yang T, Zhu P, Gao W, Zhao Y, Gao M</p>        <p>Although attention has been given to thromboprophylaxis for atrial fibrillation (AF) in present treatment guidelines, practical, clinical antithrombotic therapy is poorly developed for very elderly patients. We reviewed the records of 105 consecutive patients with AF of mean age 85 years, to determine how the greatest benefits from antithrombotic therapy could be obtained in this group. The mean CHADS2 score in these patients was 3.1 +/- 1.5. Before antithrombotic therapy, 21.0% of the patients had diseases with a risk of hemorrhage, 26.7% had diseases with a risk of thrombosis, and 8.6% had diseases with a risk of both hemorrhage and thrombosis. Moreover, 89 patients (84.8%) were receiving a single antiplatelet drug, 10 (9.5%) used aspirin plus clopidogrel, and six (5.7%) were taking an oral anticoagulant (OAC). Additionally, dual antiplatelet therapy was more commonly given to patients with permanent AF (paroxysmal and persistent versus permanent, 6.3% and 12.5% versus 30%, respectively, Chi-square = 8.4, P = 0.010). The incidence of adverse events was 25.7%, with thromboembolic events in 20.0% and hemorrhage in 5.7% of patients. There were no thromboembolic events in those patients taking OACs, but 33% of patients who took OACs had bleeding complications. It is difficult to choose appropriate antithrombotic strategies in very elderly patients. Both the thrombotic risk and the bleeding risk should be considered for helping such patients derive optimal benefit from thromboprophylaxis for AF.</p>        <p>PMID: 20517485 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20436706&#x26;dopt=Abstract\">Characteristics of P wave in patients with sinus rhythm after maze operation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://jkms.org/DOIx.php?id=10.3346/jkms.2010.25.5.712"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--jkms.org-image-jkmslogo2.jpg" border="0"/></a> <a href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&#x26;amp;pubmedid=20436706"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.pubmedcentral.nih.gov-corehtml-pmc-pmcgifs-pubmed-pmc.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20436706">Related Articles</a></td></tr></table>        <p><b>Characteristics of P wave in patients with sinus rhythm after maze operation.</b></p>        <p>J Korean Med Sci. 2010 May;25(5):712-5</p>        <p>Authors:  Park HE, Kim KH, Kim KB, Ahn H, Choi YS, Oh S</p>        <p>Maze operation could alter P wave morphology in electrocardiogram (ECG), which might prevent exact diagnosis of the cardiac rhythm of patients. However, characteristics of P wave in patients with sinus rhythm after the operation have not been elucidated systematically. Consecutive patients who underwent the modified Cox Maze operation from January to December 2007 were enrolled. The standard 12-lead ECG and echocardiography were evaluated in patients who had sinus rhythm at 6 months after the operation. The average axis of P wave was 65+/-30 degrees. The average amplitude of P wave was less than 0.1 mV in all 12-leads, with highest amplitude in V(1). The most common morphology of P wave was monophasic with positive polarity (49%), except aVR lead, which was different from those in patients with enlarged left atrium, characterized by large P-terminal force in the lead V(1). There were no significant differences in P-wave characteristics and echocardiographic parameters between patients with LA activity (30.6%) versus without LA activity (69.4%) at 6 months after the operation. In conclusion, the morphology of P wave in patients after Maze operation shows loss of typical ECG pattern of P mitrale: P wave morphology is small in amplitude, monophasic and with positive polarity.</p>        <p>PMID: 20436706 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('</ul>');
document.write('</div>');
document.write('<div class=\"rss_feed\">');
document.write('<div class=\"rss_feed_title\">pubmed: "atrial fibrillation...</div>');
document.write('<ul class=\"rss_item_list\">');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20499771&#x26;dopt=Abstract\">Very late recurrences of atrial fibrillation after pulmonary vein isolation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20499771">Related Articles</a></td></tr></table>        <p><b>Very late recurrences of atrial fibrillation after pulmonary vein isolation.</b></p>        <p>Hosp Pract (Minneap). 2010 Jun;38(3):40-4</p>        <p>Authors:  Klein EM, Steinberg JS</p>        <p>Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, accounting for approximately one-third of all hospitalizations from cardiac rhythm disturbances. Over the past decade, catheter ablation (predominantly in the form of pulmonary vein isolation [PVI]) has become an important therapy in the treatment of patients with symptomatic, drug-refractory AF. Despite the improvements in technology, operator experience, and advances in methodology that have led to higher success rates and a reduction in complications, the recurrence rate of AF after PVI is still relatively high. Published studies suggest that approximately 33% to 86% of patients undergoing catheter ablation of AF have freedom from recurrent AF, with 30% to 40% requiring a second procedure. Although most studies looking at the efficacy of PVI are limited by relatively short follow-up, recent data suggest that patients with an initially favorable procedural response may have very late recurrences of AF, even years after PVI. It is likely that the mechanism behind very late recurrences of AF is multifactorial, involving both recurrent pulmonary vein triggers and progressive remodeling of left atrial substrate over time, making it more vulnerable to triggering. These recurrences have important clinical implications in the care of patients, specifically with regard to the increased risk of stroke associated with AF.</p>        <p>PMID: 20499771 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20677363&#x26;dopt=Abstract\">Lenient versus strict rate control in atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20677363">Related Articles</a></td></tr></table>        <p><b>Lenient versus strict rate control in atrial fibrillation.</b></p>        <p>N Engl J Med. 2010 Jul 22;363(4):393; author reply 393-4</p>        <p>Authors:  Bhaskar E</p>        <p></p>        <p>PMID: 20677363 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20677362&#x26;dopt=Abstract\">Lenient versus strict rate control in atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20677362">Related Articles</a></td></tr></table>        <p><b>Lenient versus strict rate control in atrial fibrillation.</b></p>        <p>N Engl J Med. 2010 Jul 22;363(4):392-3; author reply 393-4</p>        <p>Authors:  Grimsley EW, Patel R, Persed P</p>        <p></p>        <p>PMID: 20677362 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20660409&#x26;dopt=Abstract\">Lenient versus strict rate control in atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20660409">Related Articles</a></td></tr></table>        <p><b>Lenient versus strict rate control in atrial fibrillation.</b></p>        <p>N Engl J Med. 2010 Jul 22;363(4):392; author reply 393-4</p>        <p>Authors:  Marine JE</p>        <p></p>        <p>PMID: 20660409 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20620710&#x26;dopt=Abstract\">Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry&#x27;s PINNACLE (Practice Innovation And Clinical Excellence) program.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(10)01744-4"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20620710">Related Articles</a></td></tr></table>        <p><b>Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry&#x27;s PINNACLE (Practice Innovation And Clinical Excellence) program.</b></p>        <p>J Am Coll Cardiol. 2010 Jun 29;56(1):8-14</p>        <p>Authors:  Chan PS, Oetgen WJ, Buchanan D, Mitchell K, Fiocchi FF, Tang F, Jones PG, Breeding T, Thrutchley D, Rumsfeld JS, Spertus JA</p>        <p>OBJECTIVES: We examined compliance with performance measures for 14,464 patients enrolled from July 2008 through June 2009 into the American College of Cardiology&#x27;s PINNACLE (Practice Innovation And Clinical Excellence) program to provide initial insights into the quality of outpatient cardiac care. BACKGROUND: Little is known about the quality of care of outpatients with coronary artery disease (CAD), heart failure, and atrial fibrillation, and whether sex and racial disparities exist in the treatment of outpatients. METHODS: The PINNACLE program is the first, national, prospective office-based quality improvement program of cardiac patients designed, in part, to capture, report, and improve outpatient performance measure compliance. We examined the proportion of patients whose care was compliant with established American College of Cardiology, American Heart Association, and American Medical Association-Physician Consortium for Performance Improvement (ACC/AHA/PCPI) performance measures for CAD, heart failure, and atrial fibrillation. RESULTS: There were 14,464 unique patients enrolled from 27 U.S. practices, accounting for 18,021 clinical visits. Of these, 8,132 (56.4%) had CAD, 5,012 (34.7%) had heart failure, and 2,786 (19.3%) had nonvalvular atrial fibrillation. Data from the PINNACLE program were feasibly collected for 24 of 25 ACC/AHA/PCPI performance measures. Compliance with performance measures ranged from being very low (e.g., 13.3% of CAD patients screened for diabetes mellitus) to very high (e.g., 96.7% of heart failure patients with blood pressure assessments), with moderate (70% to 90%) compliance observed for most performance measures. For 3 performance measures, there were small differences in compliance rates by race or sex. CONCLUSIONS: For more than 14,000 patients enrolled from 27 practices in the outpatient PINNACLE program, we found that compliance with performance measures was variable, even after accounting for exclusion criteria, suggesting an important opportunity to improve the quality of outpatient care.</p>        <p>PMID: 20620710 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20568394&#x26;dopt=Abstract\">[Atrial fibrillation before and after pacemaker implantation (WI and DDD) in patients with complete atrioventricular block]</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20568394">Related Articles</a></td></tr></table>        <p><b>[Atrial fibrillation before and after pacemaker implantation (WI and DDD) in patients with complete atrioventricular block]</b></p>        <p>Pol Merkur Lekarski. 2010 May;28(167):345-9</p>        <p>Authors:  Matusik P, Woznica N, Lelakowsk J</p>        <p>Atrial fibrillation (AF) is a frequent problem of patients with pacemakers, and depends not only on disease but also on stimulation method. The aim of the study was to estimate the prevalence of AF before and after pacemaker implantation as well as to assess the influence of VVI and DDD cardiac pacing on onset of AF in patients with complete atrioventricularblock (AVB). MATERIAL AND METHODS: We included 155 patients controlled between 2000 and 2008 in Pacemaker Clinic because of AVB III degree, treated with VVI or DDD pacemaker implantation. Information about the health status of the patients was gathered from medical documentation and analysis of clinical ambulatory electrocardiograms. RESULTS: The study group comprised of 68 women and 87 men, mean age 68.7 +/- 13.9 years during implantation. 69% of patients had VVI pacemaker. There were 72.3% of patients with sinus rhythm before pacemaker implantation. During follow-up 4 +/- 2.8 years in 19.6% cases onset of atrial fibrillation de novo was diagnosed (in 31.3% in VVI mode vs. 2.2% in DDD mode; p = 0.00014). Mean time to AF since implantation was approximately 2.5 years. In VVI group (21 persons) amounted 32.1 months, while in 1 patient with DDD pacemaker 18 months. Between group with AF after implantation and with sinus rhythm preserved there was no statistically significant difference in age or gender (p = 0.89512 and p = 0.1253, respectively). Prevalence of atrial fibrillation after pacemaker implantation increased to 40%. CONCLUSIONS: Atrial fibrillation is frequent in patients before and after pacemaker implantation, especially in patients stimulated in VVI mode. Major possibility of atrial fibrillation onset after pacemaker implantation should result in more attention during routine ECG examination.</p>        <p>PMID: 20568394 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20517485&#x26;dopt=Abstract\">Antithrombotic therapy in very elderly patients with atrial fibrillation: is it enough to assess thromboembolic risk?</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&#x26;amp;pubmedid=20517485"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.pubmedcentral.nih.gov-corehtml-pmc-pmcgifs-pubmed-pmc.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20517485">Related Articles</a></td></tr></table>        <p><b>Antithrombotic therapy in very elderly patients with atrial fibrillation: is it enough to assess thromboembolic risk?</b></p>        <p>Clin Interv Aging. 2010;5:157-62</p>        <p>Authors:  Guo Y, Wu Q, Zhang L, Yang T, Zhu P, Gao W, Zhao Y, Gao M</p>        <p>Although attention has been given to thromboprophylaxis for atrial fibrillation (AF) in present treatment guidelines, practical, clinical antithrombotic therapy is poorly developed for very elderly patients. We reviewed the records of 105 consecutive patients with AF of mean age 85 years, to determine how the greatest benefits from antithrombotic therapy could be obtained in this group. The mean CHADS2 score in these patients was 3.1 +/- 1.5. Before antithrombotic therapy, 21.0% of the patients had diseases with a risk of hemorrhage, 26.7% had diseases with a risk of thrombosis, and 8.6% had diseases with a risk of both hemorrhage and thrombosis. Moreover, 89 patients (84.8%) were receiving a single antiplatelet drug, 10 (9.5%) used aspirin plus clopidogrel, and six (5.7%) were taking an oral anticoagulant (OAC). Additionally, dual antiplatelet therapy was more commonly given to patients with permanent AF (paroxysmal and persistent versus permanent, 6.3% and 12.5% versus 30%, respectively, Chi-square = 8.4, P = 0.010). The incidence of adverse events was 25.7%, with thromboembolic events in 20.0% and hemorrhage in 5.7% of patients. There were no thromboembolic events in those patients taking OACs, but 33% of patients who took OACs had bleeding complications. It is difficult to choose appropriate antithrombotic strategies in very elderly patients. Both the thrombotic risk and the bleeding risk should be considered for helping such patients derive optimal benefit from thromboprophylaxis for AF.</p>        <p>PMID: 20517485 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20436706&#x26;dopt=Abstract\">Characteristics of P wave in patients with sinus rhythm after maze operation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://jkms.org/DOIx.php?id=10.3346/jkms.2010.25.5.712"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--jkms.org-image-jkmslogo2.jpg" border="0"/></a> <a href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&#x26;amp;pubmedid=20436706"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.pubmedcentral.nih.gov-corehtml-pmc-pmcgifs-pubmed-pmc.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20436706">Related Articles</a></td></tr></table>        <p><b>Characteristics of P wave in patients with sinus rhythm after maze operation.</b></p>        <p>J Korean Med Sci. 2010 May;25(5):712-5</p>        <p>Authors:  Park HE, Kim KH, Kim KB, Ahn H, Choi YS, Oh S</p>        <p>Maze operation could alter P wave morphology in electrocardiogram (ECG), which might prevent exact diagnosis of the cardiac rhythm of patients. However, characteristics of P wave in patients with sinus rhythm after the operation have not been elucidated systematically. Consecutive patients who underwent the modified Cox Maze operation from January to December 2007 were enrolled. The standard 12-lead ECG and echocardiography were evaluated in patients who had sinus rhythm at 6 months after the operation. The average axis of P wave was 65+/-30 degrees. The average amplitude of P wave was less than 0.1 mV in all 12-leads, with highest amplitude in V(1). The most common morphology of P wave was monophasic with positive polarity (49%), except aVR lead, which was different from those in patients with enlarged left atrium, characterized by large P-terminal force in the lead V(1). There were no significant differences in P-wave characteristics and echocardiographic parameters between patients with LA activity (30.6%) versus without LA activity (69.4%) at 6 months after the operation. In conclusion, the morphology of P wave in patients after Maze operation shows loss of typical ECG pattern of P mitrale: P wave morphology is small in amplitude, monophasic and with positive polarity.</p>        <p>PMID: 20436706 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('</ul>');
document.write('</div>');
document.write('<div class=\"rss_feed\">');
document.write('<div class=\"rss_feed_title\">pubmed: "atrial fibrillation...</div>');
document.write('<ul class=\"rss_item_list\">');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20499771&#x26;dopt=Abstract\">Very late recurrences of atrial fibrillation after pulmonary vein isolation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20499771">Related Articles</a></td></tr></table>        <p><b>Very late recurrences of atrial fibrillation after pulmonary vein isolation.</b></p>        <p>Hosp Pract (Minneap). 2010 Jun;38(3):40-4</p>        <p>Authors:  Klein EM, Steinberg JS</p>        <p>Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, accounting for approximately one-third of all hospitalizations from cardiac rhythm disturbances. Over the past decade, catheter ablation (predominantly in the form of pulmonary vein isolation [PVI]) has become an important therapy in the treatment of patients with symptomatic, drug-refractory AF. Despite the improvements in technology, operator experience, and advances in methodology that have led to higher success rates and a reduction in complications, the recurrence rate of AF after PVI is still relatively high. Published studies suggest that approximately 33% to 86% of patients undergoing catheter ablation of AF have freedom from recurrent AF, with 30% to 40% requiring a second procedure. Although most studies looking at the efficacy of PVI are limited by relatively short follow-up, recent data suggest that patients with an initially favorable procedural response may have very late recurrences of AF, even years after PVI. It is likely that the mechanism behind very late recurrences of AF is multifactorial, involving both recurrent pulmonary vein triggers and progressive remodeling of left atrial substrate over time, making it more vulnerable to triggering. These recurrences have important clinical implications in the care of patients, specifically with regard to the increased risk of stroke associated with AF.</p>        <p>PMID: 20499771 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20677363&#x26;dopt=Abstract\">Lenient versus strict rate control in atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20677363">Related Articles</a></td></tr></table>        <p><b>Lenient versus strict rate control in atrial fibrillation.</b></p>        <p>N Engl J Med. 2010 Jul 22;363(4):393; author reply 393-4</p>        <p>Authors:  Bhaskar E</p>        <p></p>        <p>PMID: 20677363 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20677362&#x26;dopt=Abstract\">Lenient versus strict rate control in atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20677362">Related Articles</a></td></tr></table>        <p><b>Lenient versus strict rate control in atrial fibrillation.</b></p>        <p>N Engl J Med. 2010 Jul 22;363(4):392-3; author reply 393-4</p>        <p>Authors:  Grimsley EW, Patel R, Persed P</p>        <p></p>        <p>PMID: 20677362 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20660409&#x26;dopt=Abstract\">Lenient versus strict rate control in atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20660409">Related Articles</a></td></tr></table>        <p><b>Lenient versus strict rate control in atrial fibrillation.</b></p>        <p>N Engl J Med. 2010 Jul 22;363(4):392; author reply 393-4</p>        <p>Authors:  Marine JE</p>        <p></p>        <p>PMID: 20660409 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20620710&#x26;dopt=Abstract\">Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry&#x27;s PINNACLE (Practice Innovation And Clinical Excellence) program.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(10)01744-4"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20620710">Related Articles</a></td></tr></table>        <p><b>Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry&#x27;s PINNACLE (Practice Innovation And Clinical Excellence) program.</b></p>        <p>J Am Coll Cardiol. 2010 Jun 29;56(1):8-14</p>        <p>Authors:  Chan PS, Oetgen WJ, Buchanan D, Mitchell K, Fiocchi FF, Tang F, Jones PG, Breeding T, Thrutchley D, Rumsfeld JS, Spertus JA</p>        <p>OBJECTIVES: We examined compliance with performance measures for 14,464 patients enrolled from July 2008 through June 2009 into the American College of Cardiology&#x27;s PINNACLE (Practice Innovation And Clinical Excellence) program to provide initial insights into the quality of outpatient cardiac care. BACKGROUND: Little is known about the quality of care of outpatients with coronary artery disease (CAD), heart failure, and atrial fibrillation, and whether sex and racial disparities exist in the treatment of outpatients. METHODS: The PINNACLE program is the first, national, prospective office-based quality improvement program of cardiac patients designed, in part, to capture, report, and improve outpatient performance measure compliance. We examined the proportion of patients whose care was compliant with established American College of Cardiology, American Heart Association, and American Medical Association-Physician Consortium for Performance Improvement (ACC/AHA/PCPI) performance measures for CAD, heart failure, and atrial fibrillation. RESULTS: There were 14,464 unique patients enrolled from 27 U.S. practices, accounting for 18,021 clinical visits. Of these, 8,132 (56.4%) had CAD, 5,012 (34.7%) had heart failure, and 2,786 (19.3%) had nonvalvular atrial fibrillation. Data from the PINNACLE program were feasibly collected for 24 of 25 ACC/AHA/PCPI performance measures. Compliance with performance measures ranged from being very low (e.g., 13.3% of CAD patients screened for diabetes mellitus) to very high (e.g., 96.7% of heart failure patients with blood pressure assessments), with moderate (70% to 90%) compliance observed for most performance measures. For 3 performance measures, there were small differences in compliance rates by race or sex. CONCLUSIONS: For more than 14,000 patients enrolled from 27 practices in the outpatient PINNACLE program, we found that compliance with performance measures was variable, even after accounting for exclusion criteria, suggesting an important opportunity to improve the quality of outpatient care.</p>        <p>PMID: 20620710 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20568394&#x26;dopt=Abstract\">[Atrial fibrillation before and after pacemaker implantation (WI and DDD) in patients with complete atrioventricular block]</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20568394">Related Articles</a></td></tr></table>        <p><b>[Atrial fibrillation before and after pacemaker implantation (WI and DDD) in patients with complete atrioventricular block]</b></p>        <p>Pol Merkur Lekarski. 2010 May;28(167):345-9</p>        <p>Authors:  Matusik P, Woznica N, Lelakowsk J</p>        <p>Atrial fibrillation (AF) is a frequent problem of patients with pacemakers, and depends not only on disease but also on stimulation method. The aim of the study was to estimate the prevalence of AF before and after pacemaker implantation as well as to assess the influence of VVI and DDD cardiac pacing on onset of AF in patients with complete atrioventricularblock (AVB). MATERIAL AND METHODS: We included 155 patients controlled between 2000 and 2008 in Pacemaker Clinic because of AVB III degree, treated with VVI or DDD pacemaker implantation. Information about the health status of the patients was gathered from medical documentation and analysis of clinical ambulatory electrocardiograms. RESULTS: The study group comprised of 68 women and 87 men, mean age 68.7 +/- 13.9 years during implantation. 69% of patients had VVI pacemaker. There were 72.3% of patients with sinus rhythm before pacemaker implantation. During follow-up 4 +/- 2.8 years in 19.6% cases onset of atrial fibrillation de novo was diagnosed (in 31.3% in VVI mode vs. 2.2% in DDD mode; p = 0.00014). Mean time to AF since implantation was approximately 2.5 years. In VVI group (21 persons) amounted 32.1 months, while in 1 patient with DDD pacemaker 18 months. Between group with AF after implantation and with sinus rhythm preserved there was no statistically significant difference in age or gender (p = 0.89512 and p = 0.1253, respectively). Prevalence of atrial fibrillation after pacemaker implantation increased to 40%. CONCLUSIONS: Atrial fibrillation is frequent in patients before and after pacemaker implantation, especially in patients stimulated in VVI mode. Major possibility of atrial fibrillation onset after pacemaker implantation should result in more attention during routine ECG examination.</p>        <p>PMID: 20568394 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20517485&#x26;dopt=Abstract\">Antithrombotic therapy in very elderly patients with atrial fibrillation: is it enough to assess thromboembolic risk?</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&#x26;amp;pubmedid=20517485"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.pubmedcentral.nih.gov-corehtml-pmc-pmcgifs-pubmed-pmc.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20517485">Related Articles</a></td></tr></table>        <p><b>Antithrombotic therapy in very elderly patients with atrial fibrillation: is it enough to assess thromboembolic risk?</b></p>        <p>Clin Interv Aging. 2010;5:157-62</p>        <p>Authors:  Guo Y, Wu Q, Zhang L, Yang T, Zhu P, Gao W, Zhao Y, Gao M</p>        <p>Although attention has been given to thromboprophylaxis for atrial fibrillation (AF) in present treatment guidelines, practical, clinical antithrombotic therapy is poorly developed for very elderly patients. We reviewed the records of 105 consecutive patients with AF of mean age 85 years, to determine how the greatest benefits from antithrombotic therapy could be obtained in this group. The mean CHADS2 score in these patients was 3.1 +/- 1.5. Before antithrombotic therapy, 21.0% of the patients had diseases with a risk of hemorrhage, 26.7% had diseases with a risk of thrombosis, and 8.6% had diseases with a risk of both hemorrhage and thrombosis. Moreover, 89 patients (84.8%) were receiving a single antiplatelet drug, 10 (9.5%) used aspirin plus clopidogrel, and six (5.7%) were taking an oral anticoagulant (OAC). Additionally, dual antiplatelet therapy was more commonly given to patients with permanent AF (paroxysmal and persistent versus permanent, 6.3% and 12.5% versus 30%, respectively, Chi-square = 8.4, P = 0.010). The incidence of adverse events was 25.7%, with thromboembolic events in 20.0% and hemorrhage in 5.7% of patients. There were no thromboembolic events in those patients taking OACs, but 33% of patients who took OACs had bleeding complications. It is difficult to choose appropriate antithrombotic strategies in very elderly patients. Both the thrombotic risk and the bleeding risk should be considered for helping such patients derive optimal benefit from thromboprophylaxis for AF.</p>        <p>PMID: 20517485 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20436706&#x26;dopt=Abstract\">Characteristics of P wave in patients with sinus rhythm after maze operation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://jkms.org/DOIx.php?id=10.3346/jkms.2010.25.5.712"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--jkms.org-image-jkmslogo2.jpg" border="0"/></a> <a href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&#x26;amp;pubmedid=20436706"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.pubmedcentral.nih.gov-corehtml-pmc-pmcgifs-pubmed-pmc.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20436706">Related Articles</a></td></tr></table>        <p><b>Characteristics of P wave in patients with sinus rhythm after maze operation.</b></p>        <p>J Korean Med Sci. 2010 May;25(5):712-5</p>        <p>Authors:  Park HE, Kim KH, Kim KB, Ahn H, Choi YS, Oh S</p>        <p>Maze operation could alter P wave morphology in electrocardiogram (ECG), which might prevent exact diagnosis of the cardiac rhythm of patients. However, characteristics of P wave in patients with sinus rhythm after the operation have not been elucidated systematically. Consecutive patients who underwent the modified Cox Maze operation from January to December 2007 were enrolled. The standard 12-lead ECG and echocardiography were evaluated in patients who had sinus rhythm at 6 months after the operation. The average axis of P wave was 65+/-30 degrees. The average amplitude of P wave was less than 0.1 mV in all 12-leads, with highest amplitude in V(1). The most common morphology of P wave was monophasic with positive polarity (49%), except aVR lead, which was different from those in patients with enlarged left atrium, characterized by large P-terminal force in the lead V(1). There were no significant differences in P-wave characteristics and echocardiographic parameters between patients with LA activity (30.6%) versus without LA activity (69.4%) at 6 months after the operation. In conclusion, the morphology of P wave in patients after Maze operation shows loss of typical ECG pattern of P mitrale: P wave morphology is small in amplitude, monophasic and with positive polarity.</p>        <p>PMID: 20436706 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('</ul>');
document.write('</div>');
document.write('<div class=\"rss_feed\">');
document.write('<div class=\"rss_feed_title\">pubmed: "atrial fibrillation...</div>');
document.write('<ul class=\"rss_item_list\">');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20499771&#x26;dopt=Abstract\">Very late recurrences of atrial fibrillation after pulmonary vein isolation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20499771">Related Articles</a></td></tr></table>        <p><b>Very late recurrences of atrial fibrillation after pulmonary vein isolation.</b></p>        <p>Hosp Pract (Minneap). 2010 Jun;38(3):40-4</p>        <p>Authors:  Klein EM, Steinberg JS</p>        <p>Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, accounting for approximately one-third of all hospitalizations from cardiac rhythm disturbances. Over the past decade, catheter ablation (predominantly in the form of pulmonary vein isolation [PVI]) has become an important therapy in the treatment of patients with symptomatic, drug-refractory AF. Despite the improvements in technology, operator experience, and advances in methodology that have led to higher success rates and a reduction in complications, the recurrence rate of AF after PVI is still relatively high. Published studies suggest that approximately 33% to 86% of patients undergoing catheter ablation of AF have freedom from recurrent AF, with 30% to 40% requiring a second procedure. Although most studies looking at the efficacy of PVI are limited by relatively short follow-up, recent data suggest that patients with an initially favorable procedural response may have very late recurrences of AF, even years after PVI. It is likely that the mechanism behind very late recurrences of AF is multifactorial, involving both recurrent pulmonary vein triggers and progressive remodeling of left atrial substrate over time, making it more vulnerable to triggering. These recurrences have important clinical implications in the care of patients, specifically with regard to the increased risk of stroke associated with AF.</p>        <p>PMID: 20499771 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20677363&#x26;dopt=Abstract\">Lenient versus strict rate control in atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20677363">Related Articles</a></td></tr></table>        <p><b>Lenient versus strict rate control in atrial fibrillation.</b></p>        <p>N Engl J Med. 2010 Jul 22;363(4):393; author reply 393-4</p>        <p>Authors:  Bhaskar E</p>        <p></p>        <p>PMID: 20677363 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20677362&#x26;dopt=Abstract\">Lenient versus strict rate control in atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20677362">Related Articles</a></td></tr></table>        <p><b>Lenient versus strict rate control in atrial fibrillation.</b></p>        <p>N Engl J Med. 2010 Jul 22;363(4):392-3; author reply 393-4</p>        <p>Authors:  Grimsley EW, Patel R, Persed P</p>        <p></p>        <p>PMID: 20677362 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20660409&#x26;dopt=Abstract\">Lenient versus strict rate control in atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20660409">Related Articles</a></td></tr></table>        <p><b>Lenient versus strict rate control in atrial fibrillation.</b></p>        <p>N Engl J Med. 2010 Jul 22;363(4):392; author reply 393-4</p>        <p>Authors:  Marine JE</p>        <p></p>        <p>PMID: 20660409 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20620710&#x26;dopt=Abstract\">Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry&#x27;s PINNACLE (Practice Innovation And Clinical Excellence) program.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(10)01744-4"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20620710">Related Articles</a></td></tr></table>        <p><b>Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry&#x27;s PINNACLE (Practice Innovation And Clinical Excellence) program.</b></p>        <p>J Am Coll Cardiol. 2010 Jun 29;56(1):8-14</p>        <p>Authors:  Chan PS, Oetgen WJ, Buchanan D, Mitchell K, Fiocchi FF, Tang F, Jones PG, Breeding T, Thrutchley D, Rumsfeld JS, Spertus JA</p>        <p>OBJECTIVES: We examined compliance with performance measures for 14,464 patients enrolled from July 2008 through June 2009 into the American College of Cardiology&#x27;s PINNACLE (Practice Innovation And Clinical Excellence) program to provide initial insights into the quality of outpatient cardiac care. BACKGROUND: Little is known about the quality of care of outpatients with coronary artery disease (CAD), heart failure, and atrial fibrillation, and whether sex and racial disparities exist in the treatment of outpatients. METHODS: The PINNACLE program is the first, national, prospective office-based quality improvement program of cardiac patients designed, in part, to capture, report, and improve outpatient performance measure compliance. We examined the proportion of patients whose care was compliant with established American College of Cardiology, American Heart Association, and American Medical Association-Physician Consortium for Performance Improvement (ACC/AHA/PCPI) performance measures for CAD, heart failure, and atrial fibrillation. RESULTS: There were 14,464 unique patients enrolled from 27 U.S. practices, accounting for 18,021 clinical visits. Of these, 8,132 (56.4%) had CAD, 5,012 (34.7%) had heart failure, and 2,786 (19.3%) had nonvalvular atrial fibrillation. Data from the PINNACLE program were feasibly collected for 24 of 25 ACC/AHA/PCPI performance measures. Compliance with performance measures ranged from being very low (e.g., 13.3% of CAD patients screened for diabetes mellitus) to very high (e.g., 96.7% of heart failure patients with blood pressure assessments), with moderate (70% to 90%) compliance observed for most performance measures. For 3 performance measures, there were small differences in compliance rates by race or sex. CONCLUSIONS: For more than 14,000 patients enrolled from 27 practices in the outpatient PINNACLE program, we found that compliance with performance measures was variable, even after accounting for exclusion criteria, suggesting an important opportunity to improve the quality of outpatient care.</p>        <p>PMID: 20620710 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20568394&#x26;dopt=Abstract\">[Atrial fibrillation before and after pacemaker implantation (WI and DDD) in patients with complete atrioventricular block]</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20568394">Related Articles</a></td></tr></table>        <p><b>[Atrial fibrillation before and after pacemaker implantation (WI and DDD) in patients with complete atrioventricular block]</b></p>        <p>Pol Merkur Lekarski. 2010 May;28(167):345-9</p>        <p>Authors:  Matusik P, Woznica N, Lelakowsk J</p>        <p>Atrial fibrillation (AF) is a frequent problem of patients with pacemakers, and depends not only on disease but also on stimulation method. The aim of the study was to estimate the prevalence of AF before and after pacemaker implantation as well as to assess the influence of VVI and DDD cardiac pacing on onset of AF in patients with complete atrioventricularblock (AVB). MATERIAL AND METHODS: We included 155 patients controlled between 2000 and 2008 in Pacemaker Clinic because of AVB III degree, treated with VVI or DDD pacemaker implantation. Information about the health status of the patients was gathered from medical documentation and analysis of clinical ambulatory electrocardiograms. RESULTS: The study group comprised of 68 women and 87 men, mean age 68.7 +/- 13.9 years during implantation. 69% of patients had VVI pacemaker. There were 72.3% of patients with sinus rhythm before pacemaker implantation. During follow-up 4 +/- 2.8 years in 19.6% cases onset of atrial fibrillation de novo was diagnosed (in 31.3% in VVI mode vs. 2.2% in DDD mode; p = 0.00014). Mean time to AF since implantation was approximately 2.5 years. In VVI group (21 persons) amounted 32.1 months, while in 1 patient with DDD pacemaker 18 months. Between group with AF after implantation and with sinus rhythm preserved there was no statistically significant difference in age or gender (p = 0.89512 and p = 0.1253, respectively). Prevalence of atrial fibrillation after pacemaker implantation increased to 40%. CONCLUSIONS: Atrial fibrillation is frequent in patients before and after pacemaker implantation, especially in patients stimulated in VVI mode. Major possibility of atrial fibrillation onset after pacemaker implantation should result in more attention during routine ECG examination.</p>        <p>PMID: 20568394 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20517485&#x26;dopt=Abstract\">Antithrombotic therapy in very elderly patients with atrial fibrillation: is it enough to assess thromboembolic risk?</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&#x26;amp;pubmedid=20517485"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.pubmedcentral.nih.gov-corehtml-pmc-pmcgifs-pubmed-pmc.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20517485">Related Articles</a></td></tr></table>        <p><b>Antithrombotic therapy in very elderly patients with atrial fibrillation: is it enough to assess thromboembolic risk?</b></p>        <p>Clin Interv Aging. 2010;5:157-62</p>        <p>Authors:  Guo Y, Wu Q, Zhang L, Yang T, Zhu P, Gao W, Zhao Y, Gao M</p>        <p>Although attention has been given to thromboprophylaxis for atrial fibrillation (AF) in present treatment guidelines, practical, clinical antithrombotic therapy is poorly developed for very elderly patients. We reviewed the records of 105 consecutive patients with AF of mean age 85 years, to determine how the greatest benefits from antithrombotic therapy could be obtained in this group. The mean CHADS2 score in these patients was 3.1 +/- 1.5. Before antithrombotic therapy, 21.0% of the patients had diseases with a risk of hemorrhage, 26.7% had diseases with a risk of thrombosis, and 8.6% had diseases with a risk of both hemorrhage and thrombosis. Moreover, 89 patients (84.8%) were receiving a single antiplatelet drug, 10 (9.5%) used aspirin plus clopidogrel, and six (5.7%) were taking an oral anticoagulant (OAC). Additionally, dual antiplatelet therapy was more commonly given to patients with permanent AF (paroxysmal and persistent versus permanent, 6.3% and 12.5% versus 30%, respectively, Chi-square = 8.4, P = 0.010). The incidence of adverse events was 25.7%, with thromboembolic events in 20.0% and hemorrhage in 5.7% of patients. There were no thromboembolic events in those patients taking OACs, but 33% of patients who took OACs had bleeding complications. It is difficult to choose appropriate antithrombotic strategies in very elderly patients. Both the thrombotic risk and the bleeding risk should be considered for helping such patients derive optimal benefit from thromboprophylaxis for AF.</p>        <p>PMID: 20517485 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20436706&#x26;dopt=Abstract\">Characteristics of P wave in patients with sinus rhythm after maze operation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://jkms.org/DOIx.php?id=10.3346/jkms.2010.25.5.712"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--jkms.org-image-jkmslogo2.jpg" border="0"/></a> <a href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&#x26;amp;pubmedid=20436706"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.pubmedcentral.nih.gov-corehtml-pmc-pmcgifs-pubmed-pmc.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20436706">Related Articles</a></td></tr></table>        <p><b>Characteristics of P wave in patients with sinus rhythm after maze operation.</b></p>        <p>J Korean Med Sci. 2010 May;25(5):712-5</p>        <p>Authors:  Park HE, Kim KH, Kim KB, Ahn H, Choi YS, Oh S</p>        <p>Maze operation could alter P wave morphology in electrocardiogram (ECG), which might prevent exact diagnosis of the cardiac rhythm of patients. However, characteristics of P wave in patients with sinus rhythm after the operation have not been elucidated systematically. Consecutive patients who underwent the modified Cox Maze operation from January to December 2007 were enrolled. The standard 12-lead ECG and echocardiography were evaluated in patients who had sinus rhythm at 6 months after the operation. The average axis of P wave was 65+/-30 degrees. The average amplitude of P wave was less than 0.1 mV in all 12-leads, with highest amplitude in V(1). The most common morphology of P wave was monophasic with positive polarity (49%), except aVR lead, which was different from those in patients with enlarged left atrium, characterized by large P-terminal force in the lead V(1). There were no significant differences in P-wave characteristics and echocardiographic parameters between patients with LA activity (30.6%) versus without LA activity (69.4%) at 6 months after the operation. In conclusion, the morphology of P wave in patients after Maze operation shows loss of typical ECG pattern of P mitrale: P wave morphology is small in amplitude, monophasic and with positive polarity.</p>        <p>PMID: 20436706 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('</ul>');
document.write('</div>');
document.write('<div class=\"rss_feed\">');
document.write('<div class=\"rss_feed_title\">pubmed: "atrial fibrillation...</div>');
document.write('<ul class=\"rss_item_list\">');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20499771&#x26;dopt=Abstract\">Very late recurrences of atrial fibrillation after pulmonary vein isolation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20499771">Related Articles</a></td></tr></table>        <p><b>Very late recurrences of atrial fibrillation after pulmonary vein isolation.</b></p>        <p>Hosp Pract (Minneap). 2010 Jun;38(3):40-4</p>        <p>Authors:  Klein EM, Steinberg JS</p>        <p>Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, accounting for approximately one-third of all hospitalizations from cardiac rhythm disturbances. Over the past decade, catheter ablation (predominantly in the form of pulmonary vein isolation [PVI]) has become an important therapy in the treatment of patients with symptomatic, drug-refractory AF. Despite the improvements in technology, operator experience, and advances in methodology that have led to higher success rates and a reduction in complications, the recurrence rate of AF after PVI is still relatively high. Published studies suggest that approximately 33% to 86% of patients undergoing catheter ablation of AF have freedom from recurrent AF, with 30% to 40% requiring a second procedure. Although most studies looking at the efficacy of PVI are limited by relatively short follow-up, recent data suggest that patients with an initially favorable procedural response may have very late recurrences of AF, even years after PVI. It is likely that the mechanism behind very late recurrences of AF is multifactorial, involving both recurrent pulmonary vein triggers and progressive remodeling of left atrial substrate over time, making it more vulnerable to triggering. These recurrences have important clinical implications in the care of patients, specifically with regard to the increased risk of stroke associated with AF.</p>        <p>PMID: 20499771 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20677363&#x26;dopt=Abstract\">Lenient versus strict rate control in atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20677363">Related Articles</a></td></tr></table>        <p><b>Lenient versus strict rate control in atrial fibrillation.</b></p>        <p>N Engl J Med. 2010 Jul 22;363(4):393; author reply 393-4</p>        <p>Authors:  Bhaskar E</p>        <p></p>        <p>PMID: 20677363 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20677362&#x26;dopt=Abstract\">Lenient versus strict rate control in atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20677362">Related Articles</a></td></tr></table>        <p><b>Lenient versus strict rate control in atrial fibrillation.</b></p>        <p>N Engl J Med. 2010 Jul 22;363(4):392-3; author reply 393-4</p>        <p>Authors:  Grimsley EW, Patel R, Persed P</p>        <p></p>        <p>PMID: 20677362 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20660409&#x26;dopt=Abstract\">Lenient versus strict rate control in atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20660409">Related Articles</a></td></tr></table>        <p><b>Lenient versus strict rate control in atrial fibrillation.</b></p>        <p>N Engl J Med. 2010 Jul 22;363(4):392; author reply 393-4</p>        <p>Authors:  Marine JE</p>        <p></p>        <p>PMID: 20660409 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20620710&#x26;dopt=Abstract\">Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry&#x27;s PINNACLE (Practice Innovation And Clinical Excellence) program.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(10)01744-4"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20620710">Related Articles</a></td></tr></table>        <p><b>Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry&#x27;s PINNACLE (Practice Innovation And Clinical Excellence) program.</b></p>        <p>J Am Coll Cardiol. 2010 Jun 29;56(1):8-14</p>        <p>Authors:  Chan PS, Oetgen WJ, Buchanan D, Mitchell K, Fiocchi FF, Tang F, Jones PG, Breeding T, Thrutchley D, Rumsfeld JS, Spertus JA</p>        <p>OBJECTIVES: We examined compliance with performance measures for 14,464 patients enrolled from July 2008 through June 2009 into the American College of Cardiology&#x27;s PINNACLE (Practice Innovation And Clinical Excellence) program to provide initial insights into the quality of outpatient cardiac care. BACKGROUND: Little is known about the quality of care of outpatients with coronary artery disease (CAD), heart failure, and atrial fibrillation, and whether sex and racial disparities exist in the treatment of outpatients. METHODS: The PINNACLE program is the first, national, prospective office-based quality improvement program of cardiac patients designed, in part, to capture, report, and improve outpatient performance measure compliance. We examined the proportion of patients whose care was compliant with established American College of Cardiology, American Heart Association, and American Medical Association-Physician Consortium for Performance Improvement (ACC/AHA/PCPI) performance measures for CAD, heart failure, and atrial fibrillation. RESULTS: There were 14,464 unique patients enrolled from 27 U.S. practices, accounting for 18,021 clinical visits. Of these, 8,132 (56.4%) had CAD, 5,012 (34.7%) had heart failure, and 2,786 (19.3%) had nonvalvular atrial fibrillation. Data from the PINNACLE program were feasibly collected for 24 of 25 ACC/AHA/PCPI performance measures. Compliance with performance measures ranged from being very low (e.g., 13.3% of CAD patients screened for diabetes mellitus) to very high (e.g., 96.7% of heart failure patients with blood pressure assessments), with moderate (70% to 90%) compliance observed for most performance measures. For 3 performance measures, there were small differences in compliance rates by race or sex. CONCLUSIONS: For more than 14,000 patients enrolled from 27 practices in the outpatient PINNACLE program, we found that compliance with performance measures was variable, even after accounting for exclusion criteria, suggesting an important opportunity to improve the quality of outpatient care.</p>        <p>PMID: 20620710 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20568394&#x26;dopt=Abstract\">[Atrial fibrillation before and after pacemaker implantation (WI and DDD) in patients with complete atrioventricular block]</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20568394">Related Articles</a></td></tr></table>        <p><b>[Atrial fibrillation before and after pacemaker implantation (WI and DDD) in patients with complete atrioventricular block]</b></p>        <p>Pol Merkur Lekarski. 2010 May;28(167):345-9</p>        <p>Authors:  Matusik P, Woznica N, Lelakowsk J</p>        <p>Atrial fibrillation (AF) is a frequent problem of patients with pacemakers, and depends not only on disease but also on stimulation method. The aim of the study was to estimate the prevalence of AF before and after pacemaker implantation as well as to assess the influence of VVI and DDD cardiac pacing on onset of AF in patients with complete atrioventricularblock (AVB). MATERIAL AND METHODS: We included 155 patients controlled between 2000 and 2008 in Pacemaker Clinic because of AVB III degree, treated with VVI or DDD pacemaker implantation. Information about the health status of the patients was gathered from medical documentation and analysis of clinical ambulatory electrocardiograms. RESULTS: The study group comprised of 68 women and 87 men, mean age 68.7 +/- 13.9 years during implantation. 69% of patients had VVI pacemaker. There were 72.3% of patients with sinus rhythm before pacemaker implantation. During follow-up 4 +/- 2.8 years in 19.6% cases onset of atrial fibrillation de novo was diagnosed (in 31.3% in VVI mode vs. 2.2% in DDD mode; p = 0.00014). Mean time to AF since implantation was approximately 2.5 years. In VVI group (21 persons) amounted 32.1 months, while in 1 patient with DDD pacemaker 18 months. Between group with AF after implantation and with sinus rhythm preserved there was no statistically significant difference in age or gender (p = 0.89512 and p = 0.1253, respectively). Prevalence of atrial fibrillation after pacemaker implantation increased to 40%. CONCLUSIONS: Atrial fibrillation is frequent in patients before and after pacemaker implantation, especially in patients stimulated in VVI mode. Major possibility of atrial fibrillation onset after pacemaker implantation should result in more attention during routine ECG examination.</p>        <p>PMID: 20568394 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20517485&#x26;dopt=Abstract\">Antithrombotic therapy in very elderly patients with atrial fibrillation: is it enough to assess thromboembolic risk?</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&#x26;amp;pubmedid=20517485"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.pubmedcentral.nih.gov-corehtml-pmc-pmcgifs-pubmed-pmc.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20517485">Related Articles</a></td></tr></table>        <p><b>Antithrombotic therapy in very elderly patients with atrial fibrillation: is it enough to assess thromboembolic risk?</b></p>        <p>Clin Interv Aging. 2010;5:157-62</p>        <p>Authors:  Guo Y, Wu Q, Zhang L, Yang T, Zhu P, Gao W, Zhao Y, Gao M</p>        <p>Although attention has been given to thromboprophylaxis for atrial fibrillation (AF) in present treatment guidelines, practical, clinical antithrombotic therapy is poorly developed for very elderly patients. We reviewed the records of 105 consecutive patients with AF of mean age 85 years, to determine how the greatest benefits from antithrombotic therapy could be obtained in this group. The mean CHADS2 score in these patients was 3.1 +/- 1.5. Before antithrombotic therapy, 21.0% of the patients had diseases with a risk of hemorrhage, 26.7% had diseases with a risk of thrombosis, and 8.6% had diseases with a risk of both hemorrhage and thrombosis. Moreover, 89 patients (84.8%) were receiving a single antiplatelet drug, 10 (9.5%) used aspirin plus clopidogrel, and six (5.7%) were taking an oral anticoagulant (OAC). Additionally, dual antiplatelet therapy was more commonly given to patients with permanent AF (paroxysmal and persistent versus permanent, 6.3% and 12.5% versus 30%, respectively, Chi-square = 8.4, P = 0.010). The incidence of adverse events was 25.7%, with thromboembolic events in 20.0% and hemorrhage in 5.7% of patients. There were no thromboembolic events in those patients taking OACs, but 33% of patients who took OACs had bleeding complications. It is difficult to choose appropriate antithrombotic strategies in very elderly patients. Both the thrombotic risk and the bleeding risk should be considered for helping such patients derive optimal benefit from thromboprophylaxis for AF.</p>        <p>PMID: 20517485 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20436706&#x26;dopt=Abstract\">Characteristics of P wave in patients with sinus rhythm after maze operation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://jkms.org/DOIx.php?id=10.3346/jkms.2010.25.5.712"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--jkms.org-image-jkmslogo2.jpg" border="0"/></a> <a href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&#x26;amp;pubmedid=20436706"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.pubmedcentral.nih.gov-corehtml-pmc-pmcgifs-pubmed-pmc.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20436706">Related Articles</a></td></tr></table>        <p><b>Characteristics of P wave in patients with sinus rhythm after maze operation.</b></p>        <p>J Korean Med Sci. 2010 May;25(5):712-5</p>        <p>Authors:  Park HE, Kim KH, Kim KB, Ahn H, Choi YS, Oh S</p>        <p>Maze operation could alter P wave morphology in electrocardiogram (ECG), which might prevent exact diagnosis of the cardiac rhythm of patients. However, characteristics of P wave in patients with sinus rhythm after the operation have not been elucidated systematically. Consecutive patients who underwent the modified Cox Maze operation from January to December 2007 were enrolled. The standard 12-lead ECG and echocardiography were evaluated in patients who had sinus rhythm at 6 months after the operation. The average axis of P wave was 65+/-30 degrees. The average amplitude of P wave was less than 0.1 mV in all 12-leads, with highest amplitude in V(1). The most common morphology of P wave was monophasic with positive polarity (49%), except aVR lead, which was different from those in patients with enlarged left atrium, characterized by large P-terminal force in the lead V(1). There were no significant differences in P-wave characteristics and echocardiographic parameters between patients with LA activity (30.6%) versus without LA activity (69.4%) at 6 months after the operation. In conclusion, the morphology of P wave in patients after Maze operation shows loss of typical ECG pattern of P mitrale: P wave morphology is small in amplitude, monophasic and with positive polarity.</p>        <p>PMID: 20436706 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('</ul>');
document.write('</div>');
document.write('<div class=\"rss_feed\">');
document.write('<div class=\"rss_feed_title\">pubmed: "atrial fibrillation...</div>');
document.write('<ul class=\"rss_item_list\">');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20499771&#x26;dopt=Abstract\">Very late recurrences of atrial fibrillation after pulmonary vein isolation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20499771">Related Articles</a></td></tr></table>        <p><b>Very late recurrences of atrial fibrillation after pulmonary vein isolation.</b></p>        <p>Hosp Pract (Minneap). 2010 Jun;38(3):40-4</p>        <p>Authors:  Klein EM, Steinberg JS</p>        <p>Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, accounting for approximately one-third of all hospitalizations from cardiac rhythm disturbances. Over the past decade, catheter ablation (predominantly in the form of pulmonary vein isolation [PVI]) has become an important therapy in the treatment of patients with symptomatic, drug-refractory AF. Despite the improvements in technology, operator experience, and advances in methodology that have led to higher success rates and a reduction in complications, the recurrence rate of AF after PVI is still relatively high. Published studies suggest that approximately 33% to 86% of patients undergoing catheter ablation of AF have freedom from recurrent AF, with 30% to 40% requiring a second procedure. Although most studies looking at the efficacy of PVI are limited by relatively short follow-up, recent data suggest that patients with an initially favorable procedural response may have very late recurrences of AF, even years after PVI. It is likely that the mechanism behind very late recurrences of AF is multifactorial, involving both recurrent pulmonary vein triggers and progressive remodeling of left atrial substrate over time, making it more vulnerable to triggering. These recurrences have important clinical implications in the care of patients, specifically with regard to the increased risk of stroke associated with AF.</p>        <p>PMID: 20499771 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20677363&#x26;dopt=Abstract\">Lenient versus strict rate control in atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20677363">Related Articles</a></td></tr></table>        <p><b>Lenient versus strict rate control in atrial fibrillation.</b></p>        <p>N Engl J Med. 2010 Jul 22;363(4):393; author reply 393-4</p>        <p>Authors:  Bhaskar E</p>        <p></p>        <p>PMID: 20677363 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20677362&#x26;dopt=Abstract\">Lenient versus strict rate control in atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20677362">Related Articles</a></td></tr></table>        <p><b>Lenient versus strict rate control in atrial fibrillation.</b></p>        <p>N Engl J Med. 2010 Jul 22;363(4):392-3; author reply 393-4</p>        <p>Authors:  Grimsley EW, Patel R, Persed P</p>        <p></p>        <p>PMID: 20677362 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20660409&#x26;dopt=Abstract\">Lenient versus strict rate control in atrial fibrillation.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20660409">Related Articles</a></td></tr></table>        <p><b>Lenient versus strict rate control in atrial fibrillation.</b></p>        <p>N Engl J Med. 2010 Jul 22;363(4):392; author reply 393-4</p>        <p>Authors:  Marine JE</p>        <p></p>        <p>PMID: 20660409 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;list_uids=20620710&#x26;dopt=Abstract\">Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry&#x27;s PINNACLE (Practice Innovation And Clinical Excellence) program.</a></span> <span class=\"rss_item_desc\">	<table border="0" width="100%"><tr><td align="left"><a href="http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(10)01744-4"><img src="http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif" border="0"/></a> </td><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#x26;amp;cmd=Display&#x26;amp;dopt=PubMed_PubMed&#x26;amp;from_uid=20620710">Related Articles</a></td></tr></table>        <p><b>Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry&#x27;s PINNACLE (Practice Innovation And Clinical Excellence) program.</b></p>        <p>J Am Coll Cardiol. 2010 Jun 29;56(1):8-14</p>        <p>Authors:  Chan PS, Oetgen WJ, Buchanan D, Mitchell K, Fiocchi FF, Tang F, Jones PG, Breeding T, Thrutchley D, Rumsfeld JS, Spertus JA</p>        <p>OBJECTIVES: We examined compliance with performance measures for 14,464 patients enrolled from July 2008 through June 2009 into the American College of Cardiology&#x27;s PINNACLE (Practice Innovation And Clinical Excellence) program to provide initial insights into the quality of outpatient cardiac care. BACKGROUND: Little is known about the quality of care of outpatients with coronary artery disease (CAD), heart failure, and atrial fibrillation, and whether sex and racial disparities exist in the treatment of outpatients. METHODS: The PINNACLE program is the first, national, prospective office-based quality improvement program of cardiac patients designed, in part, to capture, report, and improve outpatient performance measure compliance. We examined the proportion of patients whose care was compliant with established American College of Cardiology, American Heart Association, and American Medical Association-Physician Consortium for Performance Improvement (ACC/AHA/PCPI) performance measures for CAD, heart failure, and atrial fibrillation. RESULTS: There were 14,464 unique patients enrolled from 27 U.S. practices, accounting for 18,021 clinical visits. Of these, 8,132 (56.4%) had CAD, 5,012 (34.7%) had heart failure, and 2,786 (19.3%) had nonvalvular atrial fibrillation. Data from the PINNACLE program were feasibly collected for 24 of 25 ACC/AHA/PCPI performance measures. Compliance with performance measures ranged from being very low (e.g., 13.3% of CAD patients screened for diabetes mellitus) to very high (e.g., 96.7% of heart failure patients with blood pressure assessments), with moderate (70% to 90%) compliance observed for most performance measures. For 3 performance measures, there were small differences in compliance rates by race or sex. CONCLUSIONS: For more than 14,000 patients enrolled from 27 practices in the outpatient PINNACLE program, we found that compliance with performance measures was variable, even after accounting for exclusion criteria, suggesting an important opportunity to improve the quality of outpatient care.</p>        <p>PMID: 20620710 [PubMed - indexed for MEDLINE]</p>    </span></li>');
document.write('<li class=\"rss_item\"><span class=\"rss_item_title\"><a class=\"rss_item_link\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&#x26;db=PubMed&#x26;cmd=Retrieve&#x26;li